Human prostate cancer risk factors

Prostate cancer has the highest prevalence of any nonskin cancer in the human body, with similar likelihood of neoplastic foci found within the prostates of men around the world regardless of diet, occupation, lifestyle, or other factors. Essentially all men with circulating androgens will develop microscopic prostate cancer if they live long enough. This review is a contemporary and comprehensive, literature‐based analysis of the putative risk factors for human prostate cancer, and the results were presented at a multidisciplinary consensus conference held in Crystal City, Virginia, in the fall of 2002. The objectives were to evaluate known environmental factors and mechanisms of prostatic carcinogenesis and to identify existing data gaps and future research needs. The review is divided into four sections, including 1) epidemiology (endogenous factors [family history, hormones, race, aging and oxidative stress] and exogenous factors [diet, environmental agents, occupation and other factors, including lifestyle factors]); 2) animal and cell culture models for prediction of human risk (rodent models, transgenic models, mouse reconstitution models, severe combined immunodeficiency syndrome mouse models, canine models, xenograft models, and cell culture models); 3) biomarkers in prostate cancer, most of which have been tested only as predictive factors for patient outcome after treatment rather than as risk factors; and 4) genotoxic and nongenotoxic mechanisms of carcinogenesis. The authors conclude that most of the data regarding risk relies, of necessity, on epidemiologic studies, but animal and cell culture models offer promise in confirming some important findings. The current understanding of biomarkers of disease and risk factors is limited. An understanding of the risk factors for prostate cancer has practical importance for public health research and policy, genetic and nutritional education and chemoprevention, and prevention strategies. Cancer 2004. © 2004 American Cancer Society.

[1]  O. Cussenot,et al.  Hereditary Prostate Cancer and Other Genetic Predispositions to Prostate Cancer , 1998, Urologia Internationalis.

[2]  A. del Rosario,et al.  Sulfur-rich prostatic intraluminal crystalloids: a surgical pathologic and electron probe x-ray microanalytic study. , 1993, Human pathology.

[3]  A. Whittemore,et al.  Prostate cancer risk in relation to anthropometry and physical activity: the National Health and Nutrition Examination Survey I Epidemiological Follow-Up Study. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[4]  G. Jones,et al.  Factors involved in the high incidence of prostatic cancer among American blacks. , 1981, Progress in clinical and biological research.

[5]  A. Tefekli,et al.  Expression of E‐cadherin in prostate cancer in formalin‐fixed, paraffin‐embedded tissues: correlation with pathological features , 2002, Pathology.

[6]  K. Molberg,et al.  Crystalloids in metastatic prostatic adenocarcinoma. , 1994, American journal of clinical pathology.

[7]  P. di Sant'Agnese,et al.  Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications , 1992, Cancer.

[8]  P. Carroll,et al.  FREQUENT GENOTYPE CHANGES AT −308, AND 488 REGIONS OF THE TUMOR NECROSIS FACTOR - α (TNF-α) GENE IN PATIENTS WITH PROSTATE CANCER , 2000 .

[9]  J. Folkman,et al.  The role of angiostatin in the spontaneous bone and prostate cancers of pet dogs. , 2002, Biochemical and biophysical research communications.

[10]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[11]  E. Giovannucci Is the androgen receptor CAG repeat length significant for prostate cancer? , 2002, Cancer Epidemiology, Biomarkers and Prevention.

[12]  M. Spitz,et al.  Leptin and prostate cancer , 2001, The Prostate.

[13]  A. Partin,et al.  Association of glyceraldehyde-3-phosphate dehydrogenase expression with cell motility and metastatic potential of rat prostatic adenocarcinoma. , 1993, Cancer research.

[14]  M. Migaldi,et al.  Proliferating cell nuclear antigen/cyclin in incidental carcinoma of the prostate , 2005, Virchows Archiv A.

[15]  P. Wingo,et al.  Long-term cancer patient survival in the United States. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[16]  L. Chung,et al.  Metastasis induced by overexpression of p185neu‐T after orthotopic injection into a prostatic epithelial cell line (NbE) , 1997, Molecular carcinogenesis.

[17]  D. W. Hayden,et al.  Workgroup 4: Spontaneous prostate carcinoma in dogs and nonhuman primates , 1998, The Prostate.

[18]  C. Thompson,et al.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.

[19]  M. Parker,et al.  Effect of androgen on the transcription of rat prostatic binding protein genes , 1982, Molecular and Cellular Endocrinology.

[20]  M. Resnick,et al.  Xenografts of primary human prostatic carcinoma. , 1993, Journal of the National Cancer Institute.

[21]  P. Humphrey,et al.  Morphometric analysis and clinical followup of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate. , 1995, The Journal of urology.

[22]  M. Lijovic,et al.  KAI1/CD82 protein expression in primary prostate cancer and in BPH associated with cancer. , 2002, Cancer detection and prevention.

[23]  R. Walshaw,et al.  The influence of castration on the development of prostatic carcinoma in the dog. 43 cases (1978-1985). , 1987, Journal of veterinary internal medicine.

[24]  M. Droller Telomerase activity: a biomarker of cell proliferation, not malignant transformation. , 1998, The Journal of urology.

[25]  M. Fullerton,et al.  Ectopic hormone production by a prostatic small cell carcinoma xenograft line , 1988, Molecular and Cellular Endocrinology.

[26]  H. Peterson,et al.  Vasectomy and prostate cancer. Chance, bias, or a causal relationship? , 1993, JAMA.

[27]  M. Bosland,et al.  Hormonal factors in carcinogenesis of the prostate and testis in humans and in animal models. , 1996, Progress in clinical and biological research.

[28]  M. Spitz,et al.  Case-control study of diet and prostate cancer in China , 1998, Cancer Causes & Control.

[29]  P. Pour,et al.  Induction of prostatic carcinomas and lower urinary tract neoplasms by combined treatment of intact and castrated rats with testosterone propionate and N-nitrosobis(2-oxopropyl)amine. , 1987, Cancer research.

[30]  T. H. van der Kwast,et al.  Microvascular Invasion in Prostate Cancer: Prognostic Significance in Patients Treated by Radical Prostatectomy for Clinically Localized Carcinoma , 1998, Urologia Internationalis.

[31]  M. Becich,et al.  Incidence and prognostic significance of lymphatic and vascular invasion in radical prostatectomy specimens , 1989, The Prostate.

[32]  A. Whittemore,et al.  Personal and environmental characteristics related to epithelial ovarian cancer. II. Exposures to talcum powder, tobacco, alcohol, and coffee. , 1988, American journal of epidemiology.

[33]  D. Bostwick,et al.  Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies. , 1994, Cancer research.

[34]  B. Timms,et al.  Localization of androgen receptor and cell-specific cytokeratins in basal cells of rat ventral prostate. , 1995, Journal of andrology.

[35]  T. P. Pretlow,et al.  Transplantation of human prostatic carcinoma into nude mice in Matrigel. , 1991, Cancer research.

[36]  M. Hayama,et al.  Distribution of cathepsin D granules in normal and pathologic conditions in human prostate. , 2002, Hinyokika kiyo. Acta urologica Japonica.

[37]  J. Yang,et al.  Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas. , 2001, Cancer research.

[38]  F. Algaba,et al.  Morphological identification of the patterns of prostatic intraepithelial neoplasia and their importance , 2000, Journal of clinical pathology.

[39]  John Calvin Reed Mechanisms of Bcl-2 family protein function and dysfunction in health and disease. , 1996, Behring Institute Mitteilungen.

[40]  I. Kondo,et al.  Establishment of a new prostatic carcinoma cell line (TSU-Pr1). , 1987, The Journal of urology.

[41]  D. Grignon,et al.  Age and racial distribution of prostatic intraepithelial neoplasia. , 1996, European urology.

[42]  C. la Vecchia,et al.  Alcohol consumption and risk of prostate cancer. , 1994, Nutrition and cancer.

[43]  H. Adami,et al.  Energy, nutrient intake and prostate cancer risk: a population‐based case‐control study in Sweden , 1996, International journal of cancer.

[44]  Barrack Er Androgen receptor mutations in prostate cancer. , 1996 .

[45]  L. Terracio,et al.  Oncogenicity of rat prostate cells transformed in vitro with cadmium chloride , 1988, Archives of Toxicology.

[46]  V. Freeman,et al.  Prostatic levels of fatty acids and the histopathology of localized prostate cancer. , 2000, The Journal of urology.

[47]  D. Bostwick,et al.  Workgroup I: Rodent models of prostate cancer , 1998, The Prostate.

[48]  H. Lilja,et al.  Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. , 1997, Cancer research.

[49]  L. Blount,et al.  Point mutations in the Ki‐ras2 gene of codon 12 in the Dunning R‐3327 prostatic adenocarcinoma system , 1996, The Prostate.

[50]  W. Wolter,et al.  Diet and the duration of testosterone-dependent prostate cancer in Lobund-Wistar rats. , 2001, Cancer letters.

[51]  N. Kyprianou,et al.  Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy. , 2001, The Journal of urology.

[52]  J C Eggleston,et al.  A new method to assess metastatic potential of human prostate cancer: relative nuclear roundness. , 1982, The Journal of urology.

[53]  P. Boyle,et al.  Diet and oxidative stress in breast, colon and prostate cancer patients: a case-control study. , 1994, European journal of clinical nutrition.

[54]  Y. Eishi,et al.  Expression of Matrix Metalloproteinase-9 and Bombesin/Gastrin-Releasing Peptide in Human Prostate Cancers and their Lymph Node Metastases , 2002, Acta oncologica.

[55]  R. Nagle,et al.  Investigation into the mechanism of the loss of laminin 5 (α3β3γ2) expression in prostate cancer , 2001 .

[56]  U. Bergerheim,et al.  Clinical significance of chromosome 8p, 10q, and 16q deletions in prostate cancer , 2003, The Prostate.

[57]  D. Clemmons,et al.  Regulation of IGFBP secretion and modulation of cell growth in MDBK cells. , 1993, Growth regulation.

[58]  A. Kraft,et al.  Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells , 2002, Oncogene.

[59]  H. Ozen,et al.  Determination of prognosis in patients with prostate cancer treated with radical prostatectomy: prognostic value of CD44v6 score. , 2002, The Journal of urology.

[60]  G. Risbridger,et al.  Inhibin-related proteins in rat prostate. , 1996, The Journal of endocrinology.

[61]  H. Klingler,et al.  Local intratumoral tumor necrosis factor-alpha and systemic IFN-alpha 2b in patients with locally advanced prostate cancer. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[62]  S. Korsmeyer,et al.  BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[63]  Y. Collan,et al.  Nucleolar morphometry in fine needle aspiration biopsies of the prostate. , 2001, Analytical and quantitative cytology and histology.

[64]  T. Chen,et al.  Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[65]  Levine,et al.  MUC1 Expression in Prostate Carcinoma: Correlation with Grade and Stage. , 1999, Molecular urology.

[66]  T. Shirai,et al.  Induction of invasive carcinomas in the accessory sex organs other than the ventral prostate of rats given 3,2'-dimethyl-4-aminobiphenyl and testosterone propionate. , 1991, Cancer research.

[67]  J. Wrathall,et al.  Regulation of growth by a nerve growth factor-like protein which modulates paracrine interactions between a neoplastic epithelial cell line and stromal cells of the human prostate. , 1991, Cancer research.

[68]  W. Isaacs,et al.  Allelic loss of chromosomes 16q and 10q in human prostate cancer. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[69]  T. Shirai,et al.  Enhancing Effect of Cadmium on Rat Ventral Prostate Carcinogenesis Induced by 3,2′‐Dimethyl‐4‐aminobiphenyl , 1993, Japanese journal of cancer research : Gann.

[70]  P. Jenner,et al.  AMINES, ANTICONVULSANTS, AND EPILEPSY , 1975, The Lancet.

[71]  S. Yeh,et al.  From transforming growth factor-β signaling to androgen action: Identification of Smad3 as an androgen receptor coregulator in prostate cancer cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[72]  M. Riggs,et al.  Neuroendocrine stains and proliferative indices of prostatic adenocarcinomas in transurethral resection samples. , 1997, British Journal of Urology.

[73]  T. Barrette,et al.  α-Methylacyl-CoA Racemase: Expression Levels of this Novel Cancer Biomarker Depend on Tumor Differentiation , 2002 .

[74]  E. Bergstralh,et al.  Prognostic significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in stage T3N0M0 prostate cancer , 1998, Genes, chromosomes & cancer.

[75]  T. Liu,et al.  MMAC/PTEN tumor suppressor gene regulates vascular endothelial growth factor-mediated angiogenesis in prostate cancer. , 2002, International journal of oncology.

[76]  D. MacGrogan,et al.  Expression of Nerve Growth Factor and Nerve Growth Factor Receptor Genes in Human Tissues and in Prostatic Adenocarcinoma Cell Lines , 1992, Journal of neurochemistry.

[77]  P. Carroll,et al.  Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. , 1996, Cancer research.

[78]  B. Szende,et al.  Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma , 2001, The Prostate.

[79]  G. Fenwick,et al.  Naturally occurring oestrogens in foods--a review. , 1985, Food additives and contaminants.

[80]  F. Habib,et al.  Subcellular distribution of zinc in the benign and malignant human prostate: evidence for a direct zinc androgen interaction. , 1984, Acta endocrinologica.

[81]  M. Krieg,et al.  Kinetic analysis of androstenedione 5α-reductase in epithelium and stroma of human prostate , 1997, Steroids.

[82]  R. Monson,et al.  Mortality and cancer morbidity among workers in the rubber tire industry. , 1981, American journal of industrial medicine.

[83]  W. Isaacs,et al.  Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. , 1996, Cancer research.

[84]  D. Bostwick,et al.  Interobserver variability in the diagnosis of high-grade prostatic intraepithelial neoplasia and adenocarcinoma. , 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[85]  G. Coetzee,et al.  Identification of two germline point mutations in the 5'UTR of the androgen receptor gene in men with prostate cancer. , 1997, The Journal of urology.

[86]  Daniel S. Miller,et al.  Cancer incidence and mortality, 1973‐1995 , 1998 .

[87]  K. Pienta,et al.  Parathyroid hormone-related protein as a growth regulator of prostate carcinoma. , 1999, Cancer research.

[88]  F. Mostofi,et al.  Prostate cancer, benign prostatic hyperplasia and physical activity in Shanghai, China. , 2001, International journal of epidemiology.

[89]  D. L. McLellan,et al.  Hereditary aspects of prostate cancer. , 1995, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[90]  E. Barrett-Connor,et al.  A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. , 1990, Cancer research.

[91]  R. Bookstein Tumor suppressor genes in prostatic oncogenesis. , 1994, Journal of cellular biochemistry. Supplement.

[92]  F. Sarkar,et al.  Soy isoflavone supplementation in healthy men prevents NF-kappa B activation by TNF-alpha in blood lymphocytes. , 2001, Free radical biology & medicine.

[93]  A. Aigner,et al.  Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo , 2002, Oncogene.

[94]  Chung Lee,et al.  Growth of an androgen‐sensitive human prostate cancer cell line, LNCaP, in nude mice , 1993, The Prostate.

[95]  M. Piscator Role of cadmium in carcinogenesis with special reference to cancer of the prostate , 1981, Environmental health perspectives.

[96]  D. English,et al.  Sexual factors and prostate cancer , 2003, BJU international.

[97]  D. Djakiew,et al.  Loss of low‐affinity nerve growth factor receptor during malignant transformation of the human prostate , 1997, The Prostate.

[98]  P. Humphrey,et al.  Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. , 1995, The American journal of pathology.

[99]  C. Eaton,et al.  Growth Factor Receptors and Oncogene Expression in Prostate Cells , 1988, American journal of clinical oncology.

[100]  F. Jänicke,et al.  Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. , 1992, Biological chemistry Hoppe-Seyler.

[101]  H. Grönberg,et al.  Linkage analysis of prostate cancer susceptibility: confirmation of linkage at 8p22–23 , 2003, Human Genetics.

[102]  C. Eaton,et al.  Binding of epidermal growth factor by human normal, hypertrophic, and carcinomatous prostate , 1989, The Prostate.

[103]  S. Rabbani,et al.  Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. , 1994, Cancer research.

[104]  Teruhiko Yoshida,et al.  Cloning of human bone morphogenetic protein type IB receptor (BMPR-IB) and its expression in prostate cancer in comparison with other BMPRs , 1997, Oncogene.

[105]  J. Oxley,et al.  p53 and bcl‐2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy , 2002, BJU international.

[106]  J. Köllermann,et al.  Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue. , 2001, American journal of clinical pathology.

[107]  N. Block,et al.  Human prostatic inhibin suppresses tumor growth and inhibits clonogenic cell survival of a model prostatic adenocarcinoma, the Dunning R3327G rat tumor. , 1993, Cancer research.

[108]  F. Tsai,et al.  Osteocalcin gene HindIII C/T polymorphism is a biomarker for prostate cancer and responsiveness to hormone therapy. , 2003, European urology.

[109]  R Doll,et al.  Mortality in relation to smoking: 40 years' observations on male British doctors , 1994, BMJ.

[110]  D. Bostwick,et al.  Collagenous micronodules in prostate cancer. A specific but infrequent diagnostic finding. , 1995, Archives of pathology & laboratory medicine.

[111]  D. Bostwick,et al.  Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. , 1995, Cancer research.

[112]  C. Polychronakos,et al.  Mitogenic effects of insulin and insulin‐like growth factors on PA‐III rat prostate adenocarcinoma cells: Characterization of the receptors involved , 1991, The Prostate.

[113]  Morris Pollard,et al.  Prostate‐seminal vesicle cancers induced in noble rats , 2000, The Prostate.

[114]  R. Hayes,et al.  Serum retinal and prostate cancer , 1988 .

[115]  E. Rimm,et al.  Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[116]  G. Wilding Response of prostate cancer cells to peptide growth factors: transforming growth factor-beta. , 1991, Cancer surveys.

[117]  G R Howe,et al.  Plant foods, antioxidants, and prostate cancer risk: findings from case-control studies in Canada. , 1999, Nutrition and cancer.

[118]  J. Eastham,et al.  Androgen receptor mutations in prostate cancer. , 2000, Cancer research.

[119]  M. Katdare,et al.  Inhibition of Proliferation and Modulation of Estradiol Metabolism: Novel Mechanisms for Breast Cancer Prevention by the Phytochemical Indole-3-Carbinol , 1997, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[120]  M. Lehtinen,et al.  Sero-epidemiological association between human-papillomavirus infection and risk of prostate cancer. , 1998, International journal of cancer.

[121]  A. Hanlon,et al.  Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three‐dimensional conformal radiation therapy , 1997, Cancer.

[122]  T. Beaty,et al.  Hereditary prostate cancer: epidemiologic and clinical features. , 1993, The Journal of urology.

[123]  S. Schwartz,et al.  CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. , 1996, Cancer research.

[124]  W. Rombauts,et al.  Influence of castration and androgen treatment on the synthesis of prostatic binding protein and the concentration of its mRNA in the rat ventral prostate. , 1986, Journal of steroid biochemistry.

[125]  C. la Vecchia,et al.  Diet and prostatic cancer: a case-control study in northern Italy. , 1992, Nutrition and cancer.

[126]  B. Foster,et al.  Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[127]  I. Leav,et al.  Induction of atypical hyperplasia, apoptosis, and type II estrogen-binding sites in the ventral prostates of Noble rats treated with testosterone and pharmacologic doses of estradiol-17 beta. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[128]  O. Brawley Prostate carcinoma incidence and patient mortality , 1997, Cancer.

[129]  T. H. van der Kwast,et al.  Development of seven new human prostate tumor xenograft models and their histopathological characterization. , 1996, The American journal of pathology.

[130]  A. Meikle,et al.  Testosterone is a potential augmentor of antioxidant-induced apoptosis in human prostate cancer cells. , 2002, Cancer detection and prevention.

[131]  M. Susin,et al.  Mutational status of codons 12 and 13 of the N- and K-ras genes in tissue and cell lines derived from primary and metastatic prostate carcinomas. , 1993, Cancer investigation.

[132]  M. E. El Etreby,et al.  Differential expression of members of the tumor necrosis factor alpha-related apoptosis-inducing ligand pathway in prostate cancer cells. , 2001, Cancer research.

[133]  L. Bégin,et al.  Insulin-like growth factor-1 and insulin-like growth factor binding protein-3 for prostate cancer detection in patients undergoing prostate biopsy. , 2002, The Journal of urology.

[134]  G. Aumüller,et al.  Experimental studies of apocrine secretion in the dorsal prostate epithelium of the rat , 1979, Cell and Tissue Research.

[135]  O. Halvorsen,et al.  Maximum Ki-67 staining in prostate cancer provides independent prognostic information after radical prostatectomy. , 2001, Anticancer research.

[136]  I. Leav,et al.  Lack of association between enhanced TRPM-2/clusterin expression and increased apoptotic activity in sex-hormone-induced prostatic dysplasia of the Noble rat. , 1998, The American journal of pathology.

[137]  Y. Hamada,et al.  Autocrine expression of neurotrophins and their receptors in prostate cancer , 2001, International journal of urology : official journal of the Japanese Urological Association.

[138]  P. Spano,et al.  Nerve growth factor induces the re-expression of functional androgen receptors and p75(NGFR) in the androgen-insensitive prostate cancer cell line DU145. , 2002, European journal of endocrinology.

[139]  E. Rimm,et al.  Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[140]  H. Kanetake,et al.  Serum insulin‐like growth factor binding protein‐3/prostate‐specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer , 2003, The Prostate.

[141]  G. Bancroft,et al.  The biology of the SCID mutation. , 1989, Immunology today.

[142]  H. Shiina,et al.  Association of nm23 protein levels in human prostates with proliferating cell nuclear antigen expression at autopsy. , 1996, European urology.

[143]  W. Mckeehan,et al.  Heparin-binding keratinocyte growth factor is a candidate stromal-to-epithelial-cell andromedin. , 1992, Molecular endocrinology.

[144]  J. Brooks,et al.  Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[145]  P. Stattin,et al.  Leptin is associated with increased prostate cancer risk: a nested case-referent study. , 2001, The Journal of clinical endocrinology and metabolism.

[146]  D. Rose,et al.  Secretion of epidermal growth factor and related polypeptides by the DU 145 human prostate cancer cell line , 1989, The Prostate.

[147]  D. Paulson,et al.  Isolation of a human prostate carcinoma cell line (DU 145) , 1978, International journal of cancer.

[148]  I. Leav,et al.  Involvement of transforming growth factor alpha (TGFalpha) and epidermal growth factor receptor (EGFR) in sex hormone-induced prostatic dysplasia and the growth of an androgen-independent transplantable carcinoma of the prostate. , 1996, Carcinogenesis.

[149]  H. Klocker,et al.  Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate , 1997, The Prostate.

[150]  J. Ross,et al.  Telomerase Activity in Human Benign Prostate Tissue and Prostatic Adenocarcinomas , 1997, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[151]  J. Park,et al.  Opposing roles for the insulin-like growth factor (IGF)-II and mannose 6-phosphate (Man-6-P) binding activities of the IGF-II/Man-6-P receptor in the growth of prostate cancer cells. , 2003, Endocrinology.

[152]  R. Parwaresch,et al.  Monoclonal antibodies Ki‐S3 and Ki‐S5 yield new data on the ‘Ki‐67’proteins , 1996, Cell proliferation.

[153]  Josep M Ramon,et al.  Dietary fat intake and prostate cancer risk: a case–control study in Spain , 2000, Cancer Causes & Control.

[154]  M. Davis,et al.  T cell receptor gene diversity and selection. , 1990, Annual review of biochemistry.

[155]  T. Beaty,et al.  Transmission/disequilibrium tests of androgen receptor and glutathione S‐transferase pi variants in prostate cancer families , 2002, International Journal of Cancer.

[156]  A. Belldegrun,et al.  Tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) for treatment of prostate cancer: first results and review of the literature , 1999, Prostate Cancer and Prostatic Diseases.

[157]  D. Bostwick,et al.  Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery. , 1999, The Journal of urology.

[158]  D. English,et al.  Risk of prostate cancer associated with a family history in an era of rapid increase in prostate cancer diagnosis (Australia) , 2003, Cancer Causes & Control.

[159]  G. Combs,et al.  Serum selenium and subsequent risk of prostate cancer. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[160]  U. Studer,et al.  Abnormal p53 expression is rare in clinically localized human prostate cancer: Comparison between immunohistochemical and molecular detection of p53 mutations , 1997, The Prostate.

[161]  A. Whittemore,et al.  Early precursors of site-specific cancers in college men and women. , 1985, Journal of the National Cancer Institute.

[162]  S. Egawa,et al.  Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer. , 2002, Anticancer research.

[163]  L. Hayflick Theories of biological aging , 1985, Experimental Gerontology.

[164]  P H Bartels,et al.  Data representation and reduction for chromatin texture in nuclei from premalignant prostatic, esophageal, and colonic lesions. , 2000, Cytometry.

[165]  S. Freedland,et al.  Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. , 2002, The Journal of urology.

[166]  D. Grignon,et al.  Prostate cancer: indicators of aggressiveness. , 1997, European urology.

[167]  J. Cheville,et al.  Perineural Invasion and MIB-1 Positivity in Addition to Gleason Score Are Significant Preoperative Predictors of Progression After Radical Retropubic Prostatectomy for Prostate Cancer , 2002, The American journal of surgical pathology.

[168]  R. Nagle,et al.  Integrin alpha 6 expression in human prostate carcinoma cells is associated with a migratory and invasive phenotype in vitro and in vivo. , 1995, Clinical & experimental metastasis.

[169]  George L. Wright,et al.  Phenotypic and cytogenetic characterization of a cell line derived from primary prostatic carcinoma , 1989, International journal of cancer.

[170]  W. Blaner,et al.  Influence of vitamins A, C, and E and β‐carotene on aflatoxin B1 binding to DNA in woodchuck hepatocytes , 1994, Cancer.

[171]  P. Cerutti Prooxidant states and tumor promotion. , 1985, Science.

[172]  M. Waalkes,et al.  Cadmium and prostate cancer. , 1994, Journal of toxicology and environmental health.

[173]  A. Belldegrun,et al.  Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. , 1995, Cancer research.

[174]  A. Mazar,et al.  Prevention of prostate‐cancer metastasis in vivo by a novel synthetic inhibitor of urokinase‐type plasminogen activator (uPA) , 1995, International journal of cancer.

[175]  D. Bostwick,et al.  cis-trans lycopene isomers, carotenoids, and retinol in the human prostate. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[176]  A. Bergh,et al.  Castration‐induced reduction of vascular endothelial growth factor expression in benign human prostate tissue is lost in advanced prostate cancer , 2001, BJU international.

[177]  J. Cuzick Human papillomavirus infection of the prostate. , 1995, Cancer surveys.

[178]  L. Garfinkel,et al.  Twenty‐year follow‐up of the breast cancers diagnosed during the Breast Cancer Detection Demonstration Project , 1997, CA: a cancer journal for clinicians.

[179]  R. Monson,et al.  Mortality among rubber workers. I. White male union employees in Akron, Ohio. , 1976, American journal of epidemiology.

[180]  R. Cardiff,et al.  Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: a new mouse model for prostatic intraepithelial neoplasia. , 2002, Cancer research.

[181]  D. Gridley,et al.  Enhancement of prostate cancer xenograft growth with whole-body radiation and vascular endothelial growth factor. , 1997, Anticancer research.

[182]  J. Green,et al.  Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[183]  D. Bostwick,et al.  The association of benign prostatic hyperplasia and cancer of the prostate , 1992, Cancer.

[184]  R. deVere White,et al.  NM23 gene expression in human prostatic carcinomas and benign prostatic hyperplasias: altered expression in combined androgen blockaded carcinomas. , 1996, The Journal of urology.

[185]  C. Guillemette,et al.  Glucuronosyltransferase activity in human cancer cell line LNCaP , 1995, Molecular and Cellular Endocrinology.

[186]  H. Bartsch,et al.  Quantity and saturation degree of dietary fats as modulators of oxidative stress and chemically‐induced liver tumours in rats , 1990, International journal of cancer.

[187]  R. deVere White,et al.  Activated ras alleles in human carcinoma of the prostate are rare. , 1991, Cancer research.

[188]  Murali Varma,et al.  Morphologic criteria for the diagnosis of prostatic adenocarcinoma in needle biopsy specimens. A study of 250 consecutive cases in a routine surgical pathology practice. , 2002, Archives of pathology & laboratory medicine.

[189]  M. Stearns,et al.  Keratinocyte growth factor and receptor mRNA expression in benign and malignant human prostate. , 1995, Experimental and molecular pathology.

[190]  Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk. , 2002 .

[191]  G. Colditz Consensus conference: smoking and prostate cancer , 1996, Cancer Causes & Control.

[192]  G. Ayala,et al.  Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[193]  A. Belldegrun,et al.  In vitro modulation of tumor progression‐associated properties of hormone refractory prostate carcinoma cell lines by cytokines , 1996, Cancer.

[194]  O. Cussenot,et al.  Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. , 1997, European journal of cancer.

[195]  R. Bookstein,et al.  Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer , 1994, Genes, chromosomes & cancer.

[196]  F. Mitelman,et al.  Chromosome abnormalities are associated with unfavorable outcome in prostatic cancer patients. , 1992, The Journal of urology.

[197]  G A Colditz,et al.  Intake of carotenoids and retinol in relation to risk of prostate cancer. , 1995, Journal of the National Cancer Institute.

[198]  S. Wacholder,et al.  Associations between several sites of cancer and nine organic dusts: results from an hypothesis-generating case-control study in Montreal, 1979-1983. , 1986, American journal of epidemiology.

[199]  C. Lamartiniere,et al.  Genistein, a component of soy, inhibits the expression of the EGF and ErbB2/Neu receptors in the rat dorsolateral prostate , 1998, The Prostate.

[200]  F. Kishi,et al.  Two putative tumor suppressor genes on chromosome arm 8p may play different roles in prostate cancer. , 2001, Cancer genetics and cytogenetics.

[201]  N. Tran,et al.  Signal Transduction from N-cadherin Increases Bcl-2 , 2002, The Journal of Biological Chemistry.

[202]  J. Lechner,et al.  Establishment and characterization of a human prostatic carcinoma cell line (PC-3). , 1979, Investigative urology.

[203]  G. Eklund,et al.  Mortality in relation to cigarette and pipe smoking: 16 years' observation of 25,000 Swedish men. , 1987, Journal of epidemiology and community health.

[204]  Y. Tsujimoto,et al.  Molecular genetics of human B-cell neoplasia. , 1986, Current topics in microbiology and immunology.

[205]  M. Ittmann,et al.  Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas. , 1996, Human pathology.

[206]  O. Lukkarinen,et al.  Three independently deleted regions at chromosome arm 16q in human prostate cancer: allelic loss at 16q24.1–q24.2 is associated with aggressive behaviour of the disease, recurrent growth, poor differentiation of the tumour and poor prognosis for the patient , 1999, British journal of cancer.

[207]  E. Rimm,et al.  A prospective study of tomato products, lycopene, and prostate cancer risk. , 2002, Journal of the National Cancer Institute.

[208]  D. Chopin,et al.  Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. , 1993, The American journal of pathology.

[209]  D. Bostwick,et al.  Mucin expression in atypical adenomatous hyperplasia of the prostate. , 1995, Human pathology.

[210]  Chawnshang Chang,et al.  Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates , 1990, The Prostate.

[211]  R. Peto,et al.  Serum selenium and subsequent risk of cancer among Finnish men and women. , 1990, Journal of the National Cancer Institute.

[212]  P. Smith,et al.  Intranuclear androgen receptor deployment and protooncogene expression in human diseased prostate. , 1987, Urologia internationalis.

[213]  N. Kyprianou,et al.  Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer. , 1997, International journal of cancer.

[214]  F. S. French,et al.  Isolation of two genomic sequences encoding the Mr = 14,000 subunit of rat prostatein. , 1983, The Journal of biological chemistry.

[215]  Morris Pollard,et al.  Promotional effects of testosterone and high fat diet on the development of autochthonous prostate cancer in rats. , 1986, Cancer letters.

[216]  W. Willett,et al.  Zinc supplement use and risk of prostate cancer. , 2003, Journal of the National Cancer Institute.

[217]  A. Geldof,et al.  Radionuclide therapy for prostate cancer lumbar metastasis prolongs symptom-free survival in a rat model. , 1997, Urology.

[218]  R. Henke,et al.  Numerical chromosomal aberrations in prostate cancer: correlation with morphology and cell kinetics , 2005, Virchows Archiv A.

[219]  Y. Akimoto,et al.  Co-expression of hepatocyte growth factor and its receptor in human prostate cancer , 2004, The Histochemical Journal.

[220]  D. West,et al.  Occupation, Cadmium Exposure, and Prostate Cancer , 1990, Epidemiology.

[221]  V. Khoo,et al.  Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[222]  R. Uzzo,et al.  Zinc inhibits nuclear factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[223]  J. Serth,et al.  Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. , 2003, Oncology reports.

[224]  E A Eisen,et al.  Mortality studies of machining-fluid exposure in the automobile industry. II. Risks associated with specific fluid types. , 1992, Scandinavian journal of work, environment & health.

[225]  J. Ward,et al.  High Incidence and Histogenesis of Seminal Vesicle Adenocarcinoma and Lower Incidence of Prostate Carcinomas in the Lobund-Wistar Prostate Cancer Rat Model Using N-nitrosomethylurea and Testosterone , 1996, Veterinary pathology.

[226]  N. Block,et al.  Enhancement of radiation response of prostatic carcinoma by taxol: therapeutic potential for late-stage malignancy. , 1995, Anticancer research.

[227]  K. Cheeseman,et al.  Tissue Injury by Free Radicals , 1993, Toxicology and industrial health.

[228]  T. Fears,et al.  Insulin-like growth factors and prostate cancer: a population-based case-control study in China. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[229]  M. Vihinen,et al.  Pattern of Somatic Androgen Receptor Gene Mutations in Patients with Hormone-Refractory Prostate Cancer , 2002, Laboratory Investigation.

[230]  G. Haas,et al.  Epidemiology of prostate cancer , 1997, CA: a cancer journal for clinicians.

[231]  S. Batra,et al.  Establishment and characterization of androgen‐independent human prostate cancer LNCaP cell model , 2002, The Prostate.

[232]  M. Steiner,et al.  Expression of transforming growth factor-beta 1 in prostate cancer. , 1994, Endocrinology.

[233]  Reed Jc Mechanisms of Bcl-2 family protein function and dysfunction in health and disease. , 1996 .

[234]  D. Bostwick,et al.  Prostatic intraepithelial neoplasia: Animal models 2000 , 2000, The Prostate.

[235]  S. Fischer,et al.  Black tea polyphenols inhibit IGF-I-induced signaling through Akt in normal prostate epithelial cells and Du145 prostate carcinoma cells. , 2002, Carcinogenesis.

[236]  J. Mendelsohn,et al.  Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor alpha. , 1992, Cancer research.

[237]  A. Partin,et al.  Adenocarcinoma of the prostate invading the seminal vesicle: prognostic stratification based on pathologic parameters. , 2000, Urology.

[238]  B. Furr,et al.  The development of Casodex (bicalutamide): preclinical studies. , 1996, European urology.

[239]  S. Groshen,et al.  Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. , 2001, The Journal of urology.

[240]  C. Cordon-Cardo,et al.  Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[241]  D. Horsfall,et al.  A potential autocrine role for vascular endothelial growth factor in prostate cancer. , 2002, Cancer research.

[242]  T M Grogan,et al.  Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. , 1993, Cancer research.

[243]  S. Newell,et al.  Doppler ultrasound of the prostate in normal dogs and in dogs with chronic lymphocytic-lymphoplasmocytic prostatitis. , 1998, Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association.

[244]  R. Nagle,et al.  The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression. , 1995, Cancer metastasis reviews.

[245]  J. Schleutker,et al.  Association of E-cadherin germ-line alterations with prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[246]  T. Tong,et al.  Cancer statistics, 1993 , 1993, CA: a cancer journal for clinicians.

[247]  S. Orkin,et al.  Targeting of transgene expression to monocyte/macrophages by the gp91-phox promoter and consequent histiocytic malignancies. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[248]  G. Risbridger,et al.  The contribution of inhibins and activins to malignant prostate disease , 2001, Molecular and Cellular Endocrinology.

[249]  J. Ward,et al.  K‐ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men , 1992, Cancer.

[250]  W. Aronson,et al.  Evidence of an inhibitory effect of diet and exercise on prostate cancer cell growth. , 2001, The Journal of urology.

[251]  P. Lipponen,et al.  Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer. , 1997, European urology.

[252]  D. West,et al.  Smoking, alcohol, coffee, tea, caffeine, and theobromine: risk of prostate cancer in Utah (United States) , 1993, Cancer Causes & Control.

[253]  T. Nakamura,et al.  Regulation of fibroblast hepatocyte growth factor/scatter factor expression by human breast carcinoma cell lines and peptide growth factors. , 1993, Cancer research.

[254]  M. Takeichi,et al.  Cadherins: a molecular family important in selective cell-cell adhesion. , 1990, Annual review of biochemistry.

[255]  J. Isaacs,et al.  Response of rat and human prostatic cancers to the novel 5 alpha-reductase inhibitor, SK&F 105657. , 1992, The Prostate.

[256]  D. Neal,et al.  Regulation of FGF8 expression by the androgen receptor in human prostate cancer , 2002, Oncogene.

[257]  A. Schally,et al.  Inhibition of growth of experimental prostate cancer in rats by LH‐RH analogs linked to cytotoxic radicals , 1993, The Prostate.

[258]  M. Pike,et al.  Endogenous hormones as a major factor in human cancer. , 1982, Cancer research.

[259]  J. Papadimitriou,et al.  Progressive increase of apoptosis in prostatic intraepithelial neoplasia and carcinoma: comparison between in situ end-labeling of fragmented DNA and detection by routine hematoxylin-eosin staining. , 1997, Archives of pathology & laboratory medicine.

[260]  R. Jackson,et al.  Prostate cancer risk and consumption of fish oils: a dietary biomarker-based case–control study , 1999, British Journal of Cancer.

[261]  W Blumenfeld,et al.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.

[262]  E. Barrack TGFβ in prostate cancer: A growth inhibitor that can enhance tumorigenicity , 1997 .

[263]  P. Troncoso,et al.  Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. , 1994, Urology.

[264]  Ximing J. Yang,et al.  P504S/&agr;-Methylacyl-CoA Racemase: A Useful Marker for Diagnosis of Small Foci of Prostatic Carcinoma on Needle Biopsy , 2002, The American journal of surgical pathology.

[265]  M. Steiner,et al.  Immunohistochemical localization of TGFβ1, TGFβ2, and TGFβ3 in normal and malignant human prostate , 1997 .

[266]  A. Thorburn,et al.  Caspase- and serine protease-dependent apoptosis by the death domain of FADD in normal epithelial cells. , 2003, Molecular biology of the cell.

[267]  D. Anderson,et al.  Breast cancer risks in relatives of male breast cancer patients. , 1992, Journal of the National Cancer Institute.

[268]  W. Fair,et al.  Overexpression of protein kinase C-zeta (PKC-zeta) inhibits invasive and metastatic abilities of Dunning R-3327 MAT-LyLu rat prostate cancer cells. , 1996, Cancer research.

[269]  W. Willett,et al.  PREDIAGNOSTIC SERUM SELENIUM AND RISK OF CANCER , 1983, The Lancet.

[270]  J. Schalken,et al.  Cadherin switching in human prostate cancer progression. , 2000, Cancer research.

[271]  P. Troncoso,et al.  Loss of heterozygosity in human primary prostate carcinomas: a possible tumor suppressor gene at 7q31.1. , 1994, Cancer research.

[272]  E. Rimm,et al.  Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. , 1998, Journal of the National Cancer Institute.

[273]  H. Grönberg,et al.  Studies of genetic factors in prostate cancer in a twin population. , 1994, The Journal of urology.

[274]  J. Frelinger,et al.  Signaling to a B-cell clone by Ek, but not Ak, does not reflect alteration of Ak genes , 2004, Immunogenetics.

[275]  J. Brooks,et al.  Polymorphisms in the androgen receptor and type II 5α‐reductase genes and prostate cancer prognosis , 2002, The Prostate.

[276]  W. Isaacs,et al.  A novel human cell culture model for the study of familial prostate cancer. , 2001, Cancer research.

[277]  K. Pienta,et al.  The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells. , 1991, The Journal of urology.

[278]  L. Kolonel Nutrition and prostate cancer , 2004, Cancer Causes & Control.

[279]  E. Bergstralh,et al.  Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. , 2002, The Journal of urology.

[280]  G. Hudes,et al.  Signaling Inhibitors in the Treatment of Prostate Cancer , 2002, Investigational New Drugs.

[281]  J. Moul,et al.  Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. , 1995, The Journal of urology.

[282]  M. Papa,et al.  Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. , 1993, The Journal of clinical endocrinology and metabolism.

[283]  G. Miller,et al.  Comparison of ras activation in prostate carcinoma in Japanese and American men , 1997, The Prostate.

[284]  R. Vessella,et al.  Preclinical models of prostate cancer. , 1996, Seminars in oncology.

[285]  Z. Su,et al.  Translational infidelity and human cancer: role of the PTI-1 oncogene. , 1999, The international journal of biochemistry & cell biology.

[286]  Christoph Wagener,et al.  Down-regulation of CEACAM1 in human prostate cancer: correlation with loss of cell polarity, increased proliferation rate, and Gleason grade 3 to 4 transition. , 2002, Human pathology.

[287]  A. Waheed,et al.  Protection of prostatic acid phosphatase activity in human serum samples by plasmin inhibitors. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[288]  R. Nagle,et al.  Unique expression pattern of the alpha6beta4 integrin and laminin-5 in human prostate carcinoma. , 2001, The Prostate.

[289]  P. Humphrey,et al.  Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer. , 2001, The Journal of urology.

[290]  N. Kanomata,et al.  Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone. , 2001, Cancer research.

[291]  Wei Zhang,et al.  p63 expression profile in normal and malignant prostate epithelial cells. , 2002, Anticancer Research.

[292]  M. Shibata,et al.  Development and characterization of a mouse prostate adenocarcinoma cell line: Ductal formation determined by extracellular matrix , 1998, The Prostate.

[293]  G. Blackledge,et al.  High-dose bicalutamide monotherapy for the treatment of prostate cancer. , 1996, Urology.

[294]  H. Yamanaka,et al.  Vitamin D receptor gene polymorphism in familial prostate cancer in a Japanese population , 2003, International journal of urology : official journal of the Japanese Urological Association.

[295]  M. Webber,et al.  Acinar Differentiation by Non-malignant Immortalized Human Prostatic Epithelial Cells and Its Loss by Malignant Cells Expression of the Basement Membrane Protein Laminin, Cell Adhesion Molecules Such as Cadherins and Integrin Receptors for Extracellular Matrix (ecm) Proteins. Normal Expression Of , 2022 .

[296]  J. Lloreta,et al.  Her-2/neu Expression in Prostate Cancer , 2004, Clinical Cancer Research.

[297]  P. Chaurand,et al.  A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. , 2001, Cancer research.

[298]  E. Lund,et al.  Physical activity and the risk of prostate and testicular cancer: a cohort study of 53,000 Norwegian men , 1994, Cancer Causes & Control.

[299]  A. P. Soler,et al.  Expression of P-cadherin identifies prostate-specific-antigen-negative cells in epithelial tissues of male sexual accessory organs and in prostatic carcinomas. Implications for prostate cancer biology. , 1997, The American journal of pathology.

[300]  M. Goldacre,et al.  Incidence of disease after vasectomy: a record linkage retrospective cohort study. , 1992, BMJ.

[301]  Morris Pollard,et al.  The lobund‐wistar rat model of prostate cancer , 1992, Journal of cellular biochemistry. Supplement.

[302]  M. Parker,et al.  Tissue-specific and hormonal regulation of the gene for rat prostatic steroid-binding protein in transgenic mice , 1989, Molecular and cellular biology.

[303]  E. Bergstralh,et al.  Aneusomies of chromosomes 8 and Y detected by fluorescence in situ hybridization are prognostic markers for pathological stage C (pt3N0M0) prostate carcinoma. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[304]  L. Vatten,et al.  Prediagnostic level of fatty acids in serum phospholipids: omega-3 and omega-6 fatty acids and the risk of prostate cancer. , 1997, International journal of cancer.

[305]  R. Wennrich,et al.  Determination of the distribution of Zinc and Cadmium in cellular fractions of BPH, normal prostate and prostatic cancers of different histologies by atomic and laser absorption spectrometry in tissue slices , 2004, Urological research.

[306]  J. V. D. van der Gulden,et al.  Work environment and prostate cancer risk , 1995, The Prostate.

[307]  Inmaculada Hernández,et al.  Isolation and characterization of mouse probasin: An androgen‐regulated protein specifically expressed in the differentiated prostate , 2000, The Prostate.

[308]  R. Russell,et al.  Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. , 1992, British Journal of Cancer.

[309]  E. Gelmann,et al.  Molecular biology of the androgen receptor. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[310]  J. Blom,et al.  Morphometrically estimated variation in nuclear size , 1990, Urological Research.

[311]  S. Fosså,et al.  Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: impact on time to progression. The European Organization for Research and Treatment of Cancer Genitourinary Group. , 1993, The Journal of urology.

[312]  A J Bailey,et al.  Changes in collagen metabolism in prostate cancer: a host response that may alter progression. , 2001, The Journal of urology.

[313]  P. Walsh A prospective study on the intake of animal products and risk of prostate cancer. , 2002, The Journal of urology.

[314]  M. Barbacid,et al.  Molecular characterization of the human trk oncogene. , 1986, Cold Spring Harbor symposia on quantitative biology.

[315]  H. Klingler,et al.  Local Intratumoral Tumor Necrosis Factor-α and Systemic IFN-α2b in Patients with Locally Advanced Prostate Cancer , 2001 .

[316]  Daniel S. Miller,et al.  Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. , 2000, Archives of pathology & laboratory medicine.

[317]  E. Bergstralh,et al.  Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ‐confined prostate cancer , 2002, Genes, chromosomes & cancer.

[318]  S. Schwartz,et al.  Prostate cancer and other xenografts from cells in peripheral blood of patients. , 2000, Cancer research.

[319]  H. G. van der Poel,et al.  Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization. , 1993, Cancer research.

[320]  C. Cordon-Cardo,et al.  Inverse associations between plasma lycopene and other carotenoids and prostate cancer. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[321]  H. Grönberg,et al.  Familial prostate cancer and possible associated malignancies: Nation‐wide register cohort study in Sweden , 1998, International journal of cancer.

[322]  G. Hill,et al.  A Case-Control Study , 2006 .

[323]  W. Gage,et al.  GSTA1 expression in normal, preneoplastic, and neoplastic human prostate tissue , 2001, The Prostate.

[324]  F. S. French,et al.  Expression and localization of androgen receptor in the R-3327 Dunning rat prostatic adenocarcinoma. , 1990, Cancer research.

[325]  C. Friedenreich,et al.  A review of physical activity and prostate cancer risk , 2001, Cancer Causes & Control.

[326]  J Siemiatycki,et al.  Associations between cigarette smoking and each of 21 types of cancer: a multi-site case-control study. , 1995, International journal of epidemiology.

[327]  D. Grignon,et al.  Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. , 1995, Cancer research.

[328]  L A Kalish,et al.  Family history and the risk of prostate cancer. , 2000, Urology.

[329]  R L Vessella,et al.  Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration , 1996, International journal of cancer.

[330]  M. Spitz,et al.  Vasectomy and prostate cancer risk in China. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[331]  M. Stearns,et al.  Isolation and characterization of PC-3 human prostatic tumor sublines which preferentially metastasize to select organs in S.C.I.D. mice. , 1991, Differentiation; research in biological diversity.

[332]  R. Jackson,et al.  Height-related risk factors for prostate cancer , 1999, British Journal of Cancer.

[333]  Y. Furuya,et al.  CAG polymorphic repeat lengths in androgen receptor gene among Japanese prostate cancer patients: Potential predictor of prognosis after endocrine therapy , 2002, The Prostate.

[334]  F. Koga,et al.  Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma , 1997, Cancer.

[335]  B. Henderson,et al.  Vitamin A, β-Carotene, and the Risk of Cancer: A Prospective Study , 1987 .

[336]  C. Olsson,et al.  Development of a hammerhead ribozyme against BCL-2. II. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents. , 1997, Anticancer research.

[337]  M. Stearns,et al.  Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases. , 1992, Cancer research.

[338]  J. Stanford,et al.  The association of fatty acids with prostate cancer risk , 2001, The Prostate.

[339]  M. T. Story Regulation of prostate growth by fibroblast growth factors , 2004, World Journal of Urology.

[340]  Morris Pollard,et al.  Prevention of prostate cancer and liver tumors in L‐W rats by moderate dietary restriction , 1989, Cancer.

[341]  C. Wakasugi,et al.  Immunocytochemical demonstration of prostatic acid phosphatase: different secretion kinetics between normal, hyperplastic and neoplastic prostates. , 1985, The Journal of urology.

[342]  E. Negri,et al.  Fraction of prostate cancer incidence attributed to diet in Athens, Greece. , 2000, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[343]  A. Traish,et al.  Prostatic epidermal growth factor receptors and their regulation by androgens. , 1987, Endocrinology.

[344]  K Yogesan,et al.  Entropy-based texture analysis of chromatin structure in advanced prostate cancer. , 1996, Cytometry.

[345]  T. Therneau,et al.  Stage C prostatic adenocarcinoma: flow cytometric nuclear DNA ploidy analysis. , 1989, Mayo Clinic proceedings.

[346]  G. Miller Pathologic aspects of prostate cancer: prediction of malignant potential. , 1989, Urology.

[347]  P. Scardino,et al.  Alterations in mrna levels for growth‐related genes after transplantation into castrated hosts in oncogene‐induced clonal mouse prostate carcinoma , 1992, Molecular carcinogenesis.

[348]  K. Pienta,et al.  Stromal factors involved in prostate carcinoma metastasis to bone , 2003, Cancer.

[349]  D. Bostwick,et al.  Determination of gene and chromosome dosage in prostatic intraepithelial neoplasia and carcinoma. , 1998, Analytical and quantitative cytology and histology.

[350]  R. Eeles,et al.  Molecular markers for predicting prostate cancer stage and survival , 2000, BJU international.

[351]  R. Wennrich,et al.  Serum-Zn-levels in prostatic cancer , 2004, Urological Research.

[352]  D. Bostwick c-erbB-2 oncogene expression in prostatic intraepithelial neoplasia: mounting evidence for a precursor role. , 1994, Journal of the National Cancer Institute.

[353]  I. Thompson,et al.  Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men. , 2002, The Journal of urology.

[354]  J. Enstrom Cancer mortality among Mormons in California during 1968--75. , 1980, Journal of the National Cancer Institute.

[355]  M. Thun,et al.  Family History of Breast Cancer as a Predictor for atal Prostate Cancer , 1998, Epidemiology.

[356]  S. Devesa,et al.  International trends and patterns of prostate cancer incidence and mortality , 2000, International journal of cancer.

[357]  M. Webber,et al.  Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. , 1997, Carcinogenesis.

[358]  L. Gold,et al.  Endogenous mutagens and the causes of aging and cancer. , 1991, Mutation research.

[359]  C. Perez-stable,et al.  Prostate, adrenocortical, and brown adipose tumors in fetal globin/T antigen transgenic mice. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[360]  D. Bostwick,et al.  Independent origin of multiple foci of prostatic intraepithelial neoplasia , 1998, Cancer.

[361]  D. W. Hayden,et al.  Prostatic intraepithelial neoplasia in dogs with spontaneous prostate cancer , 1997, The Prostate.

[362]  R. Goldbohm,et al.  Vegetable and fruit consumption and prostate cancer risk: a cohort study in The Netherlands. , 1998, Cancer Epidemiology, Biomarkers and Prevention.

[363]  G. Kass,et al.  Oxidative stress in mitochondria: its relationship to cellular Ca2+ homeostasis, cell death, proliferation, and differentiation. , 1991, Chemico-biological interactions.

[364]  R. Hayes,et al.  Dietary factors and risks for prostate cancer among blacks and whites in the United States. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[365]  R. Nagle,et al.  Characterization of integrin subunits, cellular adhesion and tumorgenicity of four human prostate cell lines , 1993, Journal of Cancer Research and Clinical Oncology.

[366]  R. Hurst,et al.  Pan-cadherin as a high level phenotypic biomarker for prostate cancer. , 2002, The Journal of urology.

[367]  A. Geick,et al.  Uteroglobin promoter-targeted c-MYC expression in transgenic mice cause hyperplasia of Clara cells and malignant transformation of T-lymphoblasts and tubular epithelial cells , 2001, Transgenic Research.

[368]  M. Spitz,et al.  Phytoestrogen intake and prostate cancer: a case-control study using a new database. , 1999, Nutrition and cancer.

[369]  J. Richie,et al.  Expression of telomerase subunits in normal and neoplastic prostate epithelial cells isolated by laser capture microdissection , 2001, Cancer.

[370]  C. Mettlin,et al.  Vasectomy and prostate cancer risk. , 1990, American journal of epidemiology.

[371]  E. Wills,et al.  Site‐specific growth of the prostate xenograft line UCRU‐PR‐2 , 1989, The Prostate.

[372]  B W Turnbull,et al.  Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. , 1996, JAMA.

[373]  J. Figge,et al.  Association of p53 immunoreactivity with high gleason tumor grade in prostatic adenocarcinoma. , 1994, Human pathology.

[374]  R. Bedwal,et al.  Zinc, copper and selenium in reproduction , 1994, Experientia.

[375]  H. Steller Mechanisms and genes of cellular suicide , 1995, Science.

[376]  J. Folkman,et al.  Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. , 2001, The Journal of urology.

[377]  M. Stearns,et al.  Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue. , 1993, Cancer research.

[378]  E. Hoal-van Helden,et al.  Detection by DNA fingerprinting of somatic changes during the establishment of a new prostate cell line. , 1994, British Journal of Cancer.

[379]  B. Babior,et al.  JFC1 is transcriptionally activated by nuclear factor-kappaB and up-regulated by tumour necrosis factor alpha in prostate carcinoma cells. , 2002, The Biochemical journal.

[380]  F. Locke,et al.  Cancer mortality risk among Japanese in the United States. , 1980, Journal of the National Cancer Institute.

[381]  L. Chaudhary,et al.  Proprotein convertases regulate activity of prostate epithelial cell differentiation markers and are modulated in human prostate cancer cells , 2003, Journal of cellular biochemistry.

[382]  M. Thun,et al.  Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[383]  A. Hanlon,et al.  Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer. , 2001, Urology.

[384]  S. Rabbani,et al.  Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. , 2002, Cancer research.

[385]  T. Bouras,et al.  Expression of the prostate cancer metastasis suppressor gene KAI1 in primary prostate cancers: a biphasic relationship with tumour grade , 1999, The Journal of pathology.

[386]  Steven Shea,et al.  Diabetes Mellitus and the Risk of Prostate Cancer , 2002, Cancer investigation.

[387]  Srinivasan Vijayakumar,et al.  Race and serum prostate-specific antigen levels: current status and future directions. , 1998, Seminars in urologic oncology.

[388]  D. Bostwick,et al.  Decrease of prostatic intraepithelialneoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy , 1994 .

[389]  M. Amirkhosravi,et al.  Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer. , 1994, British Journal of Cancer.

[390]  R. Ostenson,et al.  Human primary prostate tumor cell line, ALVA‐31: A new model for studying the hormonal regulation of prostate tumor cell growth , 1993, The Prostate.

[391]  A. Angelsen,et al.  Neuroendocrine cells in the prostate of the rat, guinea pig, cat, and dog , 1997, The Prostate.

[392]  K. Miura,et al.  The expression of the KAI1 gene, a tumor metastasis suppressor, is directly activated by p53. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[393]  J. Hankin,et al.  Vitamin A and prostate cancer in elderly men: enhancement of risk. , 1987, Cancer research.

[394]  Masatoshi Watanabe,et al.  Allelic Loss and Microsatellite Instability in Prostate Cancers in Japan , 1998, Oncology.

[395]  B. Norlén,et al.  Differential gene expression of steroid 5 alpha-reductase 2 in core needle biopsies from malignant and benign prostatic tissue. , 1997, The Journal of clinical endocrinology and metabolism.

[396]  T. Sun,et al.  Proximal location of mouse prostate epithelial stem cells , 2002, The Journal of cell biology.

[397]  K. Junker,et al.  Gain in chromosome 8q correlates with early progression in hormonal treated prostate cancer. , 2002, European urology.

[398]  C. Wilson,et al.  Antipeptide antibodies to two distinct regions of the androgen receptor localize the receptor protein to the nuclei of target cells in the rat and human prostate. , 1990, Endocrinology.

[399]  L. Chung,et al.  Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. , 1994, Cancer research.

[400]  J. Barrett,et al.  Differential suppression of mammary and prostate cancer metastasis by human chromosomes 17 and 11. , 1994, Cancer research.

[401]  G. Friedman,et al.  5 alpha-reductase activity and prostate cancer: a case-control study using stored sera. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[402]  J. Horm,et al.  Socioeconomic factors and cancer incidence among blacks and whites. , 1991, Journal of the National Cancer Institute.

[403]  O. Ogawa Risk Factors for Prostate Cancer , 2004 .

[404]  P. Troncoso,et al.  c-met proto-oncogene expression in benign and malignant human prostate tissues. , 1995, The Journal of urology.

[405]  R. Goldbohm,et al.  A case-cohort study on prostate cancer risk in relation to family history of prostate cancer. , 1999, Epidemiology.

[406]  H. Morrison,et al.  The impending Canadian prostate cancer epidemic. , 1995, Canadian journal of public health = Revue canadienne de sante publique.

[407]  P. Ray,et al.  Inhibitory Effect of Amiloride on the Urokinase Plasminogen Activators in Prostatic Cancer , 1997, Tumor Biology.

[408]  G. Stemmermann,et al.  Geographic pathology of latent prostatic carcinoma , 1982, International journal of cancer.

[409]  R. Poulsom,et al.  Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. , 2002, Cancer research.

[410]  S. Loening,et al.  Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer , 2000, The Prostate.

[411]  W. Vogel,et al.  Linkage of aggressive prostate cancer to chromosome 7q31-33 in German prostate cancer families , 2003, European Journal of Human Genetics.

[412]  F. Faas,et al.  Increased phospholipid fatty acid remodeling in human and rat prostatic adenocarcinoma tissues. , 1996, The Journal of urology.

[413]  S. Fukushima,et al.  Induction of prostate carcinoma in situ at high incidence in F344 rats by a combination of 3,2'-dimethyl-4-aminobiphenyl and ethinyl estradiol. , 1986, Cancer research.

[414]  W. L. Beeson,et al.  Cohort study of diet, lifestyle, and prostate cancer in adventist men , 1989, Cancer.

[415]  J. Barton,et al.  Anti-EGF receptor therapy , 2000, Prostate Cancer and Prostatic Diseases.

[416]  J. Epstein The evaluation of radical prostatectomy specimens. Therapeutic and prognostic implications. , 1991, Pathology annual.

[417]  P. A. Sant'agnese,et al.  Neuroendocrine differentiation in prostatic adenocarcinoma does not represent true Paneth cell differentiation. , 1994 .

[418]  N. Kyprianou,et al.  bcl‐2 over‐expression delays radiation‐induced apoptosis without affecting the clonogenic survival of human prostate cancer cells , 1997, International journal of cancer.

[419]  M. Ozturk,et al.  ras, p53 and hpv status in benign and malignant prostate tumors , 1995, International journal of cancer.

[420]  W. Grant An ecologic study of dietary links to prostate cancer. , 1999, Alternative medicine review : a journal of clinical therapeutic.

[421]  F. Hamdy,et al.  The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. , 1997, British journal of urology.

[422]  G. Kramer,et al.  Differential expression of interleukin‐15, a pro‐inflammatory cytokine and T‐cell growth factor, and its receptor in human prostate , 2001, The Prostate.

[423]  W. Ahrens,et al.  Control response proportions in population-based case-control studies in Germany. , 1999, Epidemiology.

[424]  E. Sherwood,et al.  Therapeutic efficacy of recombinant tumor necrosis factor alpha in an experimental model of human prostatic carcinoma. , 1990, Journal of biological response modifiers.

[425]  J. Mohler,et al.  In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer , 1997, Clinical & Experimental Metastasis.

[426]  B. Armstrong,et al.  THE MORTALITY OF CADMIUM WORKERS , 1983, The Lancet.

[427]  T. H. van der Kwast,et al.  The prognostic influence of neuroendocrine cells in prostate cancer: Results of a long‐term follow‐up study with patients treated by radical prostatectomy , 1995, International journal of cancer.

[428]  J. Siemiatycki,et al.  Joint Effects of Smoking and Body Mass Index on Prostate Cancer Risk , 2001, Epidemiology.

[429]  J. Berg Can nutrition explain the pattern of international epidemiology of hormone-dependent cancers? , 1975, Cancer research.

[430]  X. Cai,et al.  High fat diet increases the weight of rat ventral prostate , 2001, The Prostate.

[431]  W. Jiang,et al.  Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells. , 2001, International journal of oncology.

[432]  A. Giatromanolaki,et al.  Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[433]  H. Naiki,et al.  Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. , 1992, Cancer research.

[434]  P. Walsh,et al.  Familial study of prostate cancer in Jamaica. , 1998, Urology.

[435]  S. Milham CANCER MORTALITY PATTERNS ASSOCIATED WITH EXPOSURE TO METALS * , 1976, Annals of the New York Academy of Sciences.

[436]  D. Djakiew,et al.  Expression of p75NTR in a human prostate epithelial tumor cell line reduces nerve growth factor–induced cell growth by activation of programmed cell death , 1998, Molecular carcinogenesis.

[437]  P. Ewings,et al.  A case-control study of cancer of the prostate in Somerset and east Devon. , 1996, British Journal of Cancer.

[438]  H. Nisenbaum,et al.  Strategy for repeat biopsy of patients with prostatic intraepithelial neoplasia detected by prostate needle biopsy. , 1996, The Journal of urology.

[439]  R. Kaaks,et al.  Plasma androgens, IGF-1, body size, and prostate cancer risk: a synthetic review , 2000, Prostate Cancer and Prostatic Diseases.

[440]  J. Cutts Estrone-induced Mammary Tumors in the Rat II. Effect of Alterations in the Hormonal Environment on Tumor Induction, Behavior, and Growth , 1964 .

[441]  P. Brachet,et al.  Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. , 2001, Journal of andrology.

[442]  Lois E. H. Smith,et al.  Molecular profiling of angiogenesis markers. , 2002, The American journal of pathology.

[443]  S. Shapiro,et al.  Family history and prostate cancer risk. , 1996, American journal of epidemiology.

[444]  C. Klaassen,et al.  Effect of several metallothionein inducers on oxidative stress defense mechanisms in rats. , 1995, Toxicology.

[445]  N. Verkaik,et al.  Tissue specific and androgen-regulated expression of human prostate-specific transglutaminase. , 1996, The Biochemical journal.

[446]  M. T. Story,et al.  Characteristics of FGF-receptors expressed by stromal and epithelial cells cultured from normal and hyperplastic prostates. , 1994, Growth factors.

[447]  R. Iozzo,et al.  Widespread expression of perlecan proteoglycan in basement membranes and extracellular matrices of human tissues as detected by a novel monoclonal antibody against domain III and by in situ hybridization. , 1994, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[448]  S. Gupta,et al.  Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice. , 2000, Cancer research.

[449]  K. Imaida,et al.  Lack of chemopreventive effects of lycopene and curcumin on experimental rat prostate carcinogenesis. , 2001, Carcinogenesis.

[450]  D. Grignon,et al.  Allelic loss in locally metastatic, multisampled prostate cancer. , 1994, Cancer research.

[451]  P. Lipponen,et al.  Tumor vascularity and basement membrane structure as prognostic factors in T1-2MO prostatic adenocarcinoma. , 1994, Anticancer research.

[452]  V. Speights,et al.  Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression , 1994, Cancer.

[453]  R. Hayes,et al.  Vasectomy and prostate cancer in US blacks and whites. , 1993, American journal of epidemiology.

[454]  E. U. Thiessen,et al.  Concerning a familial association between breast cancer and both prostatic and uterine malignancies , 1974, Cancer.

[455]  S. Taneja,et al.  Androgen stimulated cellular proliferation in the human prostate cancer cell line LNCaP is associated with reduced retinoblastoma protein expression , 2001, Journal of cellular biochemistry.

[456]  Richard Doll,et al.  Mortality in relation to smoking: 22 years' observations on female British doctors. , 1980, British medical journal.

[457]  A. Pegg,et al.  Effect ofO6-benzylguanine on the response to 1,3-bis(2-chloroethyl)-1-nitrosourea in the Dunning R3327G model of prostatic cancer , 2004, Cancer Chemotherapy and Pharmacology.

[458]  V. Beral,et al.  Case-control study of prostatic cancer in employees of the United Kingdom Atomic Energy Authority. , 1993, BMJ.

[459]  J. Liehr,et al.  Induction of a DNA adduct detectable by 32P-postlabeling in the dorsolateral prostate of NBL/Cr rats treated with estradiol-17 beta and testosterone. , 1995, Carcinogenesis.

[460]  Rakesh Nagarajan,et al.  FOXO Proteins Regulate Tumor Necrosis Factor-related Apoptosis Inducing Ligand Expression , 2002, The Journal of Biological Chemistry.

[461]  R. Severson,et al.  A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. , 1989, Cancer research.

[462]  E. Bruckheimer,et al.  Dihydrotestosterone enhances transforming growth factor-beta-induced apoptosis in hormone-sensitive prostate cancer cells. , 2001, Endocrinology.

[463]  K. Pienta,et al.  Effect of age and race on the survival of men with prostate cancer in the Metropolitan Detroit tricounty area, 1973 to 1987. , 1995, Urology.

[464]  D. Djakiew,et al.  Distribution of nerve growth factor-like protein and nerve growth factor receptor in human benign prostatic hyperplasia and prostatic adenocarcinoma. , 1992, The Journal of urology.

[465]  D. Tindall,et al.  The role of the androgen receptor in prostate cancer. , 2002, Critical reviews in eukaryotic gene expression.

[466]  P. Albert,et al.  Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence , 2002, Cancer.

[467]  L. Bégin,et al.  Vascular endothelial growth factor and signaling in the prostate: more than angiogenesis , 2002, Molecular and Cellular Endocrinology.

[468]  P. Sylvester,et al.  Role of prolactin in modulating the effects of tamoxifen on growth of the dunning R3327 rat prostate adenocarcinoma , 1987, The Prostate.

[469]  J. Drago The induction of NB rat prostatic carcinomas. , 1984, Anticancer research.

[470]  C. Mettlin,et al.  Beta‐carotene and animal fats and their relationship to prostate cancer risk. A case—control study , 1989, Cancer.

[471]  B. Foster,et al.  Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. , 1997, Cancer research.

[472]  R. Palmiter,et al.  Overexpression of TGFα in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast , 1990, Cell.

[473]  M. Thun,et al.  Mortality among a cohort of U.S. cadmium production workers--an update. , 1985, Journal of the National Cancer Institute.

[474]  P. Sluss,et al.  Insulin‐like growth factor I: Action and receptor characterization in human prostate cancer cell lines , 1993, The Prostate.

[475]  P. Scardino,et al.  The frequency of apoptosis correlates with the prognosis of gleason grade 3 adenocarcinoma of the prostate , 1995, Cancer.

[476]  J. Manson,et al.  Cigarette smoking and risk of prostate cancer in the physicians' health study (United States) , 2000, International journal of cancer.

[477]  R. Noble The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. , 1977, Cancer research.

[478]  J. Goldsmith,et al.  Associations of cancer site and type with occupation and industry from the Third National Cancer Survey Interview. , 1977, Journal of the National Cancer Institute.

[479]  D. Djakiew,et al.  Epidermal growth factor (EGF) promotes chemomigration of a human prostate tumor cell line, and EGF immunoreactive proteins are present at sites of metastasis in the stroma of lymph nodes and medullary bone , 1996, The Prostate.

[480]  Jun Wang,et al.  Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate. , 2002, The Journal of nutrition.

[481]  G. Chodak,et al.  Basic fibroblast growth factor in human prostate cancer cells. , 1992, Cancer research.

[482]  R. Goldbohm,et al.  Animal products, calcium and protein and prostate cancer risk in the Netherlands Cohort Study , 1999, British Journal of Cancer.

[483]  C. Lazure,et al.  Prostatic kallikrein hK2, but not prostate‐specific antigen (hK3), activates single‐chain urokinase‐type plasminogen activator , 1997, International journal of cancer.

[484]  R. Houlston,et al.  A systematic review and meta‐analysis of familial prostate cancer risk , 2003, BJU international.

[485]  W. Rosner,et al.  Characterization of ALVA-41 cells, a new human prostatic cancer cell line , 1994, Steroids.

[486]  L. Chung,et al.  LNCaP progression model of human prostate cancer: Androgen‐independence and osseous metastasis , 2000, The Prostate.

[487]  M. Webber Selenium prevents the growth stimulatory effects of cadmium on human prostatic epithelium. , 1985, Biochemical and biophysical research communications.

[488]  Ruth Etzioni,et al.  Androgen receptor polymorphisms and the incidence of prostate cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[489]  M. Steiner,et al.  Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in normal and malignant human prostate. , 1997, The Prostate.

[490]  H. Frierson,et al.  p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. , 1997, The Journal of urology.

[491]  H. Klocker,et al.  Hyperactive androgen receptor in prostate cancer: what does it mean for new therapy concepts? , 1997, Histology and histopathology.

[492]  W. Mckeehan,et al.  Fibroblast growth factor receptor 1 phosphotyrosine 766: molecular target for prevention of progression of prostate tumors to malignancy. , 2002, Cancer research.

[493]  S. Bigler,et al.  Percent free prostate specific antigen and cancer detection in black and white men with total prostate specific antigen 2.5 to 9.9 ng./ml. , 2000, The Journal of urology.

[494]  P. Lipponen,et al.  Mitotic activity and prognosis in prostatic adenocarcinoma , 1995, The Prostate.

[495]  Morris Pollard,et al.  Induction of prostate adenocarcinomas in Lobund Wistar rats by testosterone , 1982, The Prostate.

[496]  P. Guinan,et al.  Re: In vitro characterization of Mat LyLu: a Dunning rat prostate adenocarcinoma tumor subline. , 1985, The Journal of urology.

[497]  D. Williams,et al.  Prostate specific antigen and androgen receptor induction and characterization of an immortalized adult human prostatic epithelial cell line. , 1996, Carcinogenesis.

[498]  D. Rose,et al.  Production of epidermal growth factor and transforming growth factor‐α by the androgen‐responsive LNCaP human prostate cancer cell line , 1990, The Prostate.

[499]  P. Abel,et al.  Expression and functional analysis of voltage-activated Na+ channels in human prostate cancer cell lines and their contribution to invasion in vitro. , 1997, The American journal of pathology.

[500]  M. Parker,et al.  Rat prostatic steroid binding protein: DNA sequence and transcript maps of the two C3 genes. , 1983, The EMBO journal.

[501]  J. Kawamura,et al.  Change in morphological and functional cytodifferentiation induced by seminal vesicle mesenchyme in cell suspensions of rat Dunning prostatic adenocarcinoma cells , 1996, International journal of cancer.

[502]  A. Wolk,et al.  Occupational physical activity and risk for prostate cancer in a nationwide cohort study in Sweden , 2002, British Journal of Cancer.

[503]  J. McKiernan,et al.  Linkage disequilibrium between the androgen receptor gene CAG and GGC repeats in the African-American population , 2002, Current urology reports.

[504]  L. Kolonel,et al.  Vegetable and fruit consumption in relation to prostate cancer risk in Hawaii: a reevaluation of the effect of dietary beta-carotene. , 1991, American journal of epidemiology.

[505]  A. Verbeek,et al.  Smoking and drinking habits in relation to prostate cancer. , 1994, British journal of urology.

[506]  G. Murphy,et al.  LNCaP model of human prostatic carcinoma. , 1983, Cancer research.

[507]  E. Stadtman Protein oxidation and aging , 2006, Science.

[508]  D. Bostwick,et al.  Prostatic Intra‐Epithelial Neoplasia and Early Invasion in Prostate Cancer , 1987, Cancer.

[509]  R. Goldbohm,et al.  Epidemiological studies on brassica vegetables and cancer risk. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[510]  D. Grignon,et al.  Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. , 1995, Urology.

[511]  B. Tribukait Nuclear deoxyribonucleic acid determination in patients with prostate carcinomas: clinical research and application. , 1993, European urology.

[512]  D. Bostwick Progression of prostatic intraepithelial neoplasia to early invasive adenocarcinoma. , 1996, European urology.

[513]  R. Hiipakka,et al.  Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. , 1995, Cancer letters.

[514]  J. Barrett,et al.  Inhibition of tumorigenicity of a murine squamous cell carcinoma (SCC) cell line by a putative tumor suppressor gene on human chromosome 7. , 1994, Oncogene.

[515]  R. Weaver,et al.  The immunohistochemical localization of drug‐metabolizing enzymes in prostate cancer , 1995, The Journal of pathology.

[516]  G. Risbridger,et al.  An in vivo model of prostate carcinoma growth and invasion in bone , 2002, Cell and Tissue Research.

[517]  D. Grignon,et al.  Interobserver Reproducibility in the Diagnosis of Prostatic Intraepithelial Neoplasia , 1995, The American journal of surgical pathology.

[518]  M. Menon,et al.  Effect of vitamin C on prostate cancer cells in vitro: Effect on cell number, viability, and DNA synthesis , 1997, The Prostate.

[519]  I. Pastan,et al.  Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. , 1990, Cancer research.

[520]  Takeshi Urano,et al.  Expression of nm23‐Hl and nm23‐H2 Proteins in Prostate Carcinoma , 1993, Japanese journal of cancer research : Gann.

[521]  A. Carroll,et al.  The SCID mouse mutant: definition, characterization, and potential uses. , 1991, Annual review of immunology.

[522]  H. Morrison,et al.  Monograph series on aging-related diseases: X. Prostate cancer. , 1998, Chronic diseases in Canada.

[523]  B. Helpap Observations on the number, size and localization of nucleoli in hyperplastic and neoplastic prostatic disease , 1988, Histopathology.

[524]  G. Yousef,et al.  Expanded Human Tissue Kallikrein Family – A Novel Panel of Cancer Biomarkers , 2002, Tumor Biology.

[525]  E. Wynder,et al.  Cigarette smoking and prostate cancer: No relation with six measures of lifetime smoking habits in a large case‐control study among U.S. Whites , 1997, The Prostate.

[526]  W. Crowley,et al.  Activin inhibits basal and androgen-stimulated proliferation and induces apoptosis in the human prostatic cancer cell line, LNCaP. , 1996, Endocrinology.

[527]  R. Weale,et al.  FIVE YEARS' GRACE. , 1964, Lancet.

[528]  Morris Pollard,et al.  Autochthonous prostate adenocarcinomas in Lobund‐Wistar rats: A model system , 1988, The Prostate.

[529]  T. H. van der Kwast,et al.  Monoclonal antibody Ki-67 defined growth fraction in benign prostatic hyperplasia and prostatic cancer. , 1989, The Journal of urology.

[530]  V. Reuter,et al.  Glutathione S-transferase PI (GST-pi) class expression by immunohistochemistry in benign and malignant prostate tissue. , 1997, The Journal of urology.

[531]  L. A. Plaskon,et al.  Cigarette smoking and risk of prostate cancer in middle-aged men. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[532]  C. Puah,et al.  Serum testosterone and dihydrotestosterone in carcinoma of the prostate. , 1979, British Journal of Cancer.

[533]  P. Scardino,et al.  Elevated transforming growth factor-beta 1 and beta 3 mRNA levels are associated with ras + myc-induced carcinomas in reconstituted mouse prostate: evidence for a paracrine role during progression. , 1991, Molecular endocrinology.

[534]  F. Mostofi,et al.  Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[535]  I. Leav,et al.  Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma. , 2001, The Prostate.

[536]  Teruhiko Yoshida,et al.  Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. , 1997, Cancer research.

[537]  S. Venitt,et al.  Detection of telomerase activity in human prostate: a diagnostic marker for prostatic cancer? , 1997, British journal of urology.

[538]  K. Pienta,et al.  VCaP, a cell-based model system of human prostate cancer. , 2001, In vivo.

[539]  S. Ghatak,et al.  Age-related changes in the activities of antioxidant enzymes and lipid peroxidation status in ventral and dorsolateral prostate lobes of noble rats. , 1996, Biochemical and biophysical research communications.

[540]  Martin R. Schneider,et al.  Tumorigenesis disrupts hormonal regulation of tenascin expression in regressing Dunning R 3327 H prostate carcinoma. , 1996, Cancer letters.

[541]  E. Small,et al.  Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. , 1999, Cancer research.

[542]  M. Pike,et al.  Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. , 1995, Cancer research.

[543]  A. Partin,et al.  Nuclear morphometry predicts disease‐free interval for clinically localized adenocarcinoma of the prostate treated with definitive radiation therapy , 1999, International journal of cancer.

[544]  E. Bergstralh,et al.  Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy , 2002, Cancer.

[545]  A. Porter,et al.  Target to apoptosis: A hopeful weapon for prostate cancer , 1997, The Prostate.

[546]  V. Laudone,et al.  Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. , 1997, The Journal of urology.

[547]  Avri Ben-Ze've Animal cell shape changes and gene expression , 1991 .

[548]  S. Yeh,et al.  From transforming growth factor-beta signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[549]  S. Shapiro,et al.  The relation of vasectomy to the risk of cancer. , 1994, American journal of epidemiology.

[550]  A. LaCroix,et al.  Nutritional factors and prostate cancer: a case-control study of French Canadians in Montreal, Canada , 1996, Cancer Causes & Control.

[551]  M. Oshimura,et al.  Mapping of metastasis suppressor gene(s) for rat prostate cancer on the short arm of human chromosome 8 by irradiated microcell‐mediated chromosome transfer , 1996, Genes, chromosomes & cancer.

[552]  N. Guseva,et al.  Caspase‐8 activation is necessary but not sufficient for tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL)‐mediated apoptosis in the prostatic carcinoma cell line LNCaP , 2002, The Prostate.

[553]  V. Srikantan,et al.  HEPSIN inhibits cell growth/invasion in prostate cancer cells. , 2002, Cancer research.

[554]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[555]  M. Shurin,et al.  TNF-α protects dendritic cells from prostate cancer-induced apoptosis , 2001, Prostate Cancer and Prostatic Diseases.

[556]  J. Benichou,et al.  Body size and prostate cancer: a population-based case-control study in China. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[557]  R. Hiipakka,et al.  Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[558]  S. Prahalada,et al.  Effect of castration, DES, flutamide, and the 5α‐reductase inhibitor, MK‐906, on the growth of the dunning rat prostatic carcinoma, R‐3327 , 1991, The Prostate.

[559]  K. Jackson,et al.  Dibenzoylmethane induces cell cycle deregulation in human prostate cancer cells. , 2002, Cancer letters.

[560]  W. Welshons,et al.  Intrauterine position effects on steroid metabolism and steroid receptors of reproductive organs in male mice. , 1992, Biology of reproduction.

[561]  P. Humphrey,et al.  Repeat biopsy strategy in men with isolated prostatic intraepithelial neoplasia on prostate needle biopsy. , 1996, The Journal of urology.

[562]  L. Chung,et al.  Hormone-induced morphogenesis and growth: role of mesenchymal-epithelial interactions. , 1983, Recent progress in hormone research.

[563]  R. Brownson,et al.  Physical activity on the job and cancer in Missouri. , 1991, American journal of public health.

[564]  K. Griffiths,et al.  Lignans and isoflavonoids in plasma and prostatic fluid in men: Samples from Portugal, Hong Kong, and the United Kingdom , 1997, The Prostate.

[565]  J. Ravetch,et al.  FcR γ chain deletion results in pleiotrophic effector cell defects , 1994, Cell.

[566]  E. Baldi,et al.  The androgen receptor and prostate cancer invasion , 2006, Molecular and Cellular Endocrinology.

[567]  J. E. Dunn,et al.  Smoking and mortality: A prospective study , 1970, Cancer.

[568]  Z. Su,et al.  Identification of the human prostatic carcinoma oncogene PTI-1 by rapid expression cloning and differential RNA display. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[569]  V. Castronovo,et al.  Detection of the 67–kD Laminin Receptor in Prostate Cancer Biopsies as a Predictor of Recurrence after Radical Prostatectomy , 2001, European Urology.

[570]  Seong-Jin Kim,et al.  The Androgen Receptor Represses Transforming Growth Factor-β Signaling through Interaction with Smad3* , 2002, The Journal of Biological Chemistry.

[571]  J. Williams,et al.  Cloning and characterization of androgen-dependent mRNA from rat ventral prostate. , 1980, The Journal of biological chemistry.

[572]  J. Hoxie,et al.  The nerve growth factor receptor gene is at human chromosome region 17q12-17q22, distal to the chromosome 17 breakpoint in acute leukemias. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[573]  Matthias Kretzler,et al.  Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. , 2002, The American journal of pathology.

[574]  J. Epstein,et al.  Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. , 2003, The Journal of urology.

[575]  C. Dinney,et al.  Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[576]  A. Whittemore,et al.  Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[577]  L. Vatten,et al.  Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[578]  Guate,et al.  Expression of p75LNGFR and Trk neurotrophin receptors in normal and neoplastic human prostate , 1999, BJU international.

[579]  I. Eltoum,et al.  Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). , 2001, Cancer research.

[580]  D. Djakiew,et al.  Molecular characterization of the loss of p75NTR expression in human prostate tumor cells , 2001, Molecular carcinogenesis.

[581]  M. Steiner,et al.  Transforming growth factor beta as a clinical biomarker for prostate cancer. , 1997, Urology.

[582]  B. Foster,et al.  Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression , 2003, The Prostate.

[583]  W. Sakr,et al.  Fluorescence in situ hybridization analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer. , 1994, Cancer research.

[584]  M. Kornfeld,et al.  Teratogenesis and carcinogenesis in rat offspring after transplacental and transmammary exposure to diethylstilbestrol. , 1979, Biochemical pharmacology.

[585]  L. Kolonel,et al.  Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States) , 1998, Cancer Causes & Control.

[586]  M. Colecchia,et al.  Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy. , 1997, Journal of clinical pathology.

[587]  L. Vatten,et al.  Prediagnostic level of fatty acids in serum phospholipids: Ω‐3 and Ω‐6 fatty acids and the risk of prostate cancer , 1997 .

[588]  A. Potti,et al.  Prevalence of pesticide exposure in young males (, 2003, Journal of carcinogenesis.

[589]  A. Dellipizzi,et al.  TNF‐mediated cytotoxicity and resistance in human prostate cancer cell lines , 1996, The Prostate.

[590]  T. Kjellstrom,et al.  Cancer mortality of cadmium workers. , 1985, British journal of industrial medicine.

[591]  E. Schaafsma,et al.  Use of monoclonal antibodies to keratin 7 in the differential diagnosis of adenocarcinomas. , 1990, The American journal of pathology.

[592]  S. Sheng The Urokinase-type Plasminogen Activator System in Prostate Cancer Metastasis , 2004, Cancer and Metastasis Reviews.

[593]  J. Lewin,et al.  Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[594]  Clemmons Dr,et al.  Regulation of IGFBP secretion and modulation of cell growth in MDBK cells. , 1993 .

[595]  S. Greenland,et al.  Vasectomy, cigarette smoking, and age at first sexual intercourse as risk factors for prostate cancer in middle-aged men. , 1988, British Journal of Cancer.

[596]  M. Poutanen,et al.  Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer. , 1997, Cancer research.

[597]  A. Karhu,et al.  Steroid-involved transcriptional regulation of human genes encoding prostatic acid phosphatase, prostate-specific antigen, and prostate-specific glandular kallikrein. , 1997, Endocrinology.

[598]  B. Ames,et al.  Dietary carcinogens and anticarcinogens. Oxygen radicals and degenerative diseases. , 1983, Science.

[599]  H. Frierson,et al.  Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate. , 2000, Urology.

[600]  J. Brooks,et al.  Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas , 1995, The Prostate.

[601]  K. Pienta,et al.  The Role of αvβ3 in Prostate Cancer Progression , 2002 .

[602]  W. See,et al.  Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines , 1995, The Prostate.

[603]  D. Albanes,et al.  Effects of long-term alpha-tocopherol supplementation on serum hormones in older men. , 2001, The Prostate.

[604]  F. Speizer,et al.  A retrospective cohort study of vasectomy and prostate cancer in US men. , 1993, JAMA.

[605]  P. L. Haywood-Reid,et al.  Quantification of integrin subunits on human prostatic cell lines—Comparison of nontumorigenic and tumorigenic lines , 1997, The Prostate.

[606]  A. Ronco,et al.  Foods, nutrients and prostate cancer: a case–control study in Uruguay , 1999, British Journal of Cancer.

[607]  C. Mantzoros,et al.  Serum levels of insulin-like growth factor-1 and insulin-like growth factor-1 binding proteins after radical prostatectomy. , 2002, The Journal of urology.

[608]  G. Jenster,et al.  Androgen receptor mutations , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[609]  T. Koyanagi,et al.  Establishment and characterization of monoclonal antibody against androgen receptor. , 1989, Journal of steroid biochemistry.

[610]  E. Small,et al.  Independent association of angiogenesis index with outcome in prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[611]  L. Kolonel,et al.  Dietary fat and prostate cancer: current status. , 1999, Journal of the National Cancer Institute.

[612]  T. Jung,et al.  Apoptosis and nuclear shapes in benign prostate hyperplasia and prostate adenocarcinoma: Comparison with and relation to Gleason score , 1999, International journal of urology : official journal of the Japanese Urological Association.

[613]  M. O’Bryan,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Expression and Localization of Activin Subunits and Follistatins in Tissues from Men with High Grade Prostate Cancer , 2022 .

[614]  ME Gleave,et al.  Castration-induced upregulation of insulin-like growth factor binding protein-5 potentiates IGF-1 and accelerates androgen-independent progression in prostate cancer , 2000, Prostate Cancer and Prostatic Diseases.

[615]  L. Signorello,et al.  Diet and cancer of the prostate: a case‐control study in Greece , 1999, International journal of cancer.

[616]  J. Isaacs,et al.  Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. , 1996, Cancer research.

[617]  C. Magi-Galluzzi,et al.  Apoptotic bodies in prostatic intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ablation. , 1995, Pathology, research and practice.

[618]  H. Lilja,et al.  Beta microseminoprotein is not a prostate-specific protein. Its identification in mucous glands and secretions. , 1990, The American journal of pathology.

[619]  A. Polednak College athletics, body size, and cancer mortality , 1976, Cancer.

[620]  P. Lipponen,et al.  Expression of the Apoptosis suppressing protein bcl‐2 in prostatic adenocarcinoma is related to tumor malignancy , 1997, The Prostate.

[621]  M. Cohen,et al.  Cellular adhesion molecules in urologic malignancies. , 1997, American journal of clinical pathology.

[622]  R. Lahtonen Zinc and cadmium concentrations in whole tissue and in separated epithelium and stroma from human benign prostatic hypertrophic glands , 1985, The Prostate.

[623]  K. Scott,et al.  Different Phenotypes in Human Prostate Cancer: α6 or α3 Integrin in Cell-extracellular Adhesion Sites , 2002 .

[624]  U. Bergerheim,et al.  Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma , 1991, Genes, chromosomes & cancer.

[625]  N Kavantzas,et al.  Nuclear/Nucleolar morphometry and DNA image cytometry as a combined diagnostic tool in pathology of prostatic carcinoma. , 2001, Journal of experimental & clinical cancer research : CR.

[626]  M. Loda,et al.  Thymosin beta 15: a novel regulator of tumor cell motility upregulated in metastatic prostate cancer. , 1996, Nature medicine.

[627]  D. Neal,et al.  P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. , 1992, British journal of urology.

[628]  E. Schneider,et al.  Oncogene overexpression and de novo drug-resistance in human prostate cancer cells. , 1994, Biochimica et biophysica acta.

[629]  S. Shain,et al.  Biochemical and morphological characterization of clonal AXC rat prostate cancer cells. , 1984, Cancer research.

[630]  J. Southgate,et al.  Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ , 1989, Cell.

[631]  P. Kantoff,et al.  Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[632]  C. Sáez,et al.  Sialomucins are characteristically O-acylated in poorly differentiated and colloid prostatic adenocarcinomas. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[633]  J. Sohn,et al.  Caspase‐3/CPP32 immunoreactivity and its correlation with frequency of apoptotic bodies in human prostatic carcinomas and benign nodular hyperplasias , 2000, Histopathology.

[634]  M. Hearn,et al.  Expression of fibroblast growth factor-8 in adult rat tissues and human prostate carcinoma cells , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[635]  T. Hurley,et al.  Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. , 1998, Journal of the National Cancer Institute.

[636]  B. Haendler,et al.  Androgen-selective gene regulation in the prostate. , 2002, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[637]  M. Kattan,et al.  Perineural invasion of prostate carcinoma cells is associated with reduced apoptotic index , 1996, Cancer.

[638]  M. Harper,et al.  Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue. , 1996, Human Pathology.

[639]  M. Kattan,et al.  Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. , 2001, Urology.

[640]  V. Trachana,et al.  The Significance of PSA/IGF-1 Ratio in Differentiating Benign Prostate Hyperplasia from Prostate Cancer , 2002, Disease markers.

[641]  D. Bostwick,et al.  Prostatic adenocarcinoma with atrophic features: malignancy mimicking a benign process. , 1997, The American journal of surgical pathology.

[642]  E. Wilson,et al.  Zinc potentiation of androgen receptor binding to nuclei in vitro. , 1984, Biochemistry.

[643]  W. Farrell,et al.  Glutathione S-transferase GSTP1 genotypes are associated with response to androgen ablation therapy in advanced prostate cancer. , 2002, Cancer detection and prevention.

[644]  D. Schaid,et al.  Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. , 1996, Cancer research.

[645]  P. Wingo,et al.  An adjustment to the 1997 estimate for new prostate cancer cases , 1997, CA: a cancer journal for clinicians.

[646]  E. Wilson,et al.  Interaction of IGF-binding protein-related protein 1 with a novel protein, neuroendocrine differentiation factor, results in neuroendocrine differentiation of prostate cancer cells. , 2001, The Journal of clinical endocrinology and metabolism.

[647]  G G Klee,et al.  Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. , 1997, Urology.

[648]  P. Weijerman,et al.  Lipofection-mediated immortalization of human prostatic epithelial cells of normal and malignant origin using human papillomavirus type 18 DNA. , 1994, Cancer research.

[649]  A. Auquier,et al.  Association between breast cancer and family malignancies. , 1991, European journal of cancer.

[650]  D. Bell,et al.  The utility of tissue transglutaminase as a marker of apoptosis during treatment and progression of prostate cancer. , 1999, The Journal of urology.

[651]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[652]  M. Resnick,et al.  Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation. , 2002, The Journal of urology.

[653]  J. Isaacs,et al.  CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. , 1997, Cancer research.

[654]  S. Sidney,et al.  Vasectomy and the risk of prostate cancer in a cohort of multiphasic health-checkup examinees: second report , 1991, Cancer Causes & Control.

[655]  K. Miller,et al.  DNA-based detection of prostate cancer in urine after prostatic massage. , 2001, Urology.

[656]  H. Akaza,et al.  Chemoprevention of rat prostate carcinogenesis by use of finasteride or casodex. , 1995, Journal of the National Cancer Institute.

[657]  R. Reiter,et al.  Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. , 2002, Molecular cancer research : MCR.

[658]  Korsmeyer Sj Bcl-2: an antidote to programmed cell death. , 1992 .

[659]  P. Carroll,et al.  Frequent genotype changes at -308, and 488 regions of the tumor necrosis factor-alpha (TNF-alpha) gene in patients with prostate cancer. , 2000, The Journal of urology.

[660]  F. Fauvel-Lafève,et al.  Stromal cells from human benign prostate hyperplasia produce a growth‐inhibitory factor for LNCaP prostate cancer cells, identified as interleukin‐6 , 1996, International journal of cancer.

[661]  Chung Lee,et al.  Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion , 2002, Oncogene.

[662]  D. Bostwick,et al.  Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4. , 2001, The Journal of urology.

[663]  E. Keller,et al.  Interleukin-6 and prostate cancer progression. , 2001, Cytokine & growth factor reviews.

[664]  D. Fuchs,et al.  Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. , 2003, The American journal of pathology.

[665]  C. Moskaluk,et al.  Immunohistochemical expression of π‐class glutathione S‐transferase is down‐regulated in adenocarcinoma of the prostate , 1997, Cancer.

[666]  D. Grignon,et al.  Role of Eicosanoids in Prostate Cancer Progression , 2004, Cancer and Metastasis Reviews.

[667]  K. Honn,et al.  Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications. , 1997, Advances in experimental medicine and biology.

[668]  O. Cussenot,et al.  Oncogene amplifications in early‐stage human prostate carcinomas , 1994, International journal of cancer.

[669]  D. Födinger,et al.  High expression of a CD38-like molecule in normal prostatic epithelium and its differential loss in benign and malignant disease. , 1995, The Journal of urology.

[670]  Y. Hannun,et al.  12(S)-HETE enhancement of prostate tumor cell invasion: selective role of PKC alpha. , 1994, Journal of the National Cancer Institute.

[671]  T. McDonnell,et al.  Bcl-2 accelerates multistep prostate carcinogenesis in vivo , 2000, Oncogene.

[672]  S. Coughlin,et al.  Cigarette smoking as a predictor of death from prostate cancer in 348,874 men screened for the Multiple Risk Factor Intervention Trial. , 1996, American journal of epidemiology.

[673]  H. Sasaki,et al.  Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: A morphometric study , 1992, The Journal of pathology.

[674]  C. Sheehan,et al.  Co-downregulation of cell adhesion proteins alpha- and beta-catenins, p120CTN, E-cadherin, and CD44 in prostatic adenocarcinomas. , 2001, Human pathology.

[675]  B. Henderson,et al.  Intake of vegetables, fruits, beta-carotene, vitamin C and vitamin supplements and cancer incidence among the elderly: a prospective study. , 1992, British Journal of Cancer.

[676]  J. Ross,et al.  Prognostic significance of HER‐2/neu gene amplification status by fluorescence in Situ hybridization of prostate carcinoma , 1997, Cancer.

[677]  D. Grignon,et al.  Evidence for three tumor suppressor gene loci on chromosome 8p in human prostate cancer. , 1995, Cancer research.

[678]  J. Fraumeni,et al.  Tobacco use and prostate cancer: 26-year follow-up of US veterans. , 1991, American journal of epidemiology.

[679]  P. D. de Moor,et al.  Influence of the vitamin D-binding protein on the serum concentration of 1,25-dihydroxyvitamin D3. Significance of the free 1,25-dihydroxyvitamin D3 concentration. , 1981, The Journal of clinical investigation.

[680]  J. Kawamura,et al.  Stereologically estimated mean nuclear volume of prostatic cancer is a reliable prognostic parameter. , 1997, British Journal of Cancer.

[681]  D. Bostwick,et al.  Practical clinical application of predictive factors in prostate cancer. A review with an emphasis on quantitative methods in tissue specimens. , 1998, Analytical and quantitative cytology and histology.

[682]  J. Cheville,et al.  Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen , 2001 .

[683]  Y. Kubota,et al.  Fluorescence in situ hybridization evaluation of c‐myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients , 2000, The Prostate.

[684]  H. Biersack,et al.  Experimental radiotherapy of receptor‐positive human prostate adenocarcinoma with 188Re‐RC‐160, a directly‐radiolabeled somatostatin analogue , 1996, International journal of cancer.

[685]  S. Ripatti,et al.  Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. , 1998, Journal of the National Cancer Institute.

[686]  M. Rubin,et al.  Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy. , 2002, Urology.

[687]  M. Murata,et al.  Progression-linked overexpression of c-Met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers. , 1999, Cancer letters.

[688]  E. Giovannucci,et al.  Tomatoes, Lycopene, and Prostate Cancer , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[689]  J. Ward,et al.  Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: histopathological and molecular biological alterations. , 1996, Cancer research.

[690]  J. Schalken,et al.  Intermediate cells in normal and malignant prostate epithelium express c‐MET: Implications for prostate cancer invasion , 2002, The Prostate.

[691]  H. Birkedal‐Hansen,et al.  Matrix metalloproteinases: a review. , 1993, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[692]  N. Weigel,et al.  Vitamin D and Prostate Cancer , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[693]  M. Pollard Enhancement of metastasis of prostate adenocarcinoma cells by immune-suppressive cyclosporine A. , 1997, Cancer letters.

[694]  N. Clarke,et al.  E‐cadherin and β‐catenin are down‐regulated in prostatic bone metastases , 2002, BJU international.

[695]  J. Trapman,et al.  Androgen-regulated gene expression in prostate cancer. , 1997, Seminars in cancer biology.

[696]  M. Ittmann,et al.  Interleukin-6 is an autocrine growth factor in human prostate cancer. , 2001, The American journal of pathology.

[697]  K. Ellsworth,et al.  Expression of the Type 1 and Type 2 Steroid 5α-Reductases in Human Fetal Tissues , 1995 .

[698]  J. Manson,et al.  β‐carotene supplementation for patients with low baseline levels and decreased risks of total and prostate carcinoma , 1999, Cancer.

[699]  J. Bartlett,et al.  The CAG trinucleotide repeat length in the androgen receptor does not predict the early onset of prostate cancer , 2002, BJU international.

[700]  R. Severson,et al.  Body mass and prostatic cancer: a prospective study. , 1988, BMJ.

[701]  W. Fair,et al.  Growth of heterotopic LNCaP prostate cancer tumor in nude mice is not affected by dietary calcium , 2001, The Prostate.

[702]  M. Borner,et al.  Apoptosis: Its Role in the Development of Malignancies and its Potential as a Novel Therapeutic Target , 1997, The Annals of pharmacotherapy.

[703]  David L. Vaux,et al.  Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells , 1988, Nature.

[704]  M. Tatematsu,et al.  Establishment and Characterization of Three Androgen‐independent, Metastatic Carcinoma Cell Lines from 3,2′‐Dimethyl‐4‐aminobiphenyl‐induced Prostatic Tumors in F344 Rats , 1996, Japanese journal of cancer research : Gann.

[705]  R. Paffenbarger,et al.  Physical activity and its relation to cancer risk: a prospective study of college alumni. , 1994, Medicine and science in sports and exercise.

[706]  S. Clinton The dietary antioxidant network and prostate carcinoma , 1999, Cancer.

[707]  S. Shapiro,et al.  Vasectomy and the risk of prostate cancer. , 1990, American journal of epidemiology.

[708]  L. Kolonel,et al.  Prostate cancer: a current perspective. , 1991, Epidemiologic reviews.

[709]  R. Paffenbarger,et al.  Physical activity and incidence of cancer in diverse populations: a preliminary report. , 1987, The American journal of clinical nutrition.

[710]  R W Veltri,et al.  Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. , 1999, Urology.

[711]  S. Loening,et al.  The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model , 2002, Oncogene.

[712]  R. Lidereau,et al.  Gene amplifications in advanced-stage human prostate cancer , 2004, Urological Research.

[713]  Schwartz Gg,et al.  Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). , 1990 .

[714]  F. Habib,et al.  Metal-androgen interrelationships in carcinoma and hyperplasia of the human prostate. , 1976, The Journal of endocrinology.

[715]  J. Dixon,et al.  The PTEN Tumor Suppressor Protein Inhibits Tumor Necrosis Factor-induced Nuclear Factor κB Activity* , 2001, The Journal of Biological Chemistry.

[716]  D. Neal,et al.  Keratinocyte growth factor activates p38 MAPK to induce stress fibre formation in human prostate DU145 cells , 2001, Oncogene.

[717]  C. Mantzoros,et al.  Risk factors for prostate cancer: a case‐control study in Greece , 1999, International journal of cancer.

[718]  J. Rhim,et al.  ErbB kinases and NDF signaling in human prostate cancer cells , 1997, Oncogene.

[719]  A. Partin,et al.  Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in gleason sum 5 to 7 adenocarcinoma of the prostate , 1997, Cancer.

[720]  D. Chopin,et al.  Apoptosis in Prostate Cancer , 1996 .

[721]  Jun Wang,et al.  Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate , 2002, Molecular and Cellular Endocrinology.

[722]  M. T. Story,et al.  Expression of transforming growth factor beta 1 (TGFβ1), ‐β2, and ‐β3 by cultured human prostate cells , 1996 .

[723]  L. Grimelius,et al.  The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker". , 1989, Pathology, research and practice.

[724]  M. Cohen,et al.  Gross and microscopic pathology of induced prostatic complex tumors arising in Lobund-Wistar rats. , 1994, Cancer research.

[725]  N. Bouck,et al.  Thrombospondin‐1, vascular endothelial growth factor and fibroblast growth factor‐2 are key functional regulators of angiogenesis in the prostate , 2001, The Prostate.

[726]  R. Goldbohm,et al.  Association of energy and fat intake with prostate carcinoma risk: results from The Netherlands Cohort Study. , 1999, Cancer.

[727]  S. Takizawa,et al.  Role of testosterone in the development of radiation-induced prostate carcinoma in rats. , 1978, Gan.

[728]  G. Risbridger,et al.  The role of inhibins and activins in prostate cancer pathogenesis. , 2000, Endocrine-related cancer.

[729]  R. Nagle,et al.  Differential expression of laminin 5 (alpha 3 beta 3 gamma 2) by human malignant and normal prostate. , 1996, The American journal of pathology.

[730]  R. Merrill,et al.  Explaining the difference in prostate cancer mortality rates between white and black men in the United States. , 2000, Urology.

[731]  W. Isaacs,et al.  CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[732]  W. Isaacs,et al.  Detection and analysis of β‐catenin mutations in prostate cancer , 2000 .

[733]  H. Stähelin,et al.  Smoking, plasma vitamins C, E, retinol, and carotene, and fatal prostate cancer: Seventeen‐year follow‐up of the prospective Basel study , 1999, The Prostate.

[734]  R. Vessella,et al.  Glutathione and glutathione S-transferase in benign and malignant prostate cell lines and prostate tissues. , 1996, Biochemical pharmacology.

[735]  M. Pollard,et al.  Spontaneous diseases in aging Lobund-Wistar rats. , 1989, Progress in clinical and biological research.

[736]  J M Holden,et al.  Carotenoid content of fruits and vegetables: an evaluation of analytic data. , 1993, Journal of the American Dietetic Association.

[737]  A. Whittemore,et al.  Lifestyle determinants of 5alpha-reductase metabolites in older African-American, white, and Asian-American men. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[738]  E. Wynder,et al.  Case‐control study of prostate cancer and socioeconomic factors , 1988, The Prostate.

[739]  D. Russell,et al.  Expression and regulation of steroid 5 alpha-reductase in the urogenital tract of the fetal rat. , 1995, Molecular endocrinology.

[740]  S. Catz,et al.  BCL-2 in prostate cancer: A minireview , 2004, Apoptosis.

[741]  C. Dees,et al.  Estrogenic and DNA-damaging activity of Red No. 3 in human breast cancer cells. , 1997, Environmental health perspectives.

[742]  E. Bleecker,et al.  Sequence Variants of α-Methylacyl-CoA Racemase Are Associated with Prostate Cancer Risk , 2002 .

[743]  B. Henderson,et al.  Case-control studies of prostate cancer in blacks and whites in southern California. , 1987, Journal of the National Cancer Institute.

[744]  K. Pienta,et al.  The role of alpha(v)beta(3) in prostate cancer progression. , 2002, Neoplasia.

[745]  D M Parkin,et al.  Cancer Incidence in Five Continents. Comparability and quality of data. , 1992, IARC scientific publications.

[746]  R. Goldbohm,et al.  Energy restriction in childhood and adolescence and risk of prostate cancer: results from the Netherlands Cohort Study. , 2001, American journal of epidemiology.

[747]  J. Foidart,et al.  Loss of type IV collagen alpha 5 and alpha 6 chains in human invasive prostate carcinomas. , 1997, The American journal of pathology.

[748]  D. Bostwick,et al.  Androgen receptor expression in prostatic intraepithelial neoplasia and cancer. , 1999, The Journal of urology.

[749]  P. Henriksson,et al.  Use of a hormone‐sensitive (LNCaP) and a hormone‐resistant (LNCaP‐r) cell line in prostate cancer research , 1997, The Prostate.

[750]  T. Rohan,et al.  Dietary factors and risk of prostate cancer: a case-control study in Ontario, Canada , 1995, Cancer Causes & Control.

[751]  B. Henderson,et al.  Serum androgens and prostate cancer. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[752]  T. Moseley,et al.  Soluble and Transmembrane Isoforms of Novel Interleukin-17 Receptor-like Protein by RNA Splicing and Expression in Prostate Cancer* , 2002, The Journal of Biological Chemistry.

[753]  J. Brooks,et al.  An uncertain role for p53 gene alterations in human prostate cancers. , 1996, Cancer research.

[754]  A. Scorilas,et al.  Serum human glandular kallikrein (hK2) and insulin‐like growth factor 1 (IGF‐1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA , 2003, The Prostate.

[755]  S. Ross,et al.  The mouse mammary tumor virus long terminal repeat directs expression in epithelial and lymphoid cells of different tissues in transgenic mice , 1987, Journal of virology.

[756]  R. Nagle,et al.  Integrin α6 expression in human prostate carcinoma cells is associated with a migratory and invasive phenotypein vitro andin vivo , 1995, Clinical & Experimental Metastasis.

[757]  P. Troncoso,et al.  The significance of DNA‐ploidy and S‐phase fraction in node‐positive (stage D1) prostate cancer treated with androgen ablation , 1997, The Prostate.

[758]  T. Stamey,et al.  Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. , 2001, The Journal of urology.

[759]  J. Crowley,et al.  Design of the Prostate Cancer Prevention Trial (PCPT). , 1995, Controlled clinical trials.

[760]  A. Bex,et al.  Influence of pertussis toxine on local progression and metastasis after orthotopic implantation of the human prostate cancer cell line PC3 in nude mice , 1999, Prostate Cancer and Prostatic Diseases.

[761]  N Ito,et al.  The prostate: a target for carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) derived from cooked foods. , 1997, Cancer research.

[762]  J. Rosen,et al.  Metastatic prostate cancer in a transgenic mouse. , 1996, Cancer research.

[763]  T. Sugimura,et al.  Genetic alterations of androgen receptor gene in Japanese human prostate cancer. , 1997, Japanese journal of clinical oncology.

[764]  M. Kattan,et al.  Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[765]  J. Ross,et al.  Co-downregulation of cell adhesion proteins α- and β-catenins, p120CTN, E-cadherin, and CD44 in prostatic adenocarcinomas , 2001 .

[766]  L. Kolonel,et al.  Animal Fat Consumption and Prostate Cancer: A Prospective Study in Hawaii , 1994, Epidemiology.

[767]  H. Bartsch,et al.  Mechanisms of fat-related modulation of N-nitrosodiethylamine-induced tumors in rats: organ distribution, blood lipids, enzymes and pro-oxidant state. , 1991, Carcinogenesis.

[768]  L. Kolonel,et al.  CADMIUM AND PROSTATIC CARCINOMA , 1977, The Lancet.

[769]  S. Takeha,et al.  Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors. , 1997, The Journal of urology.

[770]  A. Giordano,et al.  Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[771]  J. Boyd,et al.  Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men. , 1995, Cancer research.

[772]  L. Matrisian,et al.  Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. , 1996, The international journal of biochemistry & cell biology.

[773]  G. Aumüller,et al.  Differential expression of 5α‐reductase isoenzymes in the human prostate and prostatic carcinomas , 1996, The Prostate.

[774]  P. Gumerlock,et al.  Human androgen receptor expression in prostate cancer following androgen ablation. , 1997, European urology.

[775]  R. Ziegler,et al.  Alcohol and prostate cancer in the NHANES I epidemiologic follow-up study. First National Health and Nutrition Examination Survey of the United States. , 1999, Annals of epidemiology.

[776]  R. Montironi,et al.  Precursors of prostatic cancer: progression, regression and chemoprevention. , 1996, European urology.

[777]  R. Sütçü,et al.  Prostatic fluid‐free insulin‐like growth factor‐1 in relation to prostate cancer , 2001, BJU international.

[778]  D. Grignon,et al.  Human Prostate Carcinoma Cells Express Functional αIIbβ3 Integrin , 1996 .

[779]  J. Fitzpatrick,et al.  Insulin-like growth factor I and prostate cancer. , 2001, Urology.

[780]  D. Neal,et al.  Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer , 2001, British Journal of Cancer.

[781]  L. Kuller,et al.  Cigarette smoking and serum sex hormones in men. , 1988, American journal of epidemiology.

[782]  A. Seidler,et al.  Association between diesel exposure at work and prostate cancer. , 1998, Scandinavian journal of work, environment & health.

[783]  D. Bostwick,et al.  Loss of chromosome arm 8p loci in prostate cancer: Mapping by quantitative allelic imbalance , 1994, Genes, chromosomes & cancer.

[784]  S. Lindquist,et al.  Hsp104 is required for tolerance to many forms of stress. , 1992, The EMBO journal.

[785]  S. Wannamethee,et al.  Physical activity and risk of cancer in middle-aged men , 2001, British Journal of Cancer.

[786]  R. Custer,et al.  A severe combined immunodeficiency mutation in the mouse , 1983, Nature.

[787]  P. Opolon,et al.  Adenovirus-mediated gene transfer in dog prostate: a preclinical study of a relevant model system for gene therapy of human prostatic cancer , 1999, Prostate Cancer and Prostatic Diseases.

[788]  M. Gleave,et al.  Human prostate cancer model: Roles of growth factors and extracellular matrices , 1992, Journal of cellular biochemistry. Supplement.

[789]  J. Richie,et al.  Expression of cell cycle-regulated proteins in prostate cancer. , 1996, Cancer research.

[790]  S. Loening,et al.  Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. , 2002, European urology.

[791]  A. Dellipizzi,et al.  Effect of tumor necrosis factor-α and interferon-γ on the growth of human prostate cancer cell lines , 1995, Urological Research.

[792]  B. Ireland,et al.  "Farming and prostate cancer mortality". , 1994, American journal of epidemiology.

[793]  E. Riboli,et al.  Ratios of IGF-I, IGF binding protein-3, and prostate-specific antigen in prostate cancer detection. , 2001, The Journal of clinical endocrinology and metabolism.

[794]  T. McDonnell,et al.  Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. , 1997, The Journal of urology.

[795]  P. He,et al.  Dietary butylated hydroxytoluene counteracts with paraquat to reduce the rate of hepatic DNA single strand breaks in senescence-accelerated mice , 1994, Mechanisms of Ageing and Development.

[796]  R. Hayes,et al.  Occupational physical activity, socioeconomic status, and risks of 15 cancer sites in Turkey , 1993, Cancer Causes & Control.

[797]  R. Matusik,et al.  Prostate cancer in a transgenic mouse. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[798]  D. Grignon,et al.  Human prostate carcinoma cells express functional alphaIIb(beta)3 integrin. , 1996, Cancer research.

[799]  D. English,et al.  Smoking and prostate cancer: findings from an Australian case-control study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[800]  J. Manola,et al.  Her-2-neu expression and progression toward androgen independence in human prostate cancer. , 2000, Journal of the National Cancer Institute.

[801]  S. Marklund,et al.  Levels of selenium in plasma and glutathione peroxidase in erythrocytes in patients with prostate cancer or benign hyperplasia. , 1995, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[802]  K. Akakura,et al.  Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer. , 1996, The American journal of pathology.

[803]  A. Wein,et al.  Transurethral biopsy of the prostate for persistently elevated or increasing prostate specific antigen following multiple negative transrectal biopsies. , 1997, The Journal of urology.

[804]  P. Scardino,et al.  Association of p53 mutations with metastatic prostate cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[805]  W. Isaacs,et al.  Detection and analysis of beta-catenin mutations in prostate cancer. , 2000, The Prostate.

[806]  E. Kohn,et al.  An autocrine motility factor secreted by the dunning R‐3327 rat prostatic adenocarcinoma cell subtype AT2.1 , 1991, International journal of cancer.

[807]  J. Swinnen,et al.  Coordinate regulation of lipogenic gene expression by androgens: evidence for a cascade mechanism involving sterol regulatory element binding proteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[808]  R. Kirby,et al.  Prevalence of prostatic intra-epithelial neoplasia (PIN) in biopsies from hospital practice and pilot screening: clinical implications , 1997, Prostate Cancer and Prostatic Diseases.

[809]  A. Schally,et al.  Inhibition of growth of PC‐82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC‐3095 or combination of agonist [D‐Trp6]‐luteinizing hormone‐releasing hormone and somatostatin analog RC‐160 , 1992, The Prostate.

[810]  M. Poupon,et al.  Bone sialoprotein, bone morphogenetic protein 6 and thymidine phosphorylase expression in localized human prostatic adenocarcinoma as predictors of clinical outcome: a clinicopathological and immunohistochemical study of 43 cases. , 2001, The Journal of urology.

[811]  P. Scardino,et al.  Transgenic models for the study of prostate cancer , 1993, Cancer.

[812]  E. Kruse,et al.  Identification by C‐banding of two human prostate tumour cell lines, 1013L and DU 145 , 1989, International journal of cancer.

[813]  M. Schoenberg,et al.  Androgen-receptor gene structure and function in prostate cancer , 2004, World Journal of Urology.

[814]  G. Omenn,et al.  Predictors of serum selenium in cigarette smokers and the lack of association with lung and prostate cancer risk. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[815]  R. Eeles,et al.  Influence of cytokine gene polymorphisms on the development of prostate cancer. , 2002, Cancer research.

[816]  L. Chung,et al.  Androgen-repressed phenotype in human prostate cancer. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[817]  S. Han,et al.  Platelet-derived growth factor (PDGF)-signaling mediates radiation-induced apoptosis in human prostate cancer cells with loss of p53 function. , 1997, International journal of radiation oncology, biology, physics.

[818]  S. Taneja,et al.  Phytoestrogens and prostate cancer: possible preventive role , 1998, The Medical journal of Australia.

[819]  E. Bergstralh,et al.  Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. , 2001, The Journal of urology.

[820]  G. Steiner,et al.  Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues. , 2000, The Journal of urology.

[821]  I. Mori,et al.  Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer , 2001, Pathology international.

[822]  K. Pienta,et al.  E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. , 2001, Human pathology.

[823]  J. Simons,et al.  Development of a high‐efficiency method for gene marking of Dunning prostate cancer cell lines with the enzyme β‐galactosidase , 1996 .

[824]  M. Masai,et al.  Histochemical examination of expression of ras p21 protein and R 1881-binding protein in human prostatic cancers. , 1990, European journal of cancer.

[825]  H. Wiley,et al.  Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-alpha (TGF-alpha) and epidermal growth factor (EGF)/TGF-alpha receptor. , 1993, The Journal of clinical endocrinology and metabolism.

[826]  C. Cordon-Cardo,et al.  Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. , 1994, The Journal of urology.

[827]  D. Bostwick,et al.  Prostatic intraepithelial neoplasia and the origins of prostatic carcinoma. , 1995, Pathology, research and practice.

[828]  U. Bachrach,et al.  Cancer therapy and prevention by green tea: role of ornithine decarboxylase , 2002, Amino Acids.

[829]  D. Albanes,et al.  Diet and prostate cancer risk in a cohort of smokers, with a specific focus on calcium and phosphorus (Finland) , 2000, Cancer Causes & Control.

[830]  R. Strange,et al.  Prostate cancer risk and exposure to ultraviolet radiation: further support for the protective effect of sunlight. , 2003, Cancer letters.

[831]  R. Hayes,et al.  Tobacco use and prostate cancer in Blacks and Whites in the United States , 1994, Cancer Causes & Control.

[832]  Schr,et al.  Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. , 1994, The American journal of pathology.

[833]  U. Stenram,et al.  Differential expression of uPA in an aggressive (DU 145) and a nonaggressive (1013L) human prostate cancer xenograft , 1995, The Prostate.

[834]  E. Bergstralh,et al.  Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors , 1992, Cancer.

[835]  J D Siegal,et al.  Enhanced expression of the c‐myc protooncogene in high‐grade human prostate cancers , 1988, The Prostate.

[836]  L. Oberley,et al.  Expression of antioxidant enzymes in human prostatic adenocarcinoma , 1997, The Prostate.

[837]  A. Hanlon,et al.  Plasma levels of IGF-1, IGF-2, and IGFBP-3 in white and African-American men at increased risk of prostate cancer. , 2001, Urology.

[838]  J. Michaeli,et al.  Expression of basic fibroblast growth factor mRNA in benign prostatic hyperplasia and prostatic carcinoma , 1988, The Prostate.

[839]  J. Mendelsohn,et al.  Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha. , 1991, Cancer research.

[840]  R. Eeles,et al.  Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer. , 2001, Pharmacogenetics.

[841]  E. Barrack,et al.  Image analysis of androgen receptor immunostaining in metastatic prostate cancer heterogeneity as a predictor of response to hormonal therapy , 1993, Cancer.

[842]  M. Stearns,et al.  Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor alpha and beta receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[843]  T. Shuin,et al.  Retinoblastoma gene mutations in primary human prostate cancer , 1995, The Prostate.

[844]  M. Stearns,et al.  Liarozole and 13-cis-retinoic acid anti-prostatic tumor activity. , 1993, Cancer research.

[845]  S. Mohan,et al.  Insulin‐Like Growth Factor (IGF) System Components in Human Prostatic Cancer Cell‐Lines: LNCaP, DU145, and PC‐3 Cells , 1996, International journal of urology : official journal of the Japanese Urological Association.

[846]  R. Montironi,et al.  Prostatic intra-epithelial neoplasia: Expression and location of proliferating cell nuclear antigen in epithelial, endothelial and stromal nuclei , 2005, Virchows Archiv A.

[847]  Jeffrey A. Jones,et al.  Platelet‐derived growth factor induces proliferation of hyperplastic human prostatic stromal cells , 1993, Journal of cellular biochemistry.

[848]  R. Peto,et al.  Haemodilution in acute stroke: Results of the Italian haemodilution trial , 1988 .

[849]  B. Henderson,et al.  The etiology of prostate cancer: What does the epidemiology suggest? , 1983, The Prostate.

[850]  W. Lee,et al.  Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. , 1990, Science.

[851]  F. Sarkar,et al.  Soy isoflavone supplementation in healthy men prevents NF-κB activation by TNF-α in blood lymphocytes , 2001 .

[852]  D. Boyd,et al.  A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis. , 2003, The American journal of pathology.

[853]  D. Bostwick,et al.  Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. , 1995, Cancer research.

[854]  Barrack Er,et al.  Androgen receptors and growth fraction in metastatic prostate cancer as predictors of time to tumour progression after hormonal therapy. , 1991 .

[855]  B. Helpap,et al.  Nucleolar and AgNOR-analysis of prostatic intraepithelial neoplasia (PIN), atypical adenomatous hyperplasia (AAH) and prostatic carcinoma. , 1995, Pathology, research and practice.

[856]  Yi Sun,et al.  Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis. , 2002, Current cancer drug targets.

[857]  M. Stampfer,et al.  Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. , 1998, Science.

[858]  Yan Wang,et al.  Structural analysis of the C‐CAM1 molecule for its tumor suppression function in human prostate cancer , 1999, The Prostate.

[859]  M. Eichholzer,et al.  Prediction of male cancer mortality by plasma levels of interacting vitamins: 17‐year follow‐up of the prospective Basel study , 1996, International journal of cancer.

[860]  A. Gown,et al.  P504S Immunohistochemical Detection in 405 Prostatic Specimens Including 376 18-Gauge Needle Biopsies , 2002, The American journal of surgical pathology.

[861]  D. Morrish,et al.  The role of Bcl-2 expression in EGF inhibition of TNF-alpha/IFN-gamma-induced villous trophoblast apoptosis. , 1999, Placenta.

[862]  N. Blacklock,et al.  Ratio of post-prostatic massage urinary zinc concentration to initial urinary zinc concentration. An improved method of assessing prostatic function. , 1988, British Journal of Urology.

[863]  P. Troncoso,et al.  Trisomy 7: A potential cytogenetic marker of human prostate cancer progression , 1994, Genes, chromosomes & cancer.

[864]  K. Pienta,et al.  Epidemiology of prostate cancer: molecular and environmental clues. , 1996, Urology.

[865]  R. Palmiter,et al.  Molecular biology of metallothionein gene expression. , 1987, Experientia. Supplementum.

[866]  A. Ben-Ze'ev Animal cell shape changes and gene expression. , 1991, BioEssays : news and reviews in molecular, cellular and developmental biology.

[867]  R. Hayes,et al.  Serum retinol and prostate cancer. , 1988, Cancer.

[868]  M. Pollard Thalidomide promotes metastasis of prostate adenocarcinoma cells (PA-III) in L-W rats. , 1996, Cancer letters.

[869]  H. Adami,et al.  Lifestyle factors and insulin-like growth factor 1 levels among elderly men. , 2000, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[870]  E. Riboli,et al.  Plasma prolactin and prostate cancer risk: A prospective study , 2001, International journal of cancer.

[871]  D. Russell,et al.  Immunohistochemical localization of steroid 5 alpha-reductase 2 in the human male fetal reproductive tract and adult prostate. , 1996, The Journal of clinical endocrinology and metabolism.

[872]  J. McLachlan,et al.  Developmental estrogenization and prostatic neoplasia , 1994, The Prostate.

[873]  K. Pienta,et al.  A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines. , 1993, Cancer letters.

[874]  Story Mt Regulation of prostate growth by fibroblast growth factors. , 1995 .

[875]  B. Foster,et al.  Hormone Status Selects for Spontaneous Somatic Androgen Receptor Variants That Demonstrate Specific Ligand and Cofactor Dependent Activities in Autochthonous Prostate Cancer* , 2001, The Journal of Biological Chemistry.

[876]  A. Judd,et al.  Adenosine increases interleukin 6 release and decreases tumour necrosis factor release from rat adrenal zona glomerulosa cells, ovarian cells, anterior pituitary cells, and peritoneal macrophages. , 1997, Cytokine.

[877]  O. Ll. Lloyd,et al.  RESPIRATORY-CANCER CLUSTERING ASSOCIATED WITH LOCALISED INDUSTRIAL AIR POLLUTION , 1978, The Lancet.

[878]  M. Stearns,et al.  Cytokine (IL-10, IL-6) induction of tissue inhibitor of metalloproteinase 1 in primary human prostate tumor cell lines. , 1995, Oncology research.

[879]  J. Addonizio,et al.  Establishment of new human prostatic cancer cell line (JCA-1). , 1990, Urology.

[880]  R. Hurst,et al.  Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma , 2000, Cancer.

[881]  T. Visakorpi,et al.  Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model. , 1997, British Journal of Cancer.

[882]  E. Barrett-Connor Lower Endogenous Androgen Levels and Dyslipidemia in Men with Non-Insulin-Dependent Diabetes Mellitus , 1992, Annals of Internal Medicine.

[883]  G. MacLennan,et al.  Chemoprevention of prostate carcinogenesis by α-difluoromethylornithine in TRAMP mice , 2000 .

[884]  A. Evens,et al.  Intermittent Androgen Suppression as a Treatment for Prostate Cancer: A Review. , 1998, The oncologist.

[885]  O. Yoshida,et al.  The geography of prostate cancer and its treatment in Japan. , 1995, Cancer surveys.

[886]  M. Anver,et al.  Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate. , 1995, Cancer research.

[887]  J. Manson,et al.  Risk of Uterine Leiomyomata among Premenopausal Women in Relation to Body Size and Cigarette Smoking , 1998, Epidemiology.

[888]  M. Brawer,et al.  Topography of neovascularity in human prostate carcinoma , 1995, Cancer.

[889]  J. Pedersen,et al.  Inhibins, activins, and follistatins: Expression of mRNAs and cellular localization in tissues from men with benign prostatic hyperplasia , 1998, The Prostate.

[890]  S. Hilsenbeck,et al.  p53 is mutated in a subset of advanced-stage prostate cancers. , 1993, Cancer research.

[891]  J. Schalken,et al.  Suppression of invasive ability of highly metastatic rat prostate cancer by introduction of human chromosome 8 , 1997, The Prostate.

[892]  W. Grizzle,et al.  Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. , 1994, Journal of the National Cancer Institute.

[893]  T. Kuzumaki,et al.  Effect of flavonoids on cell cycle progression in prostate cancer cells. , 2002, Cancer letters.

[894]  A. Alcaraz,et al.  High‐grade prostate intraepithelial neoplasia shares cytogenetic alterations with invasive prostate cancer , 2001, The Prostate.

[895]  O. Cussenot,et al.  Down‐regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate , 2002, The Prostate.

[896]  M. Loda,et al.  Thymosin β15: A novel regulator of tumor cell motility upregulated in metastatic prostate cancer , 1996, Nature Medicine.

[897]  L. Dennis Meta‐analysis for combining relative risks of alcohol consumption and prostate cancer , 2000, The Prostate.

[898]  N Nonomura,et al.  Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. , 2001, Journal of the National Cancer Institute.

[899]  E. di Salle,et al.  Effect of turosteride, a 5α‐reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma , 1997 .

[900]  H. Moch,et al.  Ki67 LABELLING INDEX: AN INDEPENDENT PREDICTOR OF PROGRESSION IN PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY , 1996, The Journal of pathology.

[901]  L. Kalish,et al.  Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study. , 2001, Urology.

[902]  O. Kallioniemi,et al.  Consensus review of the clinical utility of DNA content cytometry in prostate cancer. , 1993, Cytometry.

[903]  J. Isaacs,et al.  Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. , 1995, Cancer research.

[904]  B. Graubard,et al.  Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[905]  D. Djakiew Role of nerve growth factor-like protein in the paracrine regulation of prostate growth. , 1992, Journal of andrology.

[906]  J W Moul,et al.  Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. , 1996, The Journal of urology.

[907]  C. Sawyers,et al.  NF-κB Activates Prostate-Specific Antigen Expression and Is Upregulated in Androgen-Independent Prostate Cancer , 2002, Molecular and Cellular Biology.

[908]  M. Maines,et al.  Expression of heme oxygenase-1 (HSP32) in human prostate: normal, hyperplastic, and tumor tissue distribution. , 1996, Urology.

[909]  E. Bergstralh,et al.  Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer. , 1994, Cancer research.

[910]  F. Mostofi,et al.  Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen. , 2000, The Journal of urology.

[911]  J. Green,et al.  Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinoma in a transgenic mouse model. , 2000, Cancer research.

[912]  B. Polk,et al.  Serologic precursors of cancer. Retinol, carotenoids, and tocopherol and risk of prostate cancer. , 1990, Journal of the National Cancer Institute.

[913]  R. Nagle,et al.  The α6β1 and α6β4 integrins in human prostate cancer progression , 1995, Cancer and Metastasis Reviews.

[914]  D. Schaid,et al.  Confirmation of linkage of prostate cancer aggressiveness with chromosome 19q. , 2003, American journal of human genetics.

[915]  A. Perantoni,et al.  Cadmium exposure in rats and tumours of the prostate. , 1992, IARC scientific publications.

[916]  A. Schally,et al.  Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. , 1990, Cancer research.

[917]  E. Barrett-Connor,et al.  Endogenous sex hormone levels in older adult men with diabetes mellitus. , 1990, American journal of epidemiology.

[918]  B. Hulka,et al.  Medical, life‐style, and occupational risk factors for prostate cancer , 1987, The Prostate.

[919]  E. Baldi,et al.  Androgen receptor expression induces FGF2, FGF‐binding protein production, and FGF2 release in prostate carcinoma cells: Role of FGF2 in growth, survival, and androgen receptor down‐modulation , 2002, The Prostate.

[920]  I. Leav,et al.  Androgen‐supported estrogen‐enhanced epithelial proliferation in the prostates of intact noble rats , 1989, The Prostate.

[921]  C. Huckstorf,et al.  Carcinogenic effects of cadmium on the prostate of the rat , 2004, Journal of Cancer Research and Clinical Oncology.

[922]  T. DeWeese,et al.  The molecular pathogenesis of prostate cancer: Implications for prostate cancer prevention. , 2001, Urology.

[923]  J. Cheville,et al.  Factors That Influence the Measurement of Prostate Cancer DNA Ploidy and Proliferation in Paraffin Embedded Tissue Evaluated by Flow Cytometry , 2001, Modern Pathology.

[924]  M. Fornaro,et al.  Down-regulation of beta 1C integrin, an inhibitor of cell proliferation, in prostate carcinoma. , 1996, The American journal of pathology.

[925]  H. Warner,et al.  Superoxide dismutase, aging, and degenerative disease. , 1994, Free radical biology & medicine.

[926]  M. Thun,et al.  Smoking and fatal prostate cancer in a large cohort of adult men. , 1997, American journal of epidemiology.

[927]  C. la Vecchia,et al.  Nutrition, social factors and prostatic cancer in a Northern Italian population. , 1986, British Journal of Cancer.

[928]  V. Kosma,et al.  Expression and Prognostic Value of CD44 Standard and Variant v3 and v6 Isoforms in Prostate Cancer , 2001, European Urology.

[929]  A. Bergh,et al.  Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. , 1995, The American journal of pathology.

[930]  L. Kaul,et al.  Nutrition and prostate cancer: A case‐control study , 1985, The Prostate.

[931]  P. Carroll,et al.  Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki‐67 and PCNA expression , 1995, The Prostate.

[932]  D. Pa,et al.  Human prostatic endocrine-paracrine (APUD) cells. Distributional analysis with a comparison of serotonin and neuron-specific enolase immunoreactivity and silver stains. , 1985 .

[933]  J. McNeal,et al.  Differential cytokeratin expression in normal, hyperplastic and malignant epithelial cells from human prostate. , 1990, The Journal of urology.

[934]  M. Loda,et al.  Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[935]  R. Bahnson,et al.  Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. , 1994, Anticancer research.

[936]  T. Kakizoe,et al.  Trial to Induce Prostatic Cancer in ACI/Seg Rats Treated with a Combination of 3,2′‐Dimethyl‐4‐aminobiphenyl and Ethinyl Estradiol , 1991, Japanese journal of cancer research : Gann.

[937]  M. Harada,et al.  Immunohistochemical detection of proliferating cell nuclear antigen (PCNA)/cyclin in human prostate adenocarcinoma. , 1993, The Journal of urology.

[938]  O. Cussenot,et al.  Loss of heterozygosity at 7q31 is a frequent and early event in prostate cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[939]  D. West,et al.  Familial factors affecting prostatic cancer risk and plasma sex‐steroid levels , 1985, The Prostate.

[940]  D. Morrish,et al.  The Role of Bcl-2 Expression in EGF Inhibition of TNF-α/IFN-γ-induced Villous Trophoblast Apoptosis , 1999 .

[941]  H. Carter,et al.  Epidemiologic evidence regarding predisposing factors to prostate cancer , 1990, The Prostate.

[942]  T. Stamey,et al.  Immunohistochemical evidence for impaired cell differentiation in the premalignant phase of prostate carcinogenesis. , 1988, American journal of clinical pathology.

[943]  E. Rimm,et al.  Diabetes mellitus and risk of prostate cancer (United States) , 2004, Cancer Causes & Control.

[944]  William B. Isaacs,et al.  Establishment and characterization of seven dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers , 1986 .

[945]  Srinivasan Vijayakumar,et al.  Prostate-specific antigen and androgens in African-American and white normal subjects and prostate cancer patients. , 2000, Journal of the National Medical Association.

[946]  P. Walsh,et al.  Changes in the metabolism of dihydrotestosterone in the hyperplastic human prostate. , 1983, The Journal of clinical endocrinology and metabolism.

[947]  N. Kyprianou,et al.  Partial growth suppression of human prostate cancer cells by the Krev‐1 suppressor gene , 1994, The Prostate.

[948]  D. Bostwick Prospective origins of prostate carcinoma: Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia , 1996, Cancer.

[949]  C. Kwak,et al.  Thrombospondin‐1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia , 2002, BJU international.

[950]  S. Loening,et al.  Antioxidant enzymes in malignant prostate cell lines and in primary cultured prostatic cells. , 1997, Free radical biology & medicine.

[951]  A. Lacroix,et al.  Family aggregation of cancer of the prostate in quebec: The tip of the iceberg , 1991, The Prostate.

[952]  B. E. Walker,et al.  Zinc, vitamin A and prostatic cancer. , 1983, British journal of urology.

[953]  D. Djakiew,et al.  Neurotrophin receptor p75(NTR) suppresses growth and nerve growth factor-mediated metastasis of human prostate cancer cells. , 2002, International journal of cancer.

[954]  G. Wilding,et al.  Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. , 1997, Journal of the National Cancer Institute.

[955]  S. Clark,et al.  Detailed methylation analysis of the glutathione S-transferase π (GSTP1) gene in prostate cancer , 1999, Oncogene.

[956]  R. Franklin,et al.  Inhibitory effect of zinc on human prostatic carcinoma cell growth , 1999, The Prostate.

[957]  D. Bostwick,et al.  Genetic and Chromosomal Alterations in Prostatic Intraepithelial Neoplasia and Carcinoma Detected by Fluorescence in situ Hybridization , 1999, European Urology.

[958]  M. Kattan,et al.  Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[959]  K. Imaida,et al.  Beef Tallow, but Not Perilla or Corn Oil, Promotion of Rat Prostate and Intestinal Carcinogenesis by 3,2‐Dimethyl‐4‐aminobiphenyl , 2001, Japanese journal of cancer research : Gann.

[960]  Christine D. Brown,et al.  Cell proliferation and apoptosis in prostate cancer--correlation with pathologic stage? , 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[961]  G. Dhom Epidemiologic aspects of latent and clinically manifest carcinoma of the prostate , 2004, Journal of Cancer Research and Clinical Oncology.

[962]  G. Cunha Role of mesenchymal‐epithelial interactions in normal and abnormal development of the mammary gland and prostate , 1994, Cancer.

[963]  Y. Kihira,et al.  Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate. , 1998, The Journal of urology.

[964]  E. Janovitz,et al.  Spontaneous metastasis of PC‐3 cells in athymic mice after implantation in orthotopic or ectopic microenvironments , 1995, The Prostate.

[965]  H. Møller,et al.  Risk of testicular cancer after vasectomy: cohort study of over 73 000 men , 1994, BMJ.

[966]  J. Isaacs,et al.  Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. , 2001, Cancer research.

[967]  D. Bostwick,et al.  Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer , 2000, Cancer.

[968]  Stefan Joos,et al.  Mapping of chromosomal gains and losses in prostate cancer by comparative genomic hybridization , 1995, Genes, chromosomes & cancer.

[969]  J. Stanford,et al.  Vasectomy and prostate cancer: a case-control study in a health maintenance organization. , 1996, American Journal of Epidemiology.

[970]  S. Schwartz,et al.  CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. , 1994, Cancer research.

[971]  Chawnshang Chang,et al.  Immunohistochemical localization of androgen receptors with mono- and polyclonal antibodies to androgen receptor. , 1990, The Journal of endocrinology.

[972]  B. Henderson,et al.  Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. , 1991, British Journal of Cancer.

[973]  W. Jiang,et al.  Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell-cell dissociation and in vitro invasion. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[974]  T. Wheeler,et al.  Apoptotic index as a biomarker in prostatic intraepithelial neoplasia (PIN) and prostate cancer. , 1994, Journal of cellular biochemistry. Supplement.

[975]  N. Takeichi,et al.  Development of adenocarcinoma of the prostate in ICR mice locally irradiated with X-rays. , 1976, Gan.

[976]  M. Becich,et al.  Expression of cadherins and catenins in paired tumor and non-neoplastic primary prostate cultures and corresponding prostatectomy specimens , 2000, Urological Research.

[977]  D. Bostwick,et al.  Androgen deprivation as a strategy for prostate cancer chemoprevention. , 1997, Journal of the National Cancer Institute.

[978]  U. Stein,et al.  Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. , 1994, Human pathology.

[979]  L. Liotta,et al.  Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. , 1995, Cancer research.

[980]  D. Bostwick,et al.  Intraductal dysplasia: a premalignant lesion of the prostate. , 1986, Human pathology.

[981]  A. Zlotta,et al.  [High-grade intraepithelial prostatic neoplasms: diagnosis and association with prostate cancer]. , 1996, Acta urologica Belgica.

[982]  S. Brewster,et al.  Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin‐like growth factor receptor , 2003, BJU international.

[983]  R. Dahiya,et al.  Establishment and characterization of a human primary prostatic adenocarcinoma cell line (ND-1). , 1992, The Journal of urology.

[984]  M. Papotti,et al.  Arguments against the prostatic origin of the R-3327 Dunning H tumor , 1992, Virchows Archiv. B, Cell pathology including molecular pathology.

[985]  F. Bethencourt,et al.  Immunoexpression of tumour necrosis factor-alpha and its receptors 1 and 2 correlates with proliferation/apoptosis equilibrium in normal, hyperplasic and carcinomatous human prostate. , 2000, Cytokine.

[986]  A. Gown,et al.  Microvascular endothelium of human tumor xenografts expresses mouse (= host) CD31. , 1997, International journal of microcirculation, clinical and experimental.

[987]  M. Alavi,et al.  Synthesis of tissue inhibitor of metalloproteinase-1 (TIMP-1) in rabbit aortic neointima after selective de-endothelialization. , 1996, Atherosclerosis.

[988]  Ankita Patel,et al.  Frequency and pattern of karyotypic abnormalities in human prostate cancer. , 1990, Cancer research.

[989]  H. Perlman,et al.  Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. , 1995, Cancer research.

[990]  U. Falkmer,et al.  A DNA cytometric proliferation index improves the value of the DNA ploidy pattern as a prognosticating tool in patients with carcinoma of the prostate. , 1997, Urology.

[991]  L. Poirier,et al.  Cadmium carcinogenesis in male Wistar [Crl:(WI)BR] rats: dose-response analysis of tumor induction in the prostate and testes and at the injection site. , 1988, Cancer research.

[992]  Parkin Dm,et al.  Cancer Incidence in Five Continents. Comparability and quality of data. , 1992 .

[993]  L. Layfield,et al.  Proliferative index determination in prostatic carcinoma tissue: is there any additional prognostic value greater than that of Gleason score, ploidy and pathological stage? , 1997, The Journal of urology.

[994]  J. Fraumeni,et al.  Recent cancer trends in the United States. , 1995, Journal of the National Cancer Institute.

[995]  E. Corder,et al.  Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: risk of prostate cancer in black and white men. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[996]  K. A. Klein,et al.  Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice , 1997, Nature Medicine.

[997]  J. Witte,et al.  Androgen receptor CAG repeats and prostate cancer. , 2002, American journal of epidemiology.

[998]  Z. Jónsson,et al.  Proliferating cell nuclear antigen: More than a clamp for DNA polymerases , 1997, BioEssays : news and reviews in molecular, cellular and developmental biology.

[999]  I. Leav,et al.  Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats. , 1988, Journal of the National Cancer Institute.

[1000]  A. Anagnostou,et al.  dl-alpha-tocopherol induces apoptosis in erythroleukemia, prostate, and breast cancer cells. , 1997, Nutrition and cancer.

[1001]  Hammond Eh,et al.  College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Prostate Cancer Working Group. , 1995 .

[1002]  K. Matsumoto,et al.  Human androgen‐induced growth factor in prostate and breast cancer cells: its molecular cloning and growth properties , 1995, FEBS letters.

[1003]  Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. , 2001, Molecular endocrinology.

[1004]  P. Schellhammer,et al.  Deoxyribonucleic acid cytometric analysis of prostate core biopsy specimens: relationship to serum prostate specific antigen and prostatic acid phosphatase, clinical stage and histopathology. , 1993, The Journal of urology.

[1005]  J. Fraumeni,et al.  Geographic patterns of prostate cancer in the United States. , 1978, Journal of the National Cancer Institute.

[1006]  R. Beltz,et al.  Telomerase activity in prostate sextant needle cores from radical prostatectomy specimens. , 2001, Urologic oncology.

[1007]  L. Poirier,et al.  Cadmium carcinogenesis in male Wistar [Crl:(WI)BR] rats: dose-response analysis of effects of zinc on tumor induction in the prostate, in the testes, and at the injection site. , 1989, Cancer research.

[1008]  R. Matusik,et al.  Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. , 1986, Cancer research.

[1009]  T. Hirayama [A large scale cohort study of dietary habits and cancer mortality]. , 1986, Gan no rinsho. Japan journal of cancer clinics.

[1010]  N. Goldstein Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. , 2002, American journal of clinical pathology.

[1011]  R. Hayes,et al.  Physical characteristics and factors related to sexual development and behaviour and the risk for prostatic cancer. , 1992, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[1012]  H. C. Chang,et al.  Risk factors for prostate carcinoma in Taiwan , 1999, Cancer.

[1013]  M. Stampfer,et al.  Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. , 2002, Journal of the National Cancer Institute.

[1014]  Benjamin Geiger,et al.  The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells , 1982, Cell.

[1015]  N. Verkaik,et al.  Silencing of CD44 Expression in Prostate Cancer by Hypermethylation of the CD44 Promoter Region , 2000, Laboratory Investigation.

[1016]  G. Buchanan,et al.  Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[1017]  T. Visakorpi,et al.  Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. , 1995, Cancer research.

[1018]  E. Barrack TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity. , 1997, The Prostate.

[1019]  E. Skrzypczak‐Jankun,et al.  Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. , 1997, Cancer research.

[1020]  D. Djakiew,et al.  Neurotrophin receptor p75NTR suppresses growth and nerve growth factor‐mediated metastasis of human prostate cancer cells , 2002 .

[1021]  H. Adami,et al.  Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden) , 1998, Cancer Causes & Control.

[1022]  T Sorahan,et al.  Cancer incidence and cancer mortality in a cohort of semiconductor workers. , 1985, British journal of industrial medicine.

[1023]  J. Fraumeni,et al.  Insulin‐like growth factors and risk of benign prostatic hyperplasia † , 2002, The Prostate.

[1024]  J. Wozney,et al.  Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells , 1994, The Prostate.

[1025]  M. Gleave,et al.  A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice. , 1997, Cancer research.

[1026]  A. Zisman,et al.  A genetic sequence change in the 3'-noncoding region of the androgen receptor gene in prostate carcinoma. , 1997, European urology.

[1027]  M. Slater,et al.  Markers for the development of early prostate cancer , 2003, The Journal of pathology.

[1028]  P. Pour Prostatic cancer induced in MRC rats by N-nitrosobis(2-oxopropyl)-amine and N-nitrosobis(2-hydroxypropyl)amine. , 1983, Carcinogenesis.

[1029]  M Petein,et al.  Morphonuclear relationship between prostatic intraepithelial neoplasia and cancers as assessed by digital cell image analysis. , 1991, American journal of clinical pathology.

[1030]  J P Rigaut,et al.  Application of confocal scanning laser microscopy for an automated nuclear grading of prostate lesions in three dimensions , 1996, Journal of microscopy.

[1031]  C. Harris,et al.  Transformation of human neonatal prostate epithelial cells by strontium phosphate transfection with a plasmid containing SV40 early region genes. , 1989, Cancer research.

[1032]  O. Yoshida,et al.  Prognostic criteria in patients with prostate cancer: correlation with volume weighted mean nuclear volume. , 1995, The Journal of urology.

[1033]  M. Bosland,et al.  Adenocarcinomas of the prostate induced by N-nitroso-N-methylurea in rats pretreated with cyproterone acetate and testosterone. , 1983, Cancer letters.

[1034]  K. Helzlsouer,et al.  Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States) , 1995, Cancer Causes & Control.

[1035]  J. Oesterling,et al.  Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. , 1991, The Journal of urology.

[1036]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[1037]  D. S. Coffey,et al.  Telomerase activity: a prevalent marker of malignant human prostate tissue. , 1996, Cancer research.

[1038]  J. Cheville,et al.  Diagnosis of prostate cancer in needle biopsies after radiation therapy. , 1999, The American journal of surgical pathology.

[1039]  S. Shain,et al.  Spontaneous adenocarcinomas of the ventral prostate of aged A X C rats. , 1975, Journal of the National Cancer Institute.

[1040]  T. Beaty,et al.  Genetic susceptibility of benign prostatic hyperplasia. , 1994, The Journal of urology.

[1041]  M. Kattan,et al.  The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer , 2003, The Prostate.

[1042]  D. Samid,et al.  Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene. , 1996, Molecular pharmacology.

[1043]  R. Weindruch,et al.  Oxidative Stress, Caloric Restriction, and Aging , 1996, Science.

[1044]  S. A. Leadon,et al.  Production and repair of DNA damage in mammalian cells. , 1990, Health physics.

[1045]  D. Bostwick,et al.  Loss of p53 and c-myc Overrepresentation in Stage T2-3N1-3M0 Prostate Cancer are Potential Markers for Cancer Progression , 2002, Modern Pathology.

[1046]  L. Kupper,et al.  An epidemiologic study of mortality within a cohort of rubber workers, 1964-72. , 1974, Journal of occupational medicine. : official publication of the Industrial Medical Association.

[1047]  H. Akaza,et al.  Promoting effects of antiandrogenic agents on rat ventral prostate carcinogenesis induced by 3,2′-dimethyl-4-aminobiphenyl (DMAB) , 2000, Prostate Cancer and Prostatic Diseases.

[1048]  K. Pienta,et al.  Inhibition of prostate cancer growth by estramustine and colchicine , 1995, The Prostate.

[1049]  G. Hammond Endogenous steroid levels in the human prostate from birth to old age: a comparison of normal and diseased tissues. , 1978, The Journal of endocrinology.

[1050]  G. V. Vande Woude,et al.  Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. , 2001, The American journal of pathology.

[1051]  J. Isaacs,et al.  Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers , 1995, The Prostate.

[1052]  M. Campbell,et al.  Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells. , 1995, Cancer letters.

[1053]  J. Siemiatycki,et al.  Activities and exposures during leisure and prostate cancer risk. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[1054]  E. Wynder,et al.  Comparative epidemiology of cancers of the colon, rectum, prostate and breast in Shanghai, China versus the United States. , 1991, International journal of epidemiology.

[1055]  H. Miyake,et al.  Elevation of serum levels of urokinase‐type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer , 1999, The Prostate.

[1056]  P. Lipponen,et al.  A prognostic score for prostatic adenocarcinoma based on clinical, histological, biochemical and cytometric data from the primary tumour. , 1996, Anticancer research.

[1057]  L. Kaul,et al.  The role of diet in prostate cancer. , 1987, Nutrition and cancer.

[1058]  Stefania Staibano,et al.  Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[1059]  G. Stemmermann,et al.  Serum micronutrients and prostate cancer in Japanese Americans in Hawaii. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[1060]  D. Kadmon,et al.  Chemoprevention in prostate cancer: The role of difluoromethylornithine (DFMO) , 1992, Journal of cellular biochemistry. Supplement.

[1061]  A. Schally,et al.  Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. , 1997, European journal of cancer.

[1062]  J. Isaacs The aging ACI/Seg versus Copenhagen male rat as a model system for the study of prostatic carcinogenesis. , 1984, Cancer research.

[1063]  A. Brothman,et al.  Chromosome 7 abnormalities in prostate cancer detected by dual-color fluorescence in situ hybridization. , 1998, Cancer genetics and cytogenetics.

[1064]  L. Bernstein,et al.  Serum testosterone levels in healthy young black and white men. , 1986, Journal of the National Cancer Institute.

[1065]  Edward S. Kim,et al.  Epidermal growth factor receptor biology (IMC-C225) , 2001, Current opinion in oncology.

[1066]  F. Waldman,et al.  HER2 protein expression and gene amplification in androgen-independent prostate cancer. , 2001, American journal of clinical pathology.

[1067]  S. Wacholder,et al.  Diet, tobacco use, and fatal prostate cancer: results from the Lutheran Brotherhood Cohort Study. , 1990, Cancer research.

[1068]  M. Maffini,et al.  Bcl-2 correlates with tumor ploidy and nuclear morphology in early stage prostate carcinoma. A fine needle aspiration biopsy study. , 2001, Pathology, research and practice.

[1069]  P H Bartels,et al.  Chromatin texture signatures in nuclei from prostate lesions. , 1998, Analytical and quantitative cytology and histology.

[1070]  C. la Vecchia,et al.  Dairy products and the risk of prostatic cancer. , 1991, Oncology.

[1071]  .. PhD,et al.  Zinc and cadmium concentrations in indigenous blacks with normal, hypertrophic, and malignant prostate , 1989, Cancer.

[1072]  C. Sundaram,et al.  Biopsy Gleason score: how does it correlate with the final pathological diagnosis in prostate cancer? , 1997, British journal of urology.

[1073]  J. Isaacs,et al.  Production and significance of TGF-beta in AT-3 metastatic cell line established from the Dunning rat prostatic adenocarcinoma. , 1990, Biochemical and biophysical research communications.

[1074]  J. Isaacs,et al.  Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. , 1997, Cancer research.

[1075]  T. Stamey,et al.  Biological determinants of cancer progression in men with prostate cancer. , 1999, JAMA.

[1076]  A. Whittemore,et al.  Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. , 1995, American journal of epidemiology.

[1077]  K Yogesan,et al.  Nuclear texture analysis: a new prognostic tool in metastatic prostate cancer. , 1996, Cytometry.

[1078]  J. Maksem,et al.  The prostatic perineural space and its relation to tumor spread: An ultrastructural study , 1980, The American journal of surgical pathology.

[1079]  D. Albanes,et al.  Effects of long‐term α‐tocopherol supplementation on serum hormones in older men * , 2001 .

[1080]  D. Wood,et al.  Proliferating cell nuclear antigen in prostatic adenocarcinoma: correlation with established prognostic indicators. , 1994, Urology.

[1081]  D. Djakiew,et al.  Inhibition of chemomigration of a human prostatic carcinoma cell (TSU‐pr1) line by inhibition of epidermal growth factor receptor function , 1996, The Prostate.

[1082]  T. French,et al.  Adult dietary intake and prostate cancer risk in Utah: a case-control study with special emphasis on aggressive tumors , 1991, Cancer Causes & Control.

[1083]  H. Stein,et al.  Differential expression of apoptosis, Bcl‐x and c‐Myc in normal and malignant lymphoid tissues , 1997, European journal of haematology.

[1084]  J. Rhim,et al.  Cadmium-induced neoplastic transformation of human prostate epithelial cells. , 2002, International journal of oncology.

[1085]  R. Montironi,et al.  Nuclear changes in the normal-looking columnar epithelium adjacent to and distant from prostatic intraepithelial neoplasia and prostate cancer , 2000, Virchows Archiv.

[1086]  P. Walsh,et al.  The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. , 1987, The New England journal of medicine.

[1087]  J. Cauley,et al.  Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[1088]  D. Roy,et al.  Sex hormone-induced nuclear DNA damage and lipid peroxidation in the dorsolateral prostates of Noble rats. , 1994, Cancer letters.

[1089]  P. Di Mascio,et al.  Lycopene as the most efficient biological carotenoid singlet oxygen quencher. , 1989, Archives of biochemistry and biophysics.

[1090]  T. Wilt,et al.  Epidemiology of High-Grade Prostatic Intraepithelial Neoplasia , 2000, Scandinavian journal of urology and nephrology. Supplementum.

[1091]  J. Mandel,et al.  Epidemiologic study of prostatic cancer: preliminary report. , 1977, Cancer treatment reports.

[1092]  R. Fridman,et al.  Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. , 2002, Journal of the National Cancer Institute.

[1093]  E. Riboli,et al.  Interrelationships between plasma testosterone, SHBG, IGF-I, insulin and leptin in prostate cancer cases and controls , 2003, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[1094]  W. Winkelstein,et al.  Prostatic cancer: relationship to suspended particulate air pollution. , 1969, American journal of public health and the nation's health.

[1095]  N. Breslow,et al.  Latent carcinoma of prostate at autopsy in seven areas. Collaborative study organized by the International Agency for Research on Cancer, Lyons, France , 1977, International journal of cancer.

[1096]  K. Pienta,et al.  Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. , 1995, Journal of the National Cancer Institute.

[1097]  R. Ross Epidemiology of prostate cancer and bladder cancer: an overview. , 1996, Cancer treatment and research.

[1098]  F. Smedts,et al.  Tenascin-C expression in prostatic intraepithelial neoplasia (PIN): a marker of progression? , 1998, Anticancer research.

[1099]  U. Günthert,et al.  CD44 variant isoforms are preferentially expressed in basal epithelia of non-malignant human fetal and adult tissues , 1994, Histochemistry.

[1100]  J. Barrett,et al.  Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer , 1997, The Prostate.

[1101]  Yulan Jin,et al.  Characteristics of normal stromal components and their correlation with cancer occurrence in human prostate. , 2003, Oncology reports.

[1102]  M. Pollard,et al.  The inhibitory effect of 4-hydroxyphenyl retinamide (4-HPR) on metastasis of prostate adenocarcinoma-III cells in Lobund-Wistar rats. , 1991, Cancer letters.

[1103]  R. Noble Production of Nb rat carcinoma of the dorsal prostate and response of estrogen-dependent transplants to sex hormones and tamoxifen. , 1980, Cancer research.

[1104]  Mora,et al.  Stage B Prostate Cancer: Correlation of DNA Ploidy Analysis With Histological and Clinical Parameters. , 1999, Cancer control : journal of the Moffitt Cancer Center.

[1105]  C. Sheehan,et al.  HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. , 1997, Human pathology.

[1106]  P H Bartels,et al.  Chromatin texture features in hematoxylin and eosin-stained prostate tissue. , 1993, Analytical and quantitative cytology and histology.

[1107]  H. Lilja,et al.  Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. , 1997, Biochemical and biophysical research communications.

[1108]  T. Liu,et al.  Inhibition of Prostate Tumor Angiogenesis by the Tumor Suppressor CEACAM1* , 2002, The Journal of Biological Chemistry.

[1109]  P. Russell,et al.  Flow cytometric and karyotypic analysis of a primary small cell carcinoma of the prostate: a xenografted cell line. , 1987, Cancer genetics and cytogenetics.

[1110]  K. Huebner,et al.  Gene structure, promoter activity, and chromosomal location of the DR-nm23 gene, a related member of the nm23 gene family. , 1997, Cancer research.

[1111]  R. Nagle,et al.  Cleavage of β4 Integrin by Matrilysin , 1997 .

[1112]  T. Hill,et al.  Expression of human glandular kallikrein, hK2, in mammalian cells. , 1996, Cancer research.

[1113]  W. Figg,et al.  The Mutated Androgen Receptor and Its Implications for the Treatment of Metastatic Carcinoma of the Prostate , 1996, Pharmacotherapy.

[1114]  E. Bruckheimer,et al.  Dihydrotestosterone Enhances Transforming Growth Factor-β-Induced Apoptosis in Hormone-Sensitive Prostate Cancer Cells. , 2001, Endocrinology.

[1115]  D. Peehl Vitamin D and Prostate Cancer Risk , 1999, European Urology.

[1116]  W. Willett,et al.  Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. , 1999, Cancer research.

[1117]  E. Giovannucci Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: A hypothesis , 1998, Cancer Causes & Control.

[1118]  T. McDonnell,et al.  Regulation of lipid signaling pathways for cell survival and apoptosis by bcl-2 in prostate carcinoma cells. , 1997, Experimental cell research.

[1119]  U. Kim,et al.  In vitro and in vivo (SCID mice) effects of phytosterols on the growth and dissemination of human prostate cancer PC-3 cells , 2001, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[1120]  N. Oyama,et al.  Prognostic value of nuclear morphometry on needle biopsy from patients with prostate cancer: is volume-weighted mean nuclear volume superior to other morphometric parameters? , 2000, Urology.

[1121]  D. Peehl,et al.  Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. , 1991, The Journal of clinical endocrinology and metabolism.

[1122]  R. Buttyan,et al.  Rodent models for targeted oncogenesis of the prostate gland , 1993, Cancer and Metastasis Reviews.

[1123]  J. Cerhan,et al.  Family history and prostate cancer risk in a population-based cohort of Iowa men. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[1124]  C. Sawyers,et al.  In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). , 2001, Cancer research.

[1125]  E. Bleecker,et al.  Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk. , 2002, Cancer research.

[1126]  J. A. Kemppainen,et al.  Identification of androstenedione in a river containing paper mill effluent , 2001, Environmental toxicology and chemistry.

[1127]  S. Barnes,et al.  Rationale for the use of genistein‐containing soy matrices in chemoprevention trials for breast and prostate cancer , 1995, Journal of cellular biochemistry. Supplement.

[1128]  J. Halgunset,et al.  Intracellular distribution of calcium and zinc in normal, hyperplastic, and neoplastic human prostate: X‐ray microanalysis of freeze‐dried cryosections , 1989, The Prostate.

[1129]  R. deVere White,et al.  Quantitation of NM23 expression in human prostate tissues. , 1994, The Journal of urology.

[1130]  B. Liu,et al.  Type IV procollagen mRNA regulation: evidence for extracellular matrix/cytoskeleton/nuclear matrix interactions in human urothelium. , 1991, The Journal of urology.

[1131]  O. Cussenot,et al.  VEGF overexpression in clinically localized prostate tumors and neuropilin‐1 overexpression in metastatic forms , 2000, International journal of cancer.

[1132]  D. Bostwick,et al.  Prostatic intraepithelial neoplasia occurs spontaneously in the canine prostate. , 1997, The Journal of urology.

[1133]  Jian J Lu,et al.  Tumor necrosis factor-α induces the expression of DR6, a member of the TNF receptor family, through activation of NF-κB , 2001, Oncogene.

[1134]  P. di Sant’agnese Neuroendocrine differentiation in prostatic adenocarcinoma does not represent true Paneth cell differentiation. , 1994, Human Pathology.

[1135]  M. Steiner,et al.  Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. , 1992, Molecular endocrinology.

[1136]  P. Boffetta,et al.  Alpha-linolenic acid and risk of prostate cancer: a case-control study in Uruguay. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[1137]  R. deVere White,et al.  Alterations of the retinoblastoma gene in human prostate adenocarcinoma , 1996, Genes, chromosomes & cancer.

[1138]  W. R. Bishop,et al.  Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells. , 2002, Molecular cancer therapeutics.

[1139]  R. Gandour-Edwards,et al.  Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization. , 2001, Cancer journal.

[1140]  Morris Pollard,et al.  Spontaneous prostate adenocarcinomas in aged germfree Wistar rats. , 1973, Journal of the National Cancer Institute.

[1141]  V M Hawthorne,et al.  Three limitations of the body mass index. , 1986, The American journal of clinical nutrition.

[1142]  J. Ward,et al.  Expression of KAI1 in paraffin‐embedded normal, hyperplastic and neoplastic prostate and prostate carcinoma cell lines , 1998, Pathology international.

[1143]  T. Vogt,et al.  Comparison of DNA ploidy in prostatic intraepithelial neoplasia and invasive carcinoma of the prostate: an image cytometric study. , 1994, Human pathology.

[1144]  V. Molinie [Prostatic intraepithelial neoplasia]. , 2001, Annales de pathologie.

[1145]  G. Schrauzer,et al.  Selenium , 1992, Biological Trace Element Research.

[1146]  J. McNeal,et al.  Significance of demonstrable vascular space invasion for the progression of prostatic adenocarcinoma. , 1996, The American journal of surgical pathology.

[1147]  R. Hayes,et al.  Serum vitamin A and subsequent development of prostate cancer in the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. , 1990, Cancer research.

[1148]  J. Ravetch,et al.  FcR gamma chain deletion results in pleiotrophic effector cell defects. , 1994, Cell.

[1149]  M. Sporn,et al.  Development and characterization of nontumorigenic and tumorigenic epithelial cell lines from rat dorsal-lateral prostate. , 1994, Cancer research.

[1150]  B. Foster,et al.  Pathologic progression of autochthonous prostate cancer in the TRAMP model , 1999, Prostate Cancer and Prostatic Diseases.

[1151]  John Calvin Reed,et al.  Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. , 1993, Cancer research.

[1152]  B. Doré,et al.  Obesity in relation to prostate cancer risk: comparison with a population having benign prostatic hyperplasia , 2003, BJU international.

[1153]  L. Klotz,et al.  Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. , 1998, Cancer research.

[1154]  R. Paffenbarger,et al.  Alcohol consumption and risk of prostate cancer: The Harvard Alumni Health Study. , 2001, International journal of epidemiology.

[1155]  R. Nagle,et al.  Cleavage of beta 4 integrin by matrilysin. , 1997, Experimental cell research.

[1156]  H. Lilja,et al.  Biochemistry of prostate specific antigen, PSA. , 1995, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[1157]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[1158]  K. Sağlam,et al.  Leptin influences cellular differentiation and progression in prostate cancer. , 2003, The Journal of urology.

[1159]  M. Masai,et al.  Argyrophilic nucleolar organizer regions in benign hyperplastic and cancerous human prostates , 1992, The Prostate.

[1160]  D. Bostwick,et al.  Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival. , 2002, The Journal of urology.

[1161]  M. Stampfer,et al.  Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[1162]  Michael J. Wilson,et al.  Immunohistochemical localization of laminin in the basement membranes of normal, hyperplastic, and neoplastic human prostate , 1989, The Prostate.

[1163]  E. Rimm,et al.  Smoking and risk of total and fatal prostate cancer in United States health professionals. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[1164]  C. Cordon-Cardo,et al.  Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[1165]  I. Higgins The epidemiology of cancer of the prostate. , 1975, Journal of chronic diseases.

[1166]  R A Stephenson,et al.  Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. , 2001, Journal of the National Cancer Institute.

[1167]  J. Neoptolemos,et al.  Heat shock protein expression independently predicts clinical outcome in prostate cancer. , 2000, Cancer research.

[1168]  J. Rhim,et al.  A novel human cancer culture model for the study of prostate cancer , 2001, Oncogene.

[1169]  R. Kane,et al.  The results of a five‐year early prostate cancer detection intervention , 1996, Cancer.

[1170]  R. Nagle,et al.  Interleukin-1beta-induced promatrilysin expression is mediated by NFkappaB-regulated synthesis of interleukin-6 in the prostate carcinoma cell line, LNCaP. , 2001, Neoplasia.

[1171]  R. Noble,et al.  A classification of transplantable tumors in Nb rats controlled by estrogen from dormancy to autonomy. , 1975, Cancer research.

[1172]  J. Massagué,et al.  Early gene responses to transforming growth factor-beta in cells lacking growth-suppressive RB function , 1991, Molecular and cellular biology.

[1173]  M. Rubin,et al.  Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. , 2002, Cancer research.

[1174]  J. Schalken,et al.  Decreased expression of E-cadherin in the progression of rat prostatic cancer. , 1992, Cancer research.

[1175]  N. Kyprianou,et al.  Incidence of apoptosis and cell proliferation in prostate cancer: Relationship with TGF‐β1 and bcl‐2 expression , 1996, International journal of cancer.

[1176]  J. Stanford,et al.  Fruit and vegetable intakes and prostate cancer risk. , 2000, Journal of the National Cancer Institute.

[1177]  D. Neal,et al.  Androgen regulation of ornithine decarboxylase in human prostatic cells identified using differential display , 1997, FEBS letters.

[1178]  L. Boccon‐Gibod [Prostatic-specific antigen]. , 1988, Annales d'urologie.

[1179]  G. Schwartz,et al.  Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation , 1992, Cancer.

[1180]  F. Hamdy,et al.  Bone morphogenetic protein-6: potential mediator of osteoblastic metastases in prostate cancer , 2000, Prostate Cancer and Prostatic Diseases.

[1181]  W. J. Visek,et al.  Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. , 1999, Journal of the National Cancer Institute.

[1182]  C. Lieber,et al.  Effect of alcohol (ethanol) administration on sex-hormone metabolism in normal men. , 1976, The New England journal of medicine.

[1183]  Frank Dolbeare,et al.  Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part III. Proliferation in normal, injured and diseased tissue, growth factors, differentiation, DNA replication sites andin situ hybridization , 1996, The Histochemical Journal.

[1184]  G. Howe,et al.  Alcohol and other beverage use and prostate cancer risk among Canadian men , 1998, International journal of cancer.

[1185]  P. Laake,et al.  Dietary fat intake and risk of prostate cancer: A prospective study of 25,708 Norwegian men , 1997, International journal of cancer.

[1186]  F. Ozcan Correlation of perineural invasion on radical prostatectomy specimens with other pathologic prognostic factors and PSA failure. , 2001, European urology.

[1187]  D. Sternberg,et al.  K-252a inhibits nerve growth factor-induced trk proto-oncogene tyrosine phosphorylation and kinase activity. , 1992, The Journal of biological chemistry.

[1188]  J. Schleutker,et al.  Androgen receptor CAG polymorphism and prostate cancer risk , 2002, Human Genetics.

[1189]  R. Hayes,et al.  Alcohol use and prostate cancer risk in US blacks and whites. , 1996, American journal of epidemiology.

[1190]  M. Goepel,et al.  E-cadherin: a marker for differentiation and invasiveness in prostatic carcinoma , 2004, Urological Research.

[1191]  R. Nagle,et al.  Fibroblast growth factor-1 induced promatrilysin expression through the activation of extracellular-regulated kinases and STAT3. , 2002, Neoplasia.

[1192]  T. Pappas,et al.  The other estrogen receptor in the plasma membrane: implications for the actions of environmental estrogens. , 1995, Environmental health perspectives.

[1193]  A. Wells,et al.  In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals , 1995, Clinical & Experimental Metastasis.

[1194]  J. Cerhan,et al.  Lifestyle and anthropometric risk factors for prostate cancer in a cohort of Iowa men. , 2000, Annals of epidemiology.

[1195]  R. Zarbo,et al.  Computerized static DNA ploidy analysis of prostatic intraepithelial neoplasia. , 1993, Archives of pathology & laboratory medicine.

[1196]  D. Peehl,et al.  Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. , 1994, The Journal of clinical endocrinology and metabolism.

[1197]  S. Stellman,et al.  Cancer mortality in chinese immigrants to New York city. Comparison with chinese in tianjin and with United States‐born whites , 1994, Cancer.

[1198]  S. Dedhar,et al.  The receptor for the basement membrane glycoprotein entactin is the integrin alpha 3/beta 1. , 1992, The Journal of biological chemistry.

[1199]  J. Hankin,et al.  Diet and prostatic cancer: a case-control study in Hawaii. , 1988, American journal of epidemiology.

[1200]  Zhou Wang,et al.  Farnesyl diphosphate synthase is abundantly expressed and regulated by androgen in rat prostatic epithelial cells , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[1201]  I. Leav,et al.  Early alterations in ras protooncogene mRNA expression in testosterone and estradiol-17 beta induced prostatic dysplasia of noble rats. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[1202]  P. Walsh,et al.  Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy , 1991, Cancer.

[1203]  I. Bairati,et al.  Lifetime occupational physical activity and incidental prostate cancer (Canada) , 2000, Cancer Causes & Control.

[1204]  L. Kiemeney,et al.  Single‐nucleotide polymorphism in the E‐cadherin gene promoter modifies the risk of prostate cancer , 2002 .

[1205]  K. Akakura,et al.  Hypermethylation of the CD44 gene is associated with progression and metastasis of human prostate cancer , 2001, The Prostate.

[1206]  A. Dyer,et al.  Dietary Beta‐Carotene, Vitamin C, and Risk of Prostate Cancer , 1996, Epidemiology.

[1207]  T. H. van der Kwast,et al.  Value of tissue markers p27kip1, MIB‐1, and CD44s for the pre‐operative prediction of tumour features in screen‐detected prostate cancer , 2002, The Journal of pathology.

[1208]  R. deVere White,et al.  Flow cytometry as a predictive modality in prostate cancer. , 1992, Human pathology.

[1209]  T. Stamey,et al.  Tissue type plasminogen activator as a marker for functional zones, within the human prostate gland , 1988, The Prostate.

[1210]  David Handelsman,et al.  Identification of differentially expressed genes in organ‐confined prostate cancer by gene expression array , 2001, The Prostate.

[1211]  A. Seftel Meta-analysis of measures of sexual activity and prostate cancer. , 2002, The Journal of urology.

[1212]  E. Feuer,et al.  Changing trends in U.S. prostate cancer incidence rates. , 1996, Journal of the National Cancer Institute.

[1213]  R. Nagle,et al.  Investigation into the mechanism of the loss of laminin 5 (alpha3beta3gamma2) expression in prostate cancer. , 2001, The American journal of pathology.

[1214]  R. Nagle,et al.  Differential expression of extracellular matrix molecules and the alpha 6-integrins in the normal and neoplastic prostate. , 1994, The American journal of pathology.

[1215]  T. Stamey,et al.  Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. , 1993, The Journal of clinical endocrinology and metabolism.

[1216]  A. Gao,et al.  Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[1217]  Zuo-Feng Zhang,et al.  Smoking history and cancer patient survival: a hospital cancer registry study. , 1997, Cancer detection and prevention.

[1218]  L. Burd,et al.  Impact of smoking on cancer stage at diagnosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[1219]  A. Whittemore,et al.  Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. , 1995, Journal of the National Cancer Institute.

[1220]  Schwartz Gg,et al.  Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. , 1994 .

[1221]  P R Taylor,et al.  Physical activity and risk of cancer in the NHANES I population. , 1989, American journal of public health.

[1222]  Bruce W. Turnbull,et al.  Effects of Selenium Supplementation for Cancer Prevention in Patients With Carcinoma of the Skin: A Randomized Controlled Trial , 1996 .

[1223]  B. Henderson,et al.  Vitamin A, beta-carotene, and the risk of cancer: a prospective study. , 1987, Journal of the National Cancer Institute.

[1224]  E. Corder,et al.  Vitamin D and prostate cancer: a prediagnostic study with stored sera. , 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[1225]  D C Malins,et al.  Infrared spectral models demonstrate that exposure to environmental chemicals leads to new forms of DNA. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[1226]  S. Piantadosi,et al.  Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[1227]  S. Ogawa,et al.  Antitumor effect of reduction of 150‐kDa oxygen‐regulated protein expression on human prostate cancer cells , 2002, International journal of urology : official journal of the Japanese Urological Association.

[1228]  G. Stemmermann,et al.  International comparison on ras gene mutations in latent prostate carcinoma , 1994, International journal of cancer.

[1229]  L. Gray,et al.  Latent Effects of Pesticides and Toxic Substances On Sexual Differentiation of Rodents , 1996, Toxicology and industrial health.

[1230]  J. Cerhan,et al.  Association of smoking, body mass, and physical activity with risk of prostate cancer in the Iowa 65+ Rural Health Study (United States) , 1997, Cancer Causes & Control.

[1231]  C. Foster,et al.  Differential expression of voltage‐activated Na+ currents in two prostatic tumour cell lines: contribution to invasiveness in vitro , 1995, FEBS letters.

[1232]  Lightfoot,et al.  Prostate cancer risk. Medical history, sexual, and hormonal factors. , 2000, Annals of epidemiology.

[1233]  H. Yamanaka,et al.  Carcinogenesis in accessory sex organs of rats induced by 3,2′-dimethyl-4-aminobiphenyl: response to androgen deprivation , 1997, Histochemistry and Cell Biology.

[1234]  E. Gelmann,et al.  Role of transforming growth factor-alpha in human prostate cancer cell growth. , 1989, The Prostate.

[1235]  M. Pollak,et al.  Insulin-like growth factors and prostate cancer. , 2001, Epidemiologic reviews.

[1236]  David Couper,et al.  Electromagnetic fields, polychlorinated biphenyls, and prostate cancer mortality in electric utility workers. , 2003, American journal of epidemiology.

[1237]  N. Chamberlain,et al.  The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. , 1994, Nucleic acids research.

[1238]  Richard Doll,et al.  Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices , 1975, International journal of cancer.

[1239]  M. Loda,et al.  Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[1240]  J Isola,et al.  Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. , 1997, Cancer research.

[1241]  A. Andersen,et al.  Smoking habits and risk of cancers other than lung cancer: 28 years' follow-up of 26,000 Norwegian men and women , 2004, Cancer Causes & Control.

[1242]  W. Tilley,et al.  Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. , 1997, The Journal of urology.

[1243]  J. Bartlett,et al.  Amplification of the androgen receptor gene in bone metastases from hormone‐refractory prostate cancer , 2002, The Journal of pathology.

[1244]  R. Baxter,et al.  Insulin‐like growth factor‐binding protein‐2 in patients with prostate carcinoma and benign prostatic hyperplasia , 1997, Clinical endocrinology.

[1245]  J. Gustafsson,et al.  Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[1246]  Gary M Williams,et al.  Induction of proliferative lesions of ventral prostate, seminal vesicle, and other accessory sex glands in rats by N‐methyl‐N‐nitrosourea: Effect of castration, pretreatment with cyproterone acetate and testosterone propionate, and rat strain , 1992, The Prostate.

[1247]  Simon P. Kim,et al.  Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[1248]  M. Pike,et al.  5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males , 1992, The Lancet.

[1249]  Johannes Gerdes,et al.  Monoclonal antibodies against recombinant parts of the Ki‐67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave‐processed formalin‐fixed paraffin sections , 1992, The Journal of pathology.

[1250]  D. Morton,et al.  Loss of heterozygosity of the retinoblastoma and adenomatous polyposis susceptibility gene loci and in chromosomes 10p, 10q and 16q in human prostate cancer. , 1994, British journal of urology.

[1251]  A. Wolk,et al.  Fatty fish consumption and risk of prostate cancer , 2001, The Lancet.

[1252]  K. Hamil,et al.  Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. , 1997, Molecular endocrinology.

[1253]  H. Grönberg,et al.  Age specific risks of familial prostate carcinoma , 1999, Cancer.

[1254]  P. Kantoff,et al.  The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[1255]  D. Kaplan,et al.  Expression of a Trk high affinity nerve growth factor receptor in the human prostate. , 1995, Endocrinology.

[1256]  K. Tozawa,et al.  KAI1 expression can be a predictor of stage A prostate cancer progression , 2001, Prostate Cancer and Prostatic Diseases.

[1257]  T. Sakakura,et al.  Tenascin expression and postnatal development of the human prostate. , 1994, The International journal of developmental biology.

[1258]  T. Christmas,et al.  Diagnosis and treatment of urological malignancy: the prostate. , 1996, British journal of hospital medicine.

[1259]  M. Stampfer,et al.  Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. , 2002, Journal of the National Cancer Institute.

[1260]  P. A. Sant'agnese,et al.  Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. , 1992 .

[1261]  F. Grodstein,et al.  Prospective study of plasma fatty acids and risk of prostate cancer. , 1994, Journal of the National Cancer Institute.

[1262]  D. Hopster,et al.  Distribution of vascular endothelial growth factor (VEGF) in prostate disease , 2002, Prostate Cancer and Prostatic Diseases.

[1263]  R. Burk,et al.  Role of family history and ethnicity on the mode and age of prostate cancer presentation. , 2002, The Prostate.

[1264]  R. Reiter,et al.  Role of prostate stem cell antigen in prostate cancer research , 2002, Current opinion in urology.

[1265]  R. Hayes,et al.  Height and the survival of prostate cancer patients. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[1266]  H. Baloglu,et al.  Tissue sialic acid and fibronectin levels in human prostatic cancer. , 1996, Cancer letters.

[1267]  V. Speights,et al.  Aneuploidy in benign seminal vesicle epithelium: an example of the paradox of ploidy studies. , 1991, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[1268]  R. Eeles,et al.  Genetic predisposition to prostate cancer. , 2016, British medical bulletin.

[1269]  H. Ostrer,et al.  Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma , 2003, Cancer.

[1270]  J. Isaacs,et al.  Response of rat and human prostatic cancers to the novel 5α‐reductase inhibitor, SK&F 105657 , 1992 .

[1271]  W. Willett,et al.  Vitamin D receptor genotype and the risk of bone fractures in women. , 1998 .

[1272]  A. Meikle,et al.  Inhibition of nuclear factor κB induces apoptosis following treatment with tumor necrosis factor α and an antioxidant in human prostate cancer cells , 2002 .

[1273]  W. W. Nichols,et al.  p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. , 1993, Journal of the National Cancer Institute.

[1274]  R. Fine,et al.  The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[1275]  P. Kupelian,et al.  Does a family history of prostate cancer result in more aggressive disease? , 1998, Prostate Cancer and Prostatic Diseases.

[1276]  C. Perez-stable,et al.  Prostate cancer progression, metastasis, and gene expression in transgenic mice. , 1997, Cancer research.

[1277]  I. Lascu,et al.  nm23-H4, a new member of the family of human nm23/nucleoside diphosphate kinase genes localised on chromosome 16p13 , 1997, Human Genetics.

[1278]  M. Kattan,et al.  Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens. , 2001, Human pathology.

[1279]  J. V. van Dongen,et al.  Location of genes involved in invasion and metastasis on human chromosome 7. , 1987, Cancer research.

[1280]  R. Swerdloff,et al.  Immunohistochemical localization of relaxin in human prostate. , 1989, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[1281]  N. Greenberg,et al.  Autochthonous mouse models for prostate cancer: past, present and future. , 2001, Seminars in cancer biology.

[1282]  M. Dizdaroglu,et al.  DNA base modifications and antioxidant enzyme activities in human benign prostatic hyperplasia. , 1995, Free radical biology & medicine.

[1283]  M. Brawer,et al.  The relationship of basement membrane to histologic grade of human prostatic carcinoma. , 1989, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[1284]  Noble Rl,et al.  ESTRONE-INDUCED MAMMARY TUMORS IN THE RAT. I. INDUCTION AND BEHAVIOR OF TUMORS. , 1964 .

[1285]  R. Schleicher,et al.  Intravenous vs. intraprostatic administration of N‐methyl‐N‐nitrosourea to induce prostate cancer in rats , 1996, The Prostate.

[1286]  B. Goldin,et al.  Soybean phytoestrogen intake and cancer risk. , 1995, The Journal of nutrition.

[1287]  P. di Sant'Agnese,et al.  Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. , 1996, Urology.

[1288]  D. Djakiew,et al.  Molecular characterization of neurotrophin expression and the corresponding tropomyosin receptor kinases (trks) in epithelial and stromal cells of the human prostate , 1997, Molecular and Cellular Endocrinology.

[1289]  Balk,et al.  Treatment of Androgen-Independent Prostate Cancer. , 1996, The oncologist.

[1290]  Douglas S Scherr,et al.  High expression of the Met receptor in prostate cancer metastasis to bone. , 2002, Urology.

[1291]  F. Mostofi,et al.  Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. , 1996, Surgery.

[1292]  N. Greenberg,et al.  A Transgenic Mouse Prostate Cancer Model , 1996, Toxicologic pathology.

[1293]  W. Mckeehan,et al.  Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy , 1993, Molecular and cellular biology.

[1294]  H. Lilja,et al.  Three predominant prostatic proteins: Drei vorherrschende Prostataproteine , 1990 .

[1295]  D. Horsfall,et al.  Xenografted small cell undifferentiated cancer of prostate: possible common origin with prostatic adenocarcinoma. , 1988, The Prostate.

[1296]  V. Robinson,et al.  Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. , 2003, The Journal of urology.

[1297]  T. Glover,et al.  Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer. , 1996, Cancer research.

[1298]  A. Folsom,et al.  Weight and length at birth and risk of early-onset prostate cancer (United States) , 2003, Cancer Causes and Control.

[1299]  H. Yoshida,et al.  Nucleolar organizer regions and PCNA expression in prostatic cancers , 1994, Pathology international.

[1300]  R. Nagle,et al.  Unique expression pattern of the α6β4 integrin and laminin‐5 in human prostate carcinoma , 2001 .

[1301]  J. Rhim,et al.  Radiation-induced Neoplastic Transformation of Human Prostate Epithelial Cells' , 2006 .

[1302]  Soo Young Lee,et al.  Molecular ordering of ROS production, mitochondrial changes, and caspase activation during sodium salicylate-induced apoptosis. , 2003, Free radical biology & medicine.

[1303]  R. Wennrich,et al.  Zinc and cadmium concentration in prostatic carcinoma of different histological grading in comparison to normal prostate tissue and adenofibromyomatosis (BPH) , 2004, Urological Research.

[1304]  R. Eeles,et al.  Androgen receptor polymorphisms: Association with prostate cancer risk, relapse and overall survival , 1999, International journal of cancer.

[1305]  J. Schalken,et al.  Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. , 1992, Cancer research.

[1306]  L. Silverman,et al.  In vitro characterization of MAT LyLu: a Dunning rat prostate adenocarcinoma tumor subline. , 1984, The Journal of urology.

[1307]  J. V. D. van der Gulden Metal workers and repairmen at risk for prostate cancer: A review , 1997, The Prostate.

[1308]  A. Dalkin,et al.  Activin inhibition of prostate cancer cell growth: selective actions on androgen-responsive LNCaP cells. , 1996, Endocrinology.

[1309]  H. Grönberg,et al.  Links between genetic and environmental factors and prostate cancer risk , 1999, The Prostate.

[1310]  Matthew W. Strobeck,et al.  Differential requirements for ras and the retinoblastoma tumor suppressor protein in the androgen dependence of prostatic adenocarcinoma cells. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[1311]  L. Shan,et al.  Expression and somatic mutation on androgen receptor gene in prostate cancer , 2002, International journal of urology : official journal of the Japanese Urological Association.

[1312]  F. Hamdy,et al.  Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue. , 1997, Cancer research.

[1313]  O. Faroon,et al.  A Review of the Carcinogenicity of Chemicals Most Frequently Found at National Priorities List Sites , 1994, Toxicology and industrial health.

[1314]  R. Nagle,et al.  Prostate tumor cell invasion: a comparison of orthotopic and ectopic models. , 1993, Invasion & metastasis.

[1315]  S. Frizelle,et al.  Proliferative activity in benign and neoplastic prostatic epithelium , 1994, The Journal of pathology.

[1316]  M. Czech,et al.  Direct demonstration of rapid insulin-like growth factor II Receptor internalization and recycling in rat adipocytes. Insulin stimulates 125I-insulin-like growth factor II degradation by modulating the IGF-II receptor recycling process. , 1985, The Journal of biological chemistry.

[1317]  P. Troncoso,et al.  Frequency and characterization of p53 mutations in clinically localized prostate cancer. , 1995, Urology.

[1318]  L. Chung,et al.  Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. , 1996, Journal of the National Cancer Institute.

[1319]  R. Sadasivan,et al.  Urokinase-type plasminogen activator expression in human prostate carcinomas. , 1996, The American journal of the medical sciences.

[1320]  J. Lubin,et al.  Use of agricultural pesticides and prostate cancer risk in the Agricultural Health Study cohort. , 2003, American journal of epidemiology.

[1321]  J. Martínez-Jabaloyas,et al.  Prognostic value of DNA ploidy and nuclear morphometry in prostate cancer treated with androgen deprivation. , 2002, Urology.

[1322]  D. Bostwick,et al.  Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. , 1997, Cancer research.

[1323]  J. Geller Benign Prostatic Hyperplasia: Pathogenesis and Medical Therapy , 1991, Journal of the American Geriatrics Society.

[1324]  P. Stattin,et al.  Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer , 2002, The Prostate.

[1325]  F. Meyskens,et al.  Vitamin A: a potential inhibitor of human cancer. , 1983, Seminars in oncology.

[1326]  A. Whittemore,et al.  Vasectomy and prostate cancer: results from a multiethnic case-control study. , 1995, Journal of the National Cancer Institute.

[1327]  M. Nakao,et al.  Epidemiological study of prostatic cancer by matched‐pair analysis , 1986, The Prostate.

[1328]  F. V. vom Saal,et al.  Transport of steroids between fetuses via amniotic fluid in relation to the intrauterine position phenomenon in rats. , 1992, Journal of reproduction and fertility.

[1329]  X. Wu,et al.  A rare premalignant prostate tumor epithelial cell syndecan-1 forms a fibroblast growth factor-binding complex with progression-promoting ectopic fibroblast growth factor receptor 1. , 2001, Cancer research.

[1330]  K. Sikora,et al.  Establishment and in vivo characterization of multidrug‐resistant dunning R3327 rat prostate‐carcinoma cell‐lines , 1994, International journal of cancer.

[1331]  C. Lee,et al.  A proliferative effect of transforming growth factor-beta1 on a human prostate cancer cell line, TSU-Pr1. , 1998, Endocrinology.

[1332]  D. Bostwick,et al.  Platelet‐derived growth factor A and B chains and the α and β receptors in prostatic intraepithelial neoplasia , 1996 .

[1333]  P. Mills,et al.  Prostate Cancer Risk in California Farm Workers , 2003, Journal of occupational and environmental medicine.

[1334]  R. Hayes,et al.  Case‐control study of prostatic cancer in Kyoto, Japan: Demographic and some lifestyle risk factors , 1989, The Prostate.

[1335]  J. Cheville,et al.  Extranodal Extension in Lymph Node–Positive Prostate Cancer , 2000, Modern Pathology.

[1336]  R C Smith,et al.  Effect of epidermal growth factor on prostate cancer cell line PC3 growth and invasion , 1994, The Prostate.

[1337]  M. Rubin,et al.  Prevalence and location of peripheral nerve found on prostate needle biopsy. , 2001, American journal of clinical pathology.

[1338]  P. Carroll,et al.  Cell proliferation in prostatic adenocarcinoma: in vitro measurement by 5-bromodeoxyuridine incorporation and proliferating cell nuclear antigen expression. , 1993, The Journal of urology.

[1339]  H. Klocker,et al.  Androgen receptors in prostate cancer. , 2003, Endocrine-related cancer.

[1340]  M. Nevalainen,et al.  Increased Expression of FGF-8 Isoforms and FGF Receptors in Human Premalignant Prostatic Intraepithelial Neoplasia Lesions and Prostate Cancer , 2001, Laboratory Investigation.

[1341]  A. Renshaw,et al.  Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer. , 2001, The Journal of urology.

[1342]  M. Waalkes,et al.  Apparent quiescence of the metallothionein gene in the rat ventral prostate: association with cadmium-induced prostate tumors in rats. , 1994, Environmental health perspectives.

[1343]  E. Rimm,et al.  A prospective cohort study of vasectomy and prostate cancer in US men. , 1993, JAMA.

[1344]  T. Lam,et al.  Mortality of cadmium-exposed workers. A five-year update. , 1988, Scandinavian journal of work, environment & health.

[1345]  R. Hiatt,et al.  Alcohol consumption, smoking, and other risk factors and prostate cancer in a large health plan cohort in California (United States) , 2005, Cancer Causes & Control.

[1346]  L. Holmberg,et al.  Alcoholism and cancer risk: a population-based cohort study , 1992, Cancer Causes & Control.

[1347]  R. Tamimi,et al.  Are dietary influences on the risk of prostate cancer mediated through the insulin‐like growth factor system? , 2001, BJU international.

[1348]  R. Montironi,et al.  Frequency and location of mitoses in prostatic intraepithelial neoplasia (PIN). , 1993, Anticancer research.

[1349]  S. Sidney Vasectomy and the risk of prostatic cancer and benign prostatic hypertrophy. , 1987, The Journal of urology.

[1350]  E. Metter,et al.  Plasma selenium level before diagnosis and the risk of prostate cancer development. , 2001, The Journal of urology.

[1351]  A. Schally,et al.  Effect of microcapsules of luteinizing hormone‐releasing hormone antagonist SB‐75 and somatostatin analog RC‐160 on endocrine status and tumor growth in the dunning R‐3327H rat prostate cancer model , 1992, The Prostate.

[1352]  M. Brawer,et al.  Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity , 1994, Cancer.

[1353]  R. Day,et al.  Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. , 1997, Urology.

[1354]  W. Zheng,et al.  Occupation, physical activity, and risk of prostate cancer in Shanghai, People's Republic of China , 1994, Cancer Causes & Control.

[1355]  D. Bostwick,et al.  Prostatic Intraepithelial Neoplasia: The Preinvasive Stage of Prostate Cancer: Overview of the Prostate Committee Report , 2000, Scandinavian journal of urology and nephrology. Supplementum.

[1356]  T. Visakorpi,et al.  Androgen receptor gene and hormonal therapy failure of prostate cancer. , 1998, The American journal of pathology.

[1357]  D. Bostwick,et al.  Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. , 1995, The Journal of urology.

[1358]  D. Rose,et al.  Regulation of DUI45 human prostate cancer cell proliferation by insulin‐like growth factors and its interaction with the epidermal growth factor autocrine loop , 1994, The Prostate.

[1359]  J. Gingrich,et al.  Establishment and characterization of a new human prostatic carcinoma cell line (DuPro-1). , 1991, The Journal of urology.

[1360]  D. Djakiew,et al.  Anti-proliferative effect of the kinase inhibitor K252a on human prostatic carcinoma cell lines. , 1996, Journal of andrology.

[1361]  J. Loscalzo,et al.  Homocysteine, oxidative stress, and vascular disease. , 1997, Hospital practice.

[1362]  R. Nagle,et al.  Expression of hemidesmosomal and extracellular matrix proteins by normal and malignant human prostate tissue. , 1995, The American journal of pathology.

[1363]  H. Idikio Expression of proliferating cell nuclear antigen in node-negative human prostate cancer. , 1996, Anticancer research.

[1364]  P. Walsh,et al.  Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. , 1993, Cancer research.

[1365]  R. Cohen,et al.  Immunohistochemical detection of oncogene proteins and neuroendocrine differentiation in different stages of prostate cancer , 1995, Pathology.

[1366]  J. Weissenbach,et al.  Loss of the chromosomal region 10q23-25 in prostate cancer. , 1995, Cancer research.

[1367]  D. Bostwick,et al.  Overexpression of ornithine decarboxylase in prostate cancer and prostatic fluid in humans. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[1368]  P. Boyle,et al.  Cancer of the prostate: epidemiology and aetiology. , 1987, British journal of urology.

[1369]  P. Humphrey,et al.  Histologic Grade, DNA Ploidy, and Intraglandular Tumor Extent as Indicators of Tumor Progression of Clinical Stage B Prostatic Carcinoma: A Direct Comparison , 1991, The American journal of surgical pathology.

[1370]  K. Griffiths,et al.  Pathological and clinical associations of Ki‐67 defined growth fractions in human prostatic carcinoma , 1992, The Prostate.

[1371]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[1372]  C. Cordon-Cardo,et al.  Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. , 1994, The Journal of urology.

[1373]  D. Leroith,et al.  Insulin-like Growth Factors and Cancer , 1995, Annals of Internal Medicine.

[1374]  R. Saroufeem,et al.  Studies of rhodamine‐123: Effect on rat prostate cancer and human prostate cancer cells in vitro , 1995, Journal of surgical oncology.

[1375]  E. Rimm,et al.  Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. , 2000, Journal of the National Cancer Institute.

[1376]  R. Dahiya,et al.  Metastasis-associated alterations in phospholipids and fatty acids of human prostatic adenocarcinoma cell lines. , 1992, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[1377]  M. Marberger,et al.  Polymorphisms of glutathione‐S‐transferase genes (GSTP1, GSTM1 and GSTT1) and prostate‐cancer risk , 2001, International journal of cancer.

[1378]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[1379]  T. Savarese,et al.  Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma. , 2001, The American journal of pathology.

[1380]  P. di Sant'Agnese,et al.  Human prostatic endocrine-paracrine (APUD) cells. Distributional analysis with a comparison of serotonin and neuron-specific enolase immunoreactivity and silver stains. , 1985, Archives of pathology & laboratory medicine.

[1381]  J. Weissfeld,et al.  Testosterone, sex hormone-binding globulin, and body composition in young adult African American and Caucasian men. , 2001, Metabolism: clinical and experimental.

[1382]  D. Bostwick,et al.  Platelet-derived growth factor A and B chains and the alpha and beta receptors in prostatic intraepithelial neoplasia. , 1996, The Prostate.

[1383]  A. Sabichi,et al.  Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. , 2001, Cancer research.

[1384]  J. Gustafsson,et al.  Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. , 1997, Science.

[1385]  I. Leav,et al.  Adenocarcinoma of the canine prostate , 1968, Cancer.

[1386]  E. Barrack,et al.  Determination of growth fraction in advanced prostate cancer by KI‐67 immunostaining and its relationship to the time to tumor progression after hormonal therapy , 1991, Cancer.

[1387]  Y. Liu,et al.  Increase in metallothionein produced by chemicals that induce oxidative stress. , 1991, Toxicology and applied pharmacology.

[1388]  M. Bosland,et al.  Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17 beta or diethylstilbestrol. , 1995, Carcinogenesis.

[1389]  D. Neal,et al.  Keratinocyte growth factor expression in hormone insensitive prostate cancer , 1997, Oncogene.

[1390]  M. Howell Factor Analysis of International Cancer Mortality Data and per capita Food Consumption , 1974, British Journal of Cancer.

[1391]  P. Humphrey,et al.  Impaired prostate tumorigenesis in Egr1-deficient mice , 2001, Nature Medicine.

[1392]  Y. Ukai,et al.  Mechanisms of the Suppression of the Bladder Activity by Flavoxate , 1996, International journal of urology : official journal of the Japanese Urological Association.

[1393]  L. Giudice,et al.  Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. , 1992, The Journal of clinical endocrinology and metabolism.

[1394]  D. S. Coffey,et al.  Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT. , 1978, Cancer research.

[1395]  R. Goldbohm,et al.  Anthropometry in relation to prostate cancer risk in the Netherlands Cohort Study. , 2000, American journal of epidemiology.

[1396]  S. Korsmeyer Bcl-2: an antidote to programmed cell death. , 1992, Cancer surveys.

[1397]  M. Rubin,et al.  Microvessel density as a predictor of PSA recurrence after radical prostatectomy. A comparison of CD34 and CD31. , 2000, American journal of clinical pathology.

[1398]  J. Barnes,et al.  Bone morphogenetic protein-6 expression in normal and malignant prostate , 2004, World Journal of Urology.

[1399]  B. Neubauer,et al.  Epithelial-mesenchymal interactions in prostatic development. II. Biochemical observations of prostatic induction by urogenital sinus mesenchyme in epithelium of the adult rodent urinary bladder , 1983, The Journal of cell biology.

[1400]  D. Albanes,et al.  Physical activity and prostate cancer in the Alpha-Tocopherol, Beta-Carotene (ATBC) Cancer Prevention Study (Finland) , 2004, Cancer Causes & Control.

[1401]  J. Palmgren,et al.  Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. , 1995, The American journal of clinical nutrition.

[1402]  E. Barrack,et al.  Androgen receptors and growth fraction in metastatic prostate cancer as predictors of time to tumour progression after hormonal therapy. , 1991, Cancer surveys.

[1403]  M. Webber,et al.  Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression , 2001, The Prostate.

[1404]  K. Pienta,et al.  Pentosan inhibits angiogenesis in vitro and suppresses prostate tumor growth in vivo. , 1993, Anticancer research.

[1405]  T. Katoh,et al.  Impact of genetic polymorphisms of 17‐hydroxylase cytochrome P‐450 (CYP17) and steroid 5α‐reductase type II (SRD5A2) genes on prostate‐cancer risk among the Japanese population , 2001, International journal of cancer.

[1406]  G W Comstock,et al.  Serum retinol, beta-carotene, vitamin E, and selenium as related to subsequent cancer of specific sites. , 1992, American journal of epidemiology.

[1407]  S. Plymate,et al.  Insulin-like growth factor-binding protein-3 expression and secretion by cultures of human prostate epithelial cells and stromal fibroblasts. , 1994, The Journal of endocrinology.

[1408]  L. Kessler,et al.  Rise in prostatic cancer incidence associated with increased use of transurethral resection. , 1990, Journal of the National Cancer Institute.

[1409]  J. Neoptolemos,et al.  Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. , 1994, British Journal of Cancer.

[1410]  L. Klotz,et al.  Diet, Androgens, Oxidative Stress and Prostate Cancer Susceptibility , 1998, Cancer and Metastasis Reviews.

[1411]  P. Cohen,et al.  7S nerve growth factor is an insulin-like growth factor-binding protein protease. , 1996, Endocrinology.

[1412]  B. Henderson,et al.  A cohort study of mortality from cancer of the prostate in Catholic priests. , 1981, British Journal of Cancer.

[1413]  L. Shultz,et al.  Survival of human prostate carcinoma, benign hyperplastic prostate tissues, and IL‐2‐activated lymphocytes in SCID mice , 1995, The Prostate.

[1414]  E. Kikuchi,et al.  Enhancement of diethylstilbestrol induced cytotoxicity by bcl-2 antisense oligodeoxynucleotides and a glutathione depletor for prostate cancer. , 2003, The Journal of urology.

[1415]  D. Russell,et al.  Expression and regulation of steroid 5 alpha-reductase 2 in prostate disease. , 1994, The Journal of urology.

[1416]  H. Levin,et al.  Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray. , 2001, Human pathology.

[1417]  M. Ittman,et al.  Expression of fibroblast growth factors (FGFs) and FGF receptors in human prostate. , 1997, The Journal of urology.

[1418]  T. Byers,et al.  Dietary vitamin A and cancer--a multisite case-control study. , 1986, Nutrition and cancer.

[1419]  R. deVere White,et al.  Increased RB1 abnormalities in human primary prostate cancer following combined androgen blockade , 1998, The Prostate.

[1420]  N. Kyprianou,et al.  Down‐regulation of protein and mRNA expression for transforming growth factor‐β (TGF‐β1) type I and type II receptors in human prostate cancer , 1997 .

[1421]  Chung Lee,et al.  A Proliferative Effect of Transforming Growth Factor-β1 on a Human Prostate Cancer Cell Line, TSU-Pr1. , 1998, Endocrinology.

[1422]  M. Sporn,et al.  Role of retinoids in differentiation and carcinogenesis. , 1983, Cancer research.

[1423]  M. Arenas,et al.  E-, N- and P-cadherin, and alpha-, beta- and gamma-catenin protein expression in normal, hyperplastic and carcinomatous human prostate. , 2000, The Histochemical journal.

[1424]  L. Oberley,et al.  Localization of antioxidant enzymes and oxidative damage products in normal and malignant prostate epithelium , 2000, The Prostate.

[1425]  S. Chevalier,et al.  Androgen ablation promotes neuroendocrine cell differentiation in dog and human prostate , 2002, The Prostate.

[1426]  O. Cussenot,et al.  Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: identification of three independent regions. , 1997, Cancer research.

[1427]  O. Yoshida,et al.  Dietary beta-carotene and cancer of the prostate: a case-control study in Kyoto, Japan. , 1988, Cancer research.

[1428]  S. Gomez,et al.  Soy and isoflavone consumption in relation to prostate cancer risk in China. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[1429]  E. Rimm,et al.  A prospective study of dietary fat and risk of prostate cancer. , 1993, Journal of the National Cancer Institute.

[1430]  C. Kimmel,et al.  Developmental stage sensitivity and mode of action information for androgen agonists and antagonists. , 2001, The Science of the total environment.

[1431]  A. Weeraratna,et al.  Rational basis for Trk inhibition therapy for prostate cancer , 2000, The Prostate.

[1432]  R. Shi,et al.  Insulin-like growth factor-I and prostate cancer: a meta-analysis , 2001, British Journal of Cancer.

[1433]  D. Williams,et al.  Evaluation of the chemopreventive potential of retinoids using a novel in vitro human prostate carcinogenesis model. , 2001, Mutation research.

[1434]  J. Oesterling,et al.  Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.

[1435]  L. Ellison Tea and other beverage consumption and prostate cancer risk: a Canadian retrospective cohort study. , 2000, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[1436]  M. Spitz,et al.  Familial patterns of prostate cancer: a case-control analysis. , 1991, The Journal of urology.

[1437]  S. Ho,et al.  Effect of combined testosterone and estradiol‐17β treatment on the metabolism of E2 in the prostate and liver of noble rats , 1997, The Prostate.

[1438]  M. Steiner,et al.  Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model. , 2000, Cancer research.

[1439]  A. Formiconi,et al.  High and low risk prostate carcinoma determined by histologic grade and proliferative activity , 1997, Cancer.

[1440]  Y. Homma,et al.  Promotional effect of two-generation exposure to a high-fat diet on prostate carcinogenesis in ACI/Seg rats. , 1994, Cancer research.

[1441]  J. Fraumeni,et al.  Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China. , 2001, Cancer research.

[1442]  C. la Vecchia,et al.  Calcium, dairy products, and the risk of prostate cancer , 2001, The Prostate.

[1443]  R. Montironi,et al.  Quantitative analysis of prostatic intraepithelial neoplasia on tissue sections. , 1990, Analytical and quantitative cytology and histology.

[1444]  R. Weindruch,et al.  Prostatic localization of spontaneous early invasive carcinoma in Lobund-Wistar rats. , 1994, Cancer research.

[1445]  B. Norlén,et al.  Evaluation of a new tumor marker for cytokeratin 8 and 18 fragments in healthy individuals and prostate cancer patients , 1994, The Prostate.

[1446]  H. Svanholm,et al.  Histological evaluation of prostatic cancer (II): Reproducibility of a histological grading system , 1990, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[1447]  C. Magi-Galluzzi,et al.  Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. , 1994, Journal of clinical pathology.

[1448]  R. Nagle,et al.  Interleukin-1β-Induced Promatrilysin Expression is Mediated by NFκB-Regulated Synthesis of Interleukin-6 in the Prostate Carcinoma Cell Line, LNCaP , 2001 .

[1449]  J. Brooks,et al.  CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[1450]  A. Partin,et al.  Concordance rates for benign prostatic disease among twins suggest hereditary influence. , 1994, Urology.

[1451]  J. Eble,et al.  Platelet derived growth factor (PDGF), androgens and inflammation: possible etiologic factors in the development of prostatic hyperplasia. , 1993, The Journal of urology.

[1452]  D. Bostwick,et al.  Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. , 1994, Urology.

[1453]  P. Humphrey,et al.  Overexpression and regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma. , 2000, Urology.

[1454]  Gittes Rf The nude mouse--its use as tumor-bearing model of the prostate. , 1980 .

[1455]  H. G. van der Poel,et al.  Intratumoral nuclear morphologic heterogeneity in prostate cancer. , 1997, Urology.

[1456]  M. Krieg,et al.  Kinetic analysis of androstenedione 5 alpha-reductase in epithelium and stroma of human prostate. , 1997, Steroids.

[1457]  J. Richie,et al.  Derivation and application of upper limits for prostate specific antigen in men aged 50-74 years with no clinical evidence of prostatic carcinoma. , 1995, British journal of urology.

[1458]  I. Fidler,et al.  Workgroup 2: Human xenograft models of prostate cancer , 1998, The Prostate.

[1459]  J. Hudson,et al.  Tumor-specific and Photodependent Cytotoxicity of Hypericin in the Human LNCaP Prostate Tumor Model , 2001, Photochemistry and photobiology.

[1460]  K. Wiklund,et al.  Prostate cancer in pesticide applicators in Swedish agriculture , 1998, The Prostate.

[1461]  K. Cooney,et al.  Early onset prostate cancer: predictors of clinical grade. , 2002, The Journal of urology.

[1462]  J. Siemiatycki,et al.  Case–control study of alcohol consumption and prostate cancer risk in Montréal, Canada , 2001, Cancer Causes & Control.

[1463]  P. Walsh,et al.  Clinical and experimental studies of benign prostatic hyperplasia. , 1990, The Urologic clinics of North America.

[1464]  F. Greenwood,et al.  Expression of the human relaxin H1 gene in the decidua, trophoblast, and prostate. , 1991, The Journal of clinical endocrinology and metabolism.

[1465]  C. Constantinides,et al.  Immunohistochemical expression of transforming growth factor beta 1 and nm-23 H1 antioncogene in prostate cancer: divergent correlation with clinicopathological parameters. , 2000, Anticancer research.

[1466]  M. Pollard,et al.  Effects of diphosphonate and X‐Rays on bone lesions induced in rats by prostate cancer cells , 1988, Cancer.

[1467]  S. Ross,et al.  Endogenous mouse mammary tumor virus is expressed in several organs in addition to the lactating mammary gland , 1988, Journal of virology.

[1468]  L. Donehower,et al.  Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. , 1995, Oncogene.

[1469]  R. Meneghini,et al.  Metallothionein protects DNA from oxidative damage. , 1993, The Biochemical journal.

[1470]  J. Neoptolemos,et al.  Allelic loss on chromosomes 8p, 22q and 18q (DCC) in human prostate cancer , 1996, International journal of cancer.

[1471]  W. Grizzle,et al.  Biomarker expression in prostatic intraepithelial neoplasia. , 1996, European urology.

[1472]  K. Helzlsouer,et al.  Null association between insulin-like growth factors, insulin-like growth factor-binding proteins, and prostate cancer in a prospective study. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[1473]  M. Plummer,et al.  International agency for research on cancer. , 2020, Archives of pathology.

[1474]  G. Risbridger,et al.  Growth inhibitory response to activin A and B by human prostate tumour cell lines, LNCaP and DU145. , 1997, The Journal of endocrinology.

[1475]  L. Cupples,et al.  Parental age at child's birth and son's risk of prostate cancer. The Framingham Study. , 1999, American journal of epidemiology.

[1476]  J. Schleutker,et al.  Detection of subclinical cancers by prostate-specific antigen screening in asymptomatic men from high-risk prostate cancer families. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[1477]  K. Okihara,et al.  Immunohistochemical localization of platelet-derived endothelial cell growth factor expression and its relation to angiogenesis in prostate. , 2001, Urology.

[1478]  P. Walsh,et al.  Family history of prostate cancer and obesity in relation to high‐grade disease and extraprostatic extension in young men with prostate cancer , 2003, The Prostate.

[1479]  D. Djakiew,et al.  Reduced expression of the low affinity nerve growth factor receptor in benign and malignant human prostate tissue and loss of expression in four human metastatic prostate tumor cell lines. , 1992, Cancer research.

[1480]  E. Gelmann,et al.  Role of transforming growth factor ‐α in human prostate cancer cell growth , 1989 .

[1481]  A. Levine,et al.  Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. , 2000, The Journal of urology.

[1482]  A. Partin,et al.  Influence of biopsy perineural invasion on long-term biochemical disease-free survival after radical prostatectomy. , 2002, Urology.

[1483]  R. Branch,et al.  Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail. , 1998, British journal of clinical pharmacology.

[1484]  H. Scher,et al.  Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. , 1996, The Journal of clinical endocrinology and metabolism.

[1485]  M. Steiner Transforming growth factor-beta and prostate cancer. , 1995, World journal of urology.

[1486]  D. Bostwick,et al.  The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma. , 1997, Human pathology.

[1487]  R. Tamura,et al.  Experimental induction of neoplasia in the accessory sex organs of male Lobund-Wistar rats. , 1990, Cancer research.

[1488]  D. Bostwick,et al.  A molecular cytogenetic analysis of 7q31 in prostate cancer. , 1997, Cancer research.

[1489]  D. Sidransky,et al.  Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. , 2001, Journal of the National Cancer Institute.

[1490]  M. Menon,et al.  Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: a novel therapy in prostate cancer. , 1997, Urology.

[1491]  I. Leav,et al.  Rat estrogen receptor-alpha and -beta, and progesterone receptor mRNA expression in various prostatic lobes and microdissected normal and dysplastic epithelial tissues of the Noble rats. , 1998, Endocrinology.

[1492]  J. Waterbor,et al.  Prostate cancer screening (United States) , 1995, Cancer Causes & Control.

[1493]  W. Butler,et al.  Perineural invasion is not predictive of biochemical outcome following prostate brachytherapy. , 2001, Cancer journal.

[1494]  H. Bern,et al.  Long-term effects of perinatal exposure to sex steroids and diethylstilbestrol on the reproductive system of male mammals. , 1983, International review of cytology.

[1495]  J. Collins,et al.  Prostate cancer trends in Canada: rising incidence or increased detection? , 1993, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[1496]  M. Arenas,et al.  E-, N- And P-cadherin, and α-, β- and γ-catenin Protein Expression in Normal, Hyperplastic and Carcinomatous Human Prostate , 2000, The Histochemical Journal.

[1497]  A. Soto,et al.  Developmental effects of endocrine-disrupting chemicals in wildlife and humans. , 1993, Environmental health perspectives.

[1498]  J. Zenklusen,et al.  Allelic loss at 7q31.1 in human primary ovarian carcinomas suggests the existence of a tumor suppressor gene. , 1995, Oncogene.

[1499]  D. Rose,et al.  Density‐dependent regulation of epidermal growth factor receptor expression in DU 145 human prostate cancer cells , 1991, The Prostate.

[1500]  H. Olsson,et al.  Familial and hereditary prostate cancer in southern Sweden. A population-based case-control study. , 1999, European journal of cancer.

[1501]  R. Mohan,et al.  Prostate cancer chemoprevention by green tea: in vitro and in vivo inhibition of testosterone-mediated induction of ornithine decarboxylase. , 1999, Cancer research.

[1502]  S. Khuder,et al.  Meta-analyses of prostate cancer and farming. , 1997, American journal of industrial medicine.

[1503]  S. Shain,et al.  Primary and transplantable adenocarcinomas of the A times C rat ventral prostate gland: morphologic characterization and examination of C19-steroid metabolism by early-passage tumors. , 1979, Journal of the National Cancer Institute.

[1504]  John Calvin Reed,et al.  Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[1505]  P. Carroll,et al.  Methylation of the E-cadherin gene promoter correlates with progression of prostate cancer. , 2001, The Journal of urology.

[1506]  M. Becich,et al.  Association between human cancer and two polymorphisms occurring together in the p21Waf1/Cip1 cyclin‐dependent kinase inhibitor gene , 1997, Cancer.

[1507]  K. Scott,et al.  Different phenotypes in human prostate cancer: alpha6 or alpha3 integrin in cell-extracellular adhesion sites. , 2002, Neoplasia.

[1508]  G van den Engh,et al.  Cell-cell interaction in prostate gene regulation and cytodifferentiation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[1509]  A. Bex,et al.  Influence of Linomide on Local Tumor Growth and Metastasis of the Human Hormone–Resistant Prostate Cancer Cell Line PC3 in an Orthotopic Model , 2000, European Urology.

[1510]  C Sonnenschein,et al.  The E-SCREEN assay as a tool to identify estrogens: an update on estrogenic environmental pollutants. , 1995, Environmental health perspectives.

[1511]  S. Agarwal,et al.  Effects of peroxidative stress and age on the concentration of a deoxyguanosine-malondialdehyde adduct in rat DNA , 1995, Lipids.

[1512]  D. Russell,et al.  Expression and regulation of steroid 5α-reductase 2 in prostate disease , 1994 .

[1513]  W. Haenszel,et al.  Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. , 1968, Journal of the National Cancer Institute.

[1514]  R. V. Schaik,et al.  Variations in activin receptor, inhibin/activin subunit and follistatin mRNAs in human prostate tumour tissues , 1999, British Journal of Cancer.

[1515]  E. Rimm,et al.  Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[1516]  S. Kornfeld Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. , 1992, Annual review of biochemistry.

[1517]  O. Cussenot,et al.  Immortalization of human adult normal prostatic epithelial cells by liposomes containing large T-SV40 gene. , 1991, The Journal of urology.

[1518]  E. Delzell,et al.  Mortality among white and nonwhite farmers in North Carolina, 1976-1978. , 1985, American journal of epidemiology.

[1519]  J. Boreham,et al.  Serum retinol and subsequent risk of cancer. , 1986, British Journal of Cancer.

[1520]  R. Nicholson,et al.  New EGF‐R selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC‐3 and DU‐145 , 1997, International journal of cancer.

[1521]  B. Neubauer,et al.  Raloxifene (LY156758) produces antimetastatic responses and extends survival in the paiii rat prostatic adenocarcinoma model , 1995, The Prostate.

[1522]  F. Gilliland,et al.  Family history, Hispanic ethnicity, and prostate cancer risk. , 2003, Ethnicity & disease.

[1523]  C. R. Bagnell,et al.  Nuclear roundness factor: A quantitative approach to grading in prostatic carcinoma, reliability of needle biopsy tissue, and the effect of tumor stage on usefulness , 1987, The Prostate.

[1524]  R. Bahnson,et al.  Canine prostate induces new bone formation in mouse calvaria: A model of osteoinduction by prostate tissue , 2002, The Prostate.

[1525]  Three predominant prostatic proteins. , 1990, Andrologia.

[1526]  S. Plymate,et al.  Insulin‐like growth factor binding protein‐3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo , 2002, The Prostate.

[1527]  S. Ghatak,et al.  Expression and regulation of metallothionein mRNA levels in the prostates of Noble rats: Lack of expression in the ventral prostate and regulation by sex hormones in the dorsolateral prostate , 1996, The Prostate.

[1528]  N. Bruchovsky,et al.  Activation of the Androgen Receptor N-terminal Domain by Interleukin-6 via MAPK and STAT3 Signal Transduction Pathways* , 2002, The Journal of Biological Chemistry.

[1529]  J. Myers,et al.  Biochemical and immunohistochemical characterization of human type XIX defines a novel class of basement membrane zone collagens. , 1997, The American journal of pathology.

[1530]  T. Hirayama Epidemiology of prostate cancer with special reference to the role of diet. , 1979, National Cancer Institute monograph.

[1531]  J. Barrett,et al.  KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. , 1995, Science.

[1532]  J. Isaacs,et al.  Anti-angiogenic treatment with linomide as adjuvant to surgical castration in experimental prostate cancer. , 1997, The Journal of urology.

[1533]  G. Jenster,et al.  The human androgen receptor: Structure/function relationship in normal and pathological situations , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[1534]  A. Polednak Trends in prostate carcinoma incidence in Connecticut (1988–1994) by age and race , 1997, Cancer.

[1535]  N. Greenberg,et al.  Genomic instability-based transgenic models of prostate cancer. , 2000, Carcinogenesis.

[1536]  M. Lehtinen,et al.  Sero‐epidemiologal association between human‐papillomavirus infection and risk of prostate cancer , 1998 .

[1537]  W. Isaacs,et al.  ras gene mutations in human prostate cancer. , 1990, Cancer research.

[1538]  O. Axelson,et al.  Prostate cancer and exposure to pesticides in agricultural settings , 2003, International journal of cancer.

[1539]  C. Coogan,et al.  Percutaneous cryoablation of the prostate: preliminary results after 95 procedures. , 1995, The Journal of urology.

[1540]  J. Moul,et al.  Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. , 1994, Cancer research.

[1541]  V. Rangnekar,et al.  Increased levels of nm23 H1/nucleoside diphosphate kinase A mRNA associated with adenocarcinoma of the prostate , 2004, World Journal of Urology.

[1542]  T. Byers,et al.  Diet in the epidemiology of carcinoma of the prostate gland. , 1983, Journal of the National Cancer Institute.

[1543]  M. Sporn,et al.  Histogenesis of induced prostate and seminal vesicle carcinoma in Lobund-Wistar rats: a system for histological scoring and grading. , 1994, Cancer research.

[1544]  B. Dutrillaux,et al.  Growth of methionine-dependent human prostate cancer (PC-3) is inhibited by ethionine combined with methionine starvation. , 1997, British Journal of Cancer.